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ABSTRACT
Background To provide pooled longer term data from
three groups of a phase 2 study of cemiplimab in patients
with advanced cutaneous squamous cell carcinoma
(CSCC), and to determine duration of response (DOR) and
impact on quality of life (QoL).
Methods Patients received cemiplimab 3 mg/kg every
2 weeks (group 1, metastatic CSCC [mCSCC], n=59;
group 2, locally advanced CSCC, n=78) or cemiplimab
350 mg every 3 weeks (group 3, mCSCC, n=56).
Primary endpoint was objective response rate (ORR) per
independent central review (ICR). QoL was repeatedly
measured at day 1 of each treatment cycle (groups 1 and
2: 8 weeks; group 3: 9 weeks).
Results Median duration of follow-up was 15.7 months.
Overall, ORR per ICR was 46.1% (95% CI: 38.9% to
53.4%). Complete response (CR) rates were 20.3%,
12.8%, and 16.1% for groups 1, 2, and 3, respectively.
Median time to CR was 11.2 months. Among patients
with partial response or CR, the estimated proportion of
patients with ongoing response at 12 months from the
first objective response was 87.8% (95% CI: 78.5% to
93.3%), with median DOR not reached. Kaplan-Meier
estimated probability of overall survival (OS) was 73.3%
(95% CI: 66.1% to 79.2%) at 24 months, with median OS
not reached. Global Health Status (GHS)/QoL improvements
were observed as early as cycle 2 and were significantly
improved and durable until last assessment. Kaplan-Meier
estimate of median time to first clinically meaningful
improvement for pain was 2.1 (95% CI: 2.0 to 3.7) months
and was significantly improved in responders versus non-
responders (p<0.0001).
Conclusions This is the largest (n=193) clinical dataset
for a programmed cell death-1 inhibitor against advanced
CSCC, confirming the sustained substantial clinical activity
of cemiplimab in these patients, including new findings of
improved CR rates over time, increasing DOR, and durable
pain control and GHS/QoL improvement.

Trial registration number C
 linicalTrials.gov Registry
(NCT02760498), https://clinicaltrialsgov/ct2/show/
NCT02760498.

BACKGROUND
Cutaneous squamous cell carcinoma
(CSCC) is the second most common skin
cancer in the USA, with increasing incidence.1 Most cases are cured by complete
surgical excision.2 3 However, a small but
substantial number of patients present
with or subsequently develop metastatic
CSCC (mCSCC) or locally advanced CSCC
(laCSCC) not amenable to curative surgery
or curative radiation (collectively, ‘advanced
CSCC’), which has a poor prognosis.4–6
Treatment of advanced CSCC, particularly
CSCC with a primary site of head and neck,
can lead to reduced quality of life (QoL).7–9
Surgery for CSCC can result in considerable morbidity, for example, some patients
require orbital exenteration,10 which significantly reduces QoL, including increased
anxiety and depression, difficulty driving,
phantom pain, and hallucinations.11 12
Radiotherapy is associated with substantial
toxicity, including fibrosis, lymphedema,
skin necrosis, and functional deficits.13 14
Furthermore, pain is a common symptom
associated with detriments to QoL, especially among those with CSCC for which
curative surgery is not an option.15
Cemiplimab is a high-
affinity, highly
potent, human, IgG4 monoclonal antibody to programmed cell death (PD)-1.16
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In primary analyses of the phase 2 data in patients
receiving 3 mg/kg every 2 weeks (Q2W) with mCSCC
(group 1, n=59) or laCSCC (group 2, n=78), cemiplimab demonstrated substantial antitumor activity,
emerging evidence of durable response, and an acceptable safety profile.17 18 Furthermore, the primary analysis
of patients with mCSCC receiving cemiplimab 350 mg
every 3 weeks (Q3W) (group 3, n=56) and 11-month
follow-up data of group 1 showed similar activity.19
Cemiplimab (cemiplimab-rwlc in the USA) is approved
for treatment of patients with advanced CSCC in the
USA and Europe, and is approved or under review by
other health authorities.20–22 Additionally, cemiplimab
is recommended for treatment of patients with laCSCC
and mCSCC by the European Association of Dermato-
Oncology, European Organisation of Research and Treatment of Cancer (EORTC), and National Comprehensive
Cancer Network.3 23 Cemiplimab-
rwlc is also indicated
for patients with advanced basal cell carcinoma post
hedgehog inhibitors (HHIs) or for whom HHIs are not
appropriate.20
This manuscript provides additional pooled data
from these three groups, including updated duration
of response (DOR) and complete response (CR) rates,
and describes for the first time the impact of cemiplimab
on durability of pain control and QoL. This aggregation of combined long-term data from the original study
groups represents the largest (n=193) experience with
PD-1 blockade in advanced CSCC to date, with an overall
follow-up of up to 36.1 (median 15.7) months.

METHODS
Study design
The phase 2 study is an open-
label, non-
randomized,
multicenter, international study of patients with advanced
CSCC treated with cemiplimab. The study design has
previously been published.17 19
Patients
Briefly, eligible patients were aged ≥18 years with histologically confirmed diagnosis of metastatic or unresectable
laCSCC, an Eastern Cooperative Oncology Group performance status score of 0/1, adequate organ function, and
at least one measurable lesion.
Treatment
Patients with mCSCC (group 1, n=59) or laCSCC (group
2, n=78) received cemiplimab 3 mg/kg Q2W for 96 weeks,
and patients with mCSCC received cemiplimab 350 mg
Q3W for 54 weeks (group 3, n=56), with the option to
extend treatment to 96 weeks.
Assessments
The primary efficacy endpoint was objective response rate
(ORR) per independent central review (ICR). Secondary
endpoints included ORR per investigator review (INV),
DOR and progression-free survival (PFS) per ICR and
2

INV, overall survival (OS), CR rate per ICR, safety and
tolerability, and QoL.
Durable disease control rate (DCR), defined as the
proportion of patients with response or stable disease ≥105
days, was examined. An exploratory clinical activity analysis by prior systemic therapy was performed.
The EORTC Quality of Life Questionnaire Core 30
(QLQ-C30)24 was used to evaluate the impact of cemiplimab on symptoms and functioning. The QLQ-
C30
includes Global Health Status (GHS)/QoL, functioning
domains (physical, emotional, social, role, and cognitive),
and symptoms (pain, fatigue, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss).
For GHS/QoL, this scale includes two questions (‘how
would you rate your overall health?’ and ‘how would
you rate your overall QoL?’). Participants respond on a
4-point scale from ‘not at all’ to ‘very much’ for impact
of each scale over the past week, with raw scores on all
scales linearly converted to a 0–100 scale (higher scores
reflect higher levels of functioning and higher levels of
symptom burden). The questionnaire was administered
on day 1 of each treatment cycle (treatment cycle defined
as 8 weeks for groups 1 and 2 and 9 weeks for group 3).
We analyzed longitudinal effects of cemiplimab on GHS/
QoL, functioning status, and symptoms, including pain.
Assessments per cycle or time were similar and thus are
reported in cycles. Analyses of time to first clinically meaningful improvement for pain and time to first clinically
meaningful deterioration for pain were also performed.
Safety assessments included treatment-
emergent
adverse events (TEAEs), laboratory tests, vital signs, and
physical examinations. The severity of TEAEs was graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (V.4.03).
Statistical analysis
Primary results for each group have previously been
published,17–19 and clinical activity analyses presented
here are intended to describe longer term outcomes.
There is formal hypothesis testing for the October 2019
data cut (approximately 1-year additional follow-up). For
groups 1 and 3, the null hypothesis was ORR of 15% and
the alternative hypothesis was ORR not equal to 15%. For
group 2, the null hypothesis was ORR of 25% and the
alternative hypothesis was ORR not equal to 25%.
Clinical activity analyses were performed per intention-
to-treat. Safety analyses were performed for all patients
who received at least one dose of cemiplimab at data cut-
off. QoL analyses were performed for patients included
in the full analysis set with baseline and at least one post-
baseline score for any QLQ-C30 functioning or symptom
scale/item. Descriptive statistics were used to summarize
QoL scores over time. Mixed-effects repeated measures
models (SAS V.9.4) were used to estimate mean treatment
effect (change from baseline while accounting for missing
data) for all QLQ-C30 scales and items. The models used
an AR(1) covariance structure. Covariates controlled
in the model included dose group and baseline pain
Rischin D, et al. J Immunother Cancer 2021;9:e002757. doi:10.1136/jitc-2021-002757
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Table 1 Baseline characteristics
Advanced CSCC
(N=193)
Median age, years (range)

72.0 (38–96)

Male, n (%)

161 (83.4)

Eastern Cooperative Oncology Group
performance status score, n (%)
 0

86 (44.6)

 1

107 (55.4)

Primary CSCC site: head and neck, n (%)

131 (67.9)

Metastatic CSCC, n (%)

115 (59.6)

Locally advanced CSCC, n (%)

78 (40.4)

Patients with cemiplimab as first-line
therapy, n (%)

128 (66.3)

Patients with prior systemic therapy, n (%)* 65 (33.7)
Median duration of exposure to
cemiplimab, weeks (range)

51.1 (2.0–109.3)

Median number of doses of cemiplimab
administered (range)

18.0 (1–48)

*Settings for prior lines of therapy included metastatic disease,
adjuvant, chemotherapy with concurrent radiation, or other, and
the most common types of prior systemic therapy were platinum
compounds (n=46/65 [70.8%]) and monoclonal antibodies
(n=18/65 [27.7%]).
CSCC, cutaneous squamous cell carcinoma.

score. The study visit was considered as a random effect.
Change of ≥10 points from baseline was considered clinically meaningful.25 Using this criterion, the number of
patients experiencing a clinically meaningful change at
cycle 6 and cycle 12 was evaluated, and time to the first
clinically meaningful change was assessed. Data up to
October 2019 were included in this analysis. Follow-up for
patients in groups 1–3 was ongoing following the October
2019 data cut.
RESULTS
Patients
Overall, 193 patients with advanced CSCC were eligible
for inclusion in this analysis (online supplemental
figure 1). Patient characteristics are provided in table 1
(N=193). Most patients were men (n=161, 83.4%), with
median age of 72.0 (range: 38–96) years, and had a
primary cancer site of head and neck (n=131, 67.9%).
Median duration of follow-up was 15.7 months (range:
0.6–36.1) among all patients; with 18.5 months (range:
1.1–36.1) for group 1, 15.5 months (range: 0.8–35.6)
for group 2, and 17.3 months (range: 0.6–26.3) for
group 3. Median duration of exposure was 51.1 weeks
(range: 2.0–109.3). Median number of doses was 18
(range: 1–48).
Clinical activity in the overall patient group
Overall, 89 of 193 patients had a response to therapy,
for an ORR of 46.1% (95% CI: 38.9% to 53.4%);
Rischin D, et al. J Immunother Cancer 2021;9:e002757. doi:10.1136/jitc-2021-002757

overall, 16.1% of patients achieved CR (table 2). ORR
per ICR was 50.8% (95% CI: 37.5% to 64.1%) for group
1, 44.9% (95% CI: 33.6% to 56.6%) for group 2, and
42.9% (95% CI: 29.7% to 56.8%) for group 3. Per ICR,
ORR was 48.4% in patients who had not received prior
anticancer systemic therapy (n=128) and 41.5% among
those who had (n=65). CR rates for this analysis were
20.3%, 12.8%, and 16.1% for groups 1, 2, and 3, respectively. CR rates over time (compared with primary analyses) are presented in figure 1. Among 31 complete
responders, median time to CR was 11.2 months (IQR:
7.4–14.8). ORR per INV was 54.4% (95% CI: 47.1% to
61.6%) for all patients; 50.8% (95% CI: 37.5% to 64.1%)
for group 1, 56.4% (95% CI: 44.7% to 67.6%) for group
2, and 55.4% (95% CI: 41.5% to 68.7%) for group 3.
Patients had deepening responses over time as
evidenced by increasing CR rates compared with primary
analyses17–19; the CR rate for group 1 increased from 6.8%
in the primary analysis to 16.9% in the first follow-up analysis and to 20.3% at this subsequent follow-up analysis.
For group 2, there were no CRs at the interim analysis,
but the CR rate was 12.8% at the primary analysis and was
unchanged at this follow-up analysis. For group 3, the CR
rate increased from 5.4% at the primary analysis to 16.1%
at this follow-up analysis. The median time to CR was 11.2
months.
DCR, durable DCR, median DOR, and Kaplan-Meier
12-
month estimate of DOR per ICR are provided in
table 2. With 1-year additional follow-up, median DOR was
not reached (observed DOR range: 1.9–34.3 months). In
responding patients, the estimated proportion of patients
with ongoing response at 12 months was 87.8% (95%
CI: 78.5% to 93.3%) (figure 2A). Estimated median PFS
was 18.4 months (95% CI: 10.3 to 24.3) for all patients.
The Kaplan-
Meier estimated progression-
free probability at 24 months was 44.2% (95% CI: 36.1% to 52.1%)
(figure 2B). The Kaplan-Meier estimated probability of
OS at 24 months was 73.3% (95% CI: 66.1% to 79.2%)
(figure 2C). Median OS has not been reached. Percentage
change in target lesions from baseline is shown in online
supplemental figure 2, and swimmer plots are provided in
online supplemental figure 3.
Quality of life
Patient population and baseline QoL scores
Baseline scores for QLQ-
C30 indicated generally
moderate-to-high levels of functioning and moderate-
to-low symptom burden (online supplemental table 1).
The number of patients who completed QoL assessments at each cycle is provided in figure 3 and online
supplemental table 1.
Longitudinal QoL analysis
For GHS/QoL, improvements were observed from cycle
2, with statistically significant improvement from baseline observed at cycle 3 (least squares [LS] mean [SE]
change 7.8 [1.6]; p<0.0001). Improvements in GHS/
QoL had reached the clinically meaningful threshold
3
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Table 2 Tumor response to cemiplimab per independent central review
Group 1 (mCSCC) Group 2 (laCSCC)
3 mg/kg Q2W
3 mg/kg Q2W
(n=59)
(n=78)

Group 3 (mCSCC)
350 mg Q3W
(n=56)

Total
(N=193)

Median duration of follow-up, months (range)

18.5 (1.1–36.1)

15.5 (0.8–35.6)

17.3 (0.6–26.3)

15.7 (0.6–36.1)

Objective response rate, % (95% CI)

50.8 (37.5 to 64.1)

44.9 (33.6 to 56.6)

42.9 (29.7 to 56.8)

46.1 (38.9 to 53.4)

  
Complete response

12 (20.3)

10 (12.8)

9 (16.1)

31 (16.1)*

  
Partial response

18 (30.5)

25 (32.1)

15 (26.8)

58 (30.1)

  
Stable disease

9 (15.3)

27 (34.6)

10 (17.9)

46 (23.8)

  Non-complete response/non-progressive disease

3 (5.1)

0

2 (3.6)

5 (2.6)

  
Progressive disease

10 (16.9)

10 (12.8)

14 (25.0)

34 (17.6)

  
Not evaluable

7 (11.9)

6 (7.7)

6 (10.7)

19 (9.8)

DCR, % (95% CI)

71.2 (57.9 to 82.2)

79.5 (68.8 to 87.8)

64.3 (50.4 to 76.6)

72.5 (65.7 to 78.7)

Durable DCR†, % (95% CI)

61.0 (47.4 to 73.5)

62.8 (51.1 to 73.5)

57.1 (43.2 to 70.3)

60.6 (53.3 to 67.6)

Median observed time to response, months (IQR)‡

1.9 (1.8–2.0)

2.1 (1.9–3.8)

2.1 (2.1–4.2)

2.1 (1.9–3.7)

 Median observed time to complete response, months (IQR)§

11.1 (7.5–18.4)

10.5 (7.4–12.9)

12.4 (8.2–16.6)

11.2 (7.4–14.8)
NR (28.8 to NE)

 Best overall response, n (%)

Kaplan-Meier estimated median DOR, months (95% CI)‡

NR (20.7 to NE)

NR (18.4 to NE)

NR (NE to NE)

Kaplan-Meier 12-month estimate of DOR, % (95% CI)

89.5 (70.9 to 96.5)

83.2 (64.1 to 92.7)

91.7 (70.6 to 97.8)

87.8 (78.5 to 93.3)

Kaplan-Meier 24-month estimate of DOR, % (95% CI)

68.8 (46.9 to 83.2)

62.5 (38.4 to 79.4)

NE (NE to NE)

69.4 (55.6 to 79.6)

ORR per INV was 54.4% (95% CI: 47.1% to 61.6%) for all patients; 50.8% (95% CI: 37.5% to 64.1%) for group 1, 56.4% (95% CI: 44.7% to 67.6%) for group 2,
and 55.4% (95% CI: 41.5% to 68.7%) for group 3. ORR per ICR was 48.4% (95% CI: 39.5% to 57.4%) among treatment-naïve patients and 41.5% (95% CI: 29.4%
to 54.4%) among previously treated patients.
*95% CI: 11.2 to 22.0
†Defined as the proportion of patients with objective response, stable disease, or non-complete response/non-progressive disease without progressive disease for
at least 16 weeks, measured at least 105 days to account for scheduling windows in the protocol.
‡Based on number of patients with confirmed complete or partial response.
§Based on number of patients with confirmed complete response.
DCR, disease control rate; DOR, duration of response; ICR, independent central review; INV, investigator review; laCSCC, locally advanced cutaneous squamous
cell carcinoma; mCSCC, metastatic cutaneous squamous cell carcinoma; NE, not evaluable; NR, not reported; ORR, objective response rate; Q2W, every 2 weeks;
Q3W, every 3 weeks.

(≥10-point change) by cycle 12 (LS mean [SE] change
11.1 [2.6]; p<0.0001) (figure 3). Among functioning
scales, significant improvements were observed in
emotional functioning and social functioning scales at
cycle 3 and cycle 12 (online supplemental table 1). Physical functioning, role functioning, and cognitive functioning did not deteriorate and remained stable relative
to baseline (online supplemental table 1). Regarding
symptoms, significant improvements from baseline

were also observed for symptoms of nausea/vomiting,
pain, insomnia, appetite loss, and constipation by cycle
3 (online supplemental table 1), and as early as cycle
2 for pain (figure 3). These symptoms had all reached
the clinically meaningful threshold (≥10-point change)
by cycle 12 (online supplemental table 1). Across all
functioning scales and symptom scales, the proportion
of patients with clinically meaningful deterioration was
generally low at both cycle 6 and cycle 12.

Figure 1 Complete response rates per independent central
review. †At the time of the group 1 primary analysis, a
prespecified group 2 interim analysis was performed. Among
the 23 patients with laCSCC included in this prespecified
interim analysis, there were no complete responses. laCSCC,
locally advanced cutaneous squamous cell carcinoma;
mCSCC, metastatic cutaneous squamous cell carcinoma;
Q2W, every 2 weeks; Q3W, every 3 weeks.

Early onset and durability of pain control
The Kaplan-Meier estimate of median time (95% CI)
to first clinically meaningful improvement for pain
was 2.1 (2.0 to 3.7) months overall. The Kaplan-Meier
estimate of median time (95% CI) to first clinically
meaningful deterioration for pain was 14.8 (9.2 to not
evaluable [NE]) months overall. LS mean (SE) change
from baseline in pain score was –11.5 (1.9) at cycle 3,
and –14.3 (3.1) at cycle 12 (figure 3). LS mean change
(SE) from baseline in pain score at first tumor response
was –15.2 (1.5) in patients with objective response and
–3.86 (2.1) in patients without objective response. The
difference in LS mean change (95% CI) from baseline
for pain score for responders versus non-responders
was –11.3 (–16.3 to –6.3; p<0.0001). Among patients
with objective response, the Kaplan-Meier estimate of

4

Rischin D, et al. J Immunother Cancer 2021;9:e002757. doi:10.1136/jitc-2021-002757

J Immunother Cancer: first published as 10.1136/jitc-2021-002757 on 19 August 2021. Downloaded from http://jitc.bmj.com/ on August 31, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

Probability of no progression
or death

A

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Group 1 (mCSCC) cemiplimab 3 mg/kg Q2W (n = 59)
Group 2 (laCSCC) cemiplimab 3 mg/kg Q2W (n = 78)
Group 3 (mCSCC) cemiplimab 350 mg Q3W (n = 56)
Total (N = 193)
0

2

4

Number of patients at risk
Group 1 (n = 59) 30 30 29
Group 2 (n = 78) 35 33 32
Group 3 (n = 56) 24 24 24
Total (N = 193) 89 87 85

Probability of PFS

B

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

40

16
8
0
24

16
6
0
22

16
6
0
22

10
5
0
15

9
4
0
13

6
0
0
6

2
0
0
2

0
0
0
0

0
0
0
0

0
0
0
0

Month
28
30
23
81

23
27
21
71

23
25
21
69

23
22
20
65

23
21
19
63

23
17
17
57

20
14
11
45

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

18
10
5
33

Group 1 (mCSCC) cemiplimab 3 mg/kg Q2W (n = 59)
Group 2 (laCSCC) cemiplimab 3 mg/kg Q2W (n = 78)
Group 3 (mCSCC) cemiplimab 350 mg Q3W (n = 56)
Total (N = 193)

0

2

4

Number of patients at risk
Group 1 (n = 59) 59 42 38
Group 2 (n = 78) 78 61 48
Group 3 (n = 56) 56 48 33
Total (N = 193) 193 151 119

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

40

24
16
10
50

21
12
1
34

20
10
1
31

20
7
0
27

12
5
0
17

9
5
0
14

6
2
0
8

1
0
0
1

0
0
0
0

0
0
0
0

Month
36
43
31
110

32
39
31
102

27
37
28
92

27
33
26
86

27
29
26
82

27
26
24
77

27
20
24
71

24
17
17
58

Probability of OS

C
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Group 1 (mCSCC) cemiplimab 3 mg/kg Q2W (n = 59)
Group 2 (laCSCC) cemiplimab 3 mg/kg Q2W (n = 78)
Group 3 (mCSCC) cemiplimab 350 mg Q3W (n = 56)
Total (N = 193)

0

2

4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

40

38
41
20
99

37
33
9
79

35
25
2
62

33
22
0
55

24
15
0
39

16
12
0
28

11
8
0
19

4
3
0
7

1
1
0
2

0
0
0
0

Month
Number of patients at risk
Group 1 (n = 59) 59 56 52
Group 2 (n = 78) 78 76 73
Group 3 (n = 56) 56 52 49
Total (N = 193) 193 184 174

49
67
46
162

47
65
45
157

47
65
44
156

46
64
38
148

41
62
38
141

39
59
38
136

39
54
37
130

38
44
29
111

Figure 2 Kaplan-Meier curves for (A) DOR per ICR, (B) PFS per ICR and (C) OS. DOR, duration of response; ICR, independent
central review; laCSCC, locally advanced cutaneous squamous cell carcinoma; mCSCC, metastatic cutaneous squamous cell
carcinoma; OS, overall survival; PFS, progression-free survival; Q2W, every 2 weeks; Q3W, every 3 weeks.

median time (95% CI) to first clinically meaningful
improvement for pain was 2.1 (1.9 to 2.1) months and
the Kaplan-Meier estimate of median time (95% CI) to
first clinically meaningful worsening for pain was 20.6
(9.2 to NE) months.
Responder analysis for QoL assessment
A substantial fraction of patients benefitted from treatment. Among all patients reporting clinically meaningful
Rischin D, et al. J Immunother Cancer 2021;9:e002757. doi:10.1136/jitc-2021-002757

change (≥10-point change) by cycle 6, most patients
experienced clinically meaningful improvements or
stability in GHS/QoL (83%), functioning scales (68%–
85%), and symptoms (68%–95%) (figure 4). Overall,
91% of responders experienced clinically meaningful
improvement or stability in GHS/QoL scores at cycle 12,
and most patients showed sustained improvement and
stabilization across all functioning scales (77%–86%)
5
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Safety
In total, 192 (99.5%) patients experienced at least one
TEAE of any grade regardless of attribution (online
supplemental table 2). TEAEs leading to discontinuation
were low (any grade: n=19, 9.8%; grade ≥3: n=14, 7.3%).
The most common TEAEs (all grades) were fatigue
(n=67, 34.7%), diarrhea (n=53, 27.5%), and nausea/
vomiting (n=46, 23.8%). Overall, 94 (48.7%) patients
experienced at least one grade ≥3 TEAE regardless of
attribution. The most common grade ≥3 TEAEs were
hypertension (n=9, 4.7%), anemia, and cellulitis (each
n=8, 4.1%). No new TEAEs or treatment-related adverse
events (TRAEs) resulting in death were reported for
any group in this longer term follow-up, compared with
previous reports.17–19 Grade ≥3 TRAEs were reported in
33 (17.1%) patients; the most common were pneumonitis
(n=5, 2.6%), autoimmune hepatitis (n=3, 1.6%), anemia,
colitis, and diarrhea (all n=2, 1.0%) (online supplemental
table 3). In total, 57 patients (29.5%) experienced at least
identified immune-
related adverse event
one sponsor-
(irAE) of any grade, and 18 patients (9.3%) experienced
at least one grade ≥3 irAE (online supplemental table
4). The most common grade ≥3 irAEs were pneumonitis
(n=5, 2.6%), autoimmune hepatitis (n=2, 1.0%), and
diarrhea (n=2, 1.0%).
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Figure 3 Change from baseline in (A) Global Health Status/
quality of life (GHS/QoL) and (B) pain scores. *p<0.0001. An
increase of ≥10 points from baseline is considered a clinically
meaningful improvement, while a decrease of ≥10 points from
baseline is considered a clinically meaningful deterioration.
Data are shown for day 1 of each cycle. The questionnaire
was administered on day 1 of each cemiplimab treatment
cycle (treatment cycle defined as 8 weeks for groups 1 and 2
and 9 weeks for group 3). Equivalent months are shown. QoL,
quality of life; LS, least squares.

DISCUSSION
The pooled analysis presented here demonstrates durability of responses to cemiplimab in CSCC, increasing CR
rates over time, and confirms the substantial antitumor
activity of cemiplimab in patients with advanced CSCC
established in previously published primary analyses.17–19
An estimated 87.8% of responders had not progressed at

and symptoms (74%–95%) by cycle 12 (figure 4). The
proportions of patients with clinically meaningful deterioration in functioning scales were generally low at
both evaluated time points (figure 4).
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Figure 4 Proportion of responding patients reporting clinically meaningful change (≥10-point change) at cycle 6 and cycle 12.
The questionnaire was administered on day 1 of each treatment cycle (treatment cycle defined as 8 weeks for groups 1 and 2
and 9 weeks for group 3). QoL, quality of life.

6

Rischin D, et al. J Immunother Cancer 2021;9:e002757. doi:10.1136/jitc-2021-002757

J Immunother Cancer: first published as 10.1136/jitc-2021-002757 on 19 August 2021. Downloaded from http://jitc.bmj.com/ on August 31, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

12 months. With median DOR not reached after an additional year of follow-up, the present analysis reinforces the
activity of cemiplimab in a patient population that previously had no widely accepted standard of care. Furthermore, DOR and OS are longer than has been previously
described with other agents, prior to the approval of
cemiplimab.26 Additionally, this analysis demonstrates
that cemiplimab treatment is associated with improvement in GHS/QoL and pain scores.
Compared with primary analyses,17–19 patients had deepening responses over time, as evidenced by increasing CR
rates. The median time to CR was 11.2 months, raising the
possibility that prolonged cemiplimab treatment may be
necessary for continued clinical activity in many patients
with advanced CSCC.
In the KEYNOTE-629 Study (NCT03284424), patients
(n=105; follow-up 9.5 months) with recurrent/mCSCC
were treated with pembrolizumab 200 mg Q3W.27 ORR
per ICR was 34.3% with an estimated DOR at 12 months
of 65.6%. The overall CR rate during the follow-up period
was 3.8%. It should be noted 86.7% of patients included in
KEYNOTE-629 had previously received ≥1 line of systemic
therapy, and this group achieved an ORR of 31.9%.27
Results for the laCSCC cohort in KEYNOTE-629 have not
been published. Additionally, preliminary results from
the CARSKIN trial of pembrolizumab (NCT02883556)
reported an ORR of 38.5%, a CR rate of 5.1%, and a
median DOR of 12.5 months in patients with no prior
systemic therapy.28 In the present study, acknowledging
that this may be in part due to longer follow-up, we report
a higher ORR per ICR of 46.1%, an estimated DOR at
12 months of 87.8%, and a CR rate of 16.1%. However,
given differences in trial designs, caution is required
when comparing response rates across studies. There are
no head-to-head trials assessing the comparative clinical
activity of cemiplimab and pembrolizumab.
Pain is a key issue for patients with advanced CSCC,
especially those with unresectable disease.15 The mean
(SD) baseline pain score of patients with advanced CSCC
receiving cemiplimab of 29.8 (30.4) was significantly
worse than reported by patients with advanced head
and neck cancer (24.9 [26.3]; p<0.05; n=1722) and the
general population (20.9 [27.6]; p<0.0001; n=7802).29
Here, the clinical responses observed correlated well
with pain improvement, which positively impacted
patient QoL. Cemiplimab resulted in pain reduction
by cycle 2, with clinically meaningful reduction (≥10
points) from cycle 3, maintained through to cycle 12.
The Kaplan-Meier estimate of median time (95% CI) to
first clinically meaningful improvement for pain was 2.1
months overall, and this was sustained to 14.8 months,
demonstrating durability of pain control with cemiplimab. GHS/QoL improvement was observed as early
as cycle 3, with clinically meaningful improvement seen
by cycle 12. By cycle 6, most patients experienced clinically meaningful improvement or stability in GHS/QoL
and functioning status, while maintaining low symptom
burden.
Rischin D, et al. J Immunother Cancer 2021;9:e002757. doi:10.1136/jitc-2021-002757

Eighteen patients (9.3%) experienced at least one
grade ≥3 irAE, with a low treatment discontinuation rate
of 9.8%. As previously reported,19 the safety profile for
cemiplimab continues to be consistent with that previously reported for other anti-PD-1/PD-ligand 1 agents.30
There were no new safety signals or types of toxicities
compared with previous analyses.
This analysis confirms the substantial clinical activity
of cemiplimab, including new findings of improved CR
rates over time compared with primary analyses, and an
impressive and increasing DOR based on Kaplan-Meier
estimate at key landmarks in patients with advanced
CSCC. Additionally, cemiplimab treatment resulted in a
clinically meaningful reduction in pain as early as cycle
2, maintained to cycle 12. Further, clinical response to
cemiplimab was associated with a reduction in pain. Most
patients experienced clinically meaningful improvements
or maintenance in GHS/QoL, functioning, and symptoms. These results provide further support for cemiplimab as an agent with favorable data to support its use
for the treatment of advanced CSCC.
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Supplementary Table 1. Baseline Scores and Change from Baseline (MMRM) in
Patients in the Full Analysis Set who had Baseline and Post-Baseline
Assessments on each QLQ-C30 Scale or Item
QLQ-C30 scale/item

Baseline, mean
± SD (n)

LS mean change ± SE (n)
Cycle 3

Cycle 12

65.1 ± 22.9 (150)

7.8 ± 1.6 (122)**

11.1 ± 2.6 (43)**

Physical function

80.1 ± 22.8 (151)

1.1 ± 1.3 (124)

4.0 ± 2.1 (43)

Role function

75.8 ± 30.0 (151)

0.4 ± 2.1 (123)

5.6 ± 3.4 (43)

Emotional function

80.2 ± 21.2 (151)

4.2 ± 1.3 (123)*

5.3 ± 2.2 (43)*

Cognitive function

83.4 ± 22.2 (151)

1.7 ± 1.4 (123)

2.5 ± 2.3 (43)

Social function

74.4 ± 31.8 (150)

5.3 ± 1.8 (122)*

8.6 ± 3.0 (43)*

Fatigue

30.2 ± 24.6 (152)

–2.8 ± 1.7 (125)

–4.8 ± 2.8 (43)

Nausea/vomiting

4.6 ± 12.2 (152)

–1.6 ± 0.8 (125)*

–2.9 ± 1.3 (43)*

Pain

29.8 ± 30.4 (152)

–11.5 ± 1.9 (125)**

–14.3 ± 3.1 (43)**

Dyspnea

12.9 ± 23.4 (152)

0.7 ± 1.7 (125)

1.5 ± 2.9 (43)

Insomnia

27.4 ± 28.0 (151)

–9.1 ± 2.0 (123)**

–17.4 ± 3.3 (43)**

Appetite loss

19.5 ± 29.3 (152)

–8.4 ± 1.6 (124)**

–13.7 ± 2.7 (43)**

Constipation

13.6 ± 24.1 (152)

–4.5 ± 1.5 (125)*

–11.2 ± 2.5 (43)**

Diarrhea

4.9 ± 13.6 (150)

3.6 ± 1.4 (121)*

0.6 ± 2.3 (43)

Financial difficulty

19.1 ± 30.7 (150)

0.5 ± 2.0 (122)

Global Health
Status/HRQoL
Functioning scales

Symptoms

†

‡

†

–3.4 ± 3.3 (43)
‡

*p<0.05 and **p<0.001 versus baseline. Higher scores reflect better outcomes. Lower scores reflect better
outcomes.
The questionnaire was administered on day 1 of each treatment cycle (treatment cycle defined as 8 weeks for
Groups 1 and 2 and 9 weeks for Group 3).

HRQoL, health-related quality of life; LS, least squares; MMRM, mixed-effects repeated measures models; QLQC30, European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire; SD,
standard deviation; SE, standard error.
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Supplementary Table 2. Treatment-Emergent Adverse Events
Advanced CSCC
(N=193)
n (%)

Any grade

Grade ≥3

Any TEAE

192 (99.5)

94 (48.7)

19 (9.8)

14 (7.3)

TEAEs leading to discontinuation

TEAEs of any grade reported in ≥10% of patients or Grade ≥3 TEAEs reported in at least one
†
patient
Fatigue

67 (34.7)

5 (2.6)

Diarrhea

53 (27.5)

2 (1.0)

Nausea

46 (23.8)

0

Pruritus

41 (21.2)

0

Cough

32 (16.6)

0

Rash

32 (16.6)

1 (0.5)

Arthralgia

28 (14.5)

1 (0.5)

Constipation

26 (13.5)

1 (0.5)

Vomiting

24 (12.4)

1 (0.5)

Actinic keratosis

23 (11.9)

0

23 (11.9)

1 (0.5)

Anemia

22 (11.4)

8 (4.1)

Hypothyroidism

22 (11.4)

0

Headache

21 (10.9)

0

Upper respiratory tract infection

20 (10.4)

0

Abdominal pain

17 (8.8)

1 (0.5)

Basal cell carcinoma

15 (7.8)

3 (1.6)

Dizziness

15 (7.8)

1 (0.5)

Dyspnea

15 (7.8)

3 (1.6)

Fall

15 (7.8)

3 (1.6)

Urinary tract infection

15 (7.8)

3 (1.6)

‡

Maculopapular rash

‡
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Wound infection

15 (7.8)

2 (1.0)

Hypertension

14 (7.3)

9 (4.7)

Increased blood creatine

14 (7.3)

1 (0.5)

Pain in extremity

14 (7.3)

2 (1.0)

Cellulitis

13 (6.7)

8 (4.1)

Hypokalemia

13 (6.7)

3 (1.6)

Pneumonitis

13 (6.7)

5 (2.6)

Increased aspartate aminotransferase

12 (6.2)

1 (0.5)

Skin infection

12 (6.2)

3 (1.6)

Hyperuricemia

10 (5.2)

1 (0.5)

Squamous cell carcinoma of skin

10 (5.2)

3 (1.6)

Dysphagia

9 (4.7)

2 (1.0)

Musculoskeletal pain

9 (4.7)

2 (1.0)

Pneumonia

9 (4.7)

7 (3.6)

Dehydration

8 (4.1)

3 (1.6)

Depression

8 (4.1)

2 (1.0)

Hyperglycemia

8 (4.1)

4 (2.1)

Hypotension

8 (4.1)

1 (0.5)

Neck pain

8 (4.1)

2 (1.0)

Atrial fibrillation

6 (3.1)

1 (0.5)

Delirium

6 (3.1)

1 (0.5)

Hypercalcemia

6 (3.1)

3 (1.6)

Hyponatremia

6 (3.1)

3 (1.6)

Squamous cell carcinoma

6 (3.1)

2 (1.0)

Colitis

5 (2.6)

2 (1.0)

Decreased lymphocyte count

5 (2.6)

1 (0.5)

Hematuria

5 (2.6)

2 (1.0)

Lymphopenia

5 (2.6)

3 (1.6)

Muscular weakness

5 (2.6)

2 (1.0)
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Pleural effusion

5 (2.6)

2 (1.0)

Sepsis

5 (2.6)

5 (2.6)

Tumor pain

5 (2.6)

1 (0.5)

Acute kidney injury

4 (2.1)

1 (0.5)

Decreased platelet count

4 (2.1)

1 (0.5)

Deep vein thrombosis

4 (2.1)

2 (1.0)

Hypoglycemia

4 (2.1)

1 (0.5)

Pain

4 (2.1)

1 (0.5)

Tumor hemorrhage

4 (2.1)

1 (0.5)

Autoimmune hepatitis

3 (1.6)

3 (1.6)

Confusional state

3 (1.6)

1 (0.5)

Hypophosphatemia

3 (1.6)

2 (1.0)

Increased international normalized ratio

3 (1.6)

1 (0.5)

Influenza

3 (1.6)

1 (0.5)

Polyarthritis

3 (1.6)

1 (0.5)

Soft tissue infection

3 (1.6)

1 (0.5)

Staphylococcal infection

3 (1.6)

1 (0.5)

Syncope

3 (1.6)

3 (1.6)

B-cell lymphoma

2 (1.0)

2 (1.0)

Breast cancer

2 (1.0)

2 (1.0)

Catheter site infection

2 (1.0)

1 (0.5)

2 (1.0)

2 (1.0)

Decreased neutrophil count

2 (1.0)

1 (0.5)

Fungal skin infection

2 (1.0)

1 (0.5)

Gastroenteritis

2 (1.0)

1 (0.5)

Hip fracture

2 (1.0)

2 (1.0)

Increased weight

2 (1.0)

1 (0.5)

Myocardial infarction

2 (1.0)

2 (1.0)

Esophagitis

2 (1.0)

1 (0.5)

Death

§
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Peripheral swelling

2 (1.0)

1 (0.5)

Pneumonia aspiration

2 (1.0)

1 (0.5)

Postoperative wound infection

2 (1.0)

1 (0.5)

Presyncope

2 (1.0)

1 (0.5)

Psoriasis

2 (1.0)

1 (0.5)

Pulmonary embolism

2 (1.0)

2 (1.0)

Urinary retention

2 (1.0)

1 (0.5)

Wound complication

2 (1.0)

1 (0.5)

Acute respiratory distress syndrome

1 (0.5)

1 (0.5)

Acute respiratory failure

1 (0.5)

1 (0.5)

Adjustment disorder

1 (0.5)

1 (0.5)

Angina pectoris

1 (0.5)

1 (0.5)

Arterial hemorrhage

1 (0.5)

1 (0.5)

Aseptic meningitis

1 (0.5)

1 (0.5)

Atopic dermatitis

1 (0.5)

1 (0.5)

Autoimmune dermatitis

1 (0.5)

1 (0.5)

Cardiogenic shock

1 (0.5)

1 (0.5)

Cerebral infarction

1 (0.5)

1 (0.5)

Cholecystitis

1 (0.5)

1 (0.5)

Chronic obstructive pulmonary disease

1 (0.5)

1 (0.5)

Clostridium difficile colitis

1 (0.5)

1 (0.5)

Complete atrioventricular block

1 (0.5)

1 (0.5)

Decreased white blood cell count

1 (0.5)

1 (0.5)

Device related infection

1 (0.5)

1 (0.5)

Duodenal ulcer

1 (0.5)

1 (0.5)

Encephalitis

1 (0.5)

1 (0.5)

Erysipelas

1 (0.5)

1 (0.5)

Extradural abscess

1 (0.5)

1 (0.5)

Facial neuralgia

1 (0.5)

1 (0.5)
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Fungating wound

1 (0.5)

1 (0.5)

Groin infection

1 (0.5)

1 (0.5)

Hematemesis

1 (0.5)

1 (0.5)

Hepatitis

1 (0.5)

1 (0.5)

Hypertensive crisis

1 (0.5)

1 (0.5)

Hypophysitis

1 (0.5)

1 (0.5)

Increased lipase

1 (0.5)

1 (0.5)

Influenza pneumonia

1 (0.5)

1 (0.5)

Limb abscess

1 (0.5)

1 (0.5)

Myocarditis

1 (0.5)

1 (0.5)

Nasal cavity cancer

1 (0.5)

1 (0.5)

Optic atrophy

1 (0.5)

1 (0.5)

Osteomyelitis

1 (0.5)

1 (0.5)

Pancytopenia

1 (0.5)

1 (0.5)

Pericarditis

1 (0.5)

1 (0.5)

Positive influenza A virus test

1 (0.5)

1 (0.5)

Proctitis

1 (0.5)

1 (0.5)

Psoas abscess

1 (0.5)

1 (0.5)

Pulmonary edema

1 (0.5)

1 (0.5)

Radius fracture

1 (0.5)

1 (0.5)

Renal cell carcinoma

1 (0.5)

1 (0.5)

Respiratory failure

1 (0.5)

1 (0.5)

Septic shock

1 (0.5)

1 (0.5)

Small intestinal hemorrhage

1 (0.5)

1 (0.5)

Small intestinal obstruction

1 (0.5)

1 (0.5)

Soft tissue necrosis

1 (0.5)

1 (0.5)

Subdural hematoma

1 (0.5)

1 (0.5)

Suicidal ideation

1 (0.5)

1 (0.5)

Urinary tract obstruction

1 (0.5)

1 (0.5)
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Ordered by frequency of adverse events of any grade.
Although rash and maculopapular rash might reflect the same condition, they were listed as two distinct events

for the safety report of the study.
§

The two patients with AE term of death, and other patients who experienced TEAEs leading to death have been

previously reported, and there have been no new fatal AEs since those reports (Migden NEJM 2018, Migden
Lancet Oncol 2020, Rischin JITC 2020).

1-3

AE, adverse event; CSCC, cutaneous squamous cell carcinoma; TEAE, treatment-emergent AE.
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Supplementary Table 3. Treatment-Related Adverse Events Reported in ≥5% of
Patients from the Phase 2 Study
Patients with advanced CSCC
(N=193)
n (%)

Any grade

Grade ≥3

Any TRAE

148 (76.7)

33 (17.1)

TRAEs of any grade reported in ≥5% of patients or Grade ≥3 TRAEs reported in at least one
†
patient
Fatigue

40 (20.7)

1 (0.5)

Pruritus

29 (15.0)

0

Diarrhea

24 (12.4)

2 (1.0)

Rash

23 (11.9)

1 (0.5)

Hypothyroidism

21 (10.9)

0

21 (10.9)

1 (0.5)

Nausea

18 (9.3)

0

Pneumonitis

13 (6.7)

5 (2.6)

Arthralgia

12 (6.2)

0

Increased alanine aminotransferase

12 (6.2)

0

Increased aspartate aminotransferase

11 (5.7)

1 (0.5)

Colitis

5 (2.6)

2 (1.0)

Dizziness

5 (2.6)

1 (0.5)

Vomiting

5 (2.6)

2 (1.0)

Anemia

4 (2.1)

2 (1.0)

Autoimmune hepatitis

3 (1.6)

3 (1.6)

Hypokalemia

3 (1.6)

1 (0.5)

Polyarthritis

3 (1.6)

1 (0.5)

Decreased lymphocyte count

2 (1.0)

1 (0.5)

Decreased neutrophil count

2 (1.0)

1 (0.5)

Decreased platelet count

2 (1.0)

1 (0.5)

‡

Maculopapular rash

‡
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Neck pain

2 (1.0)

1 (0.5)

Psoriasis

2 (1.0)

1 (0.5)

Autoimmune dermatitis

1 (0.5)

1 (0.5)

Aseptic meningitis

1 (0.5)

1 (0.5)

B-cell lymphoma

1 (0.5)

1 (0.5)

Confusional state

1 (0.5)

1 (0.5)

1 (0.5)

1 (0.5)

Decreased white blood cell count

1 (0.5)

1 (0.5)

Duodenal ulcer

1 (0.5)

1 (0.5)

Encephalitis

1 (0.5)

1 (0.5)

Esophagitis

1 (0.5)

1 (0.5)

Gastroenteritis

1 (0.5)

1 (0.5)

Hepatitis

1 (0.5)

1 (0.5)

Hypophosphatemia

1 (0.5)

1 (0.5)

Hypophysitis

1 (0.5)

1 (0.5)

Increased lipase

1 (0.5)

1 (0.5)

Myocarditis

1 (0.5)

1 (0.5)

Pericarditis

1 (0.5)

1 (0.5)

Pneumonia

1 (0.5)

1 (0.5)

Proctitis

1 (0.5)

1 (0.5)

Small intestinal hemorrhage

1 (0.5)

1 (0.5)

Death

†
‡

§

J Immunother Cancer

Ordered by frequency of any grade.
Although rash and maculopapular rash might reflect the same condition, they were listed as two distinct events

for the safety report of the study.
CSCC, cutaneous squamous cell carcinoma; TRAE, treatment-related adverse event.
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Supplementary Table 4. Immune-Related Adverse Events Based on SponsorProvided List

Patients with advanced CSCC
(N=193)
n (%)
Any irAE

Any grade

Grade ≥3

57 (29.5)

18 (9.3)

irAEs of any grade reported in ≥5% of patients or Grade ≥3 irAEs reported in at least one
†
patient

†

Hypothyroidism

21 (10.9)

0

Pneumonitis

12 (6.2)

5 (2.6)

Diarrhea

4 (2.1)

2 (1.0)

Colitis

3 (1.6)

1 (0.5)

Autoimmune hepatitis

2 (1.0)

2 (1.0)

Polyarthritis

2 (1.0)

1 (0.5)

Rash

2 (1.0)

1 (0.5)

Aseptic meningitis

1 (0.5)

1 (0.5)

Autoimmune dermatitis

1 (0.5)

1 (0.5)

Encephalitis

1 (0.5)

1 (0.5)

Hepatitis

1 (0.5)

1 (0.5)

Hypophysitis

1 (0.5)

1 (0.5)

Increase aspartate aminotransferase

1 (0.5)

1 (0.5)

Myocarditis

1 (0.5)

1 (0.5)

Pericarditis

1 (0.5)

1 (0.5)

Ordered by frequency of any grade.

CSCC, cutaneous squamous cell carcinoma; irAE, immune-related adverse event.
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Supplementary Figure 1. Patient Disposition in the Phase 2 Study

AE, adverse event; IV, intravenous; laCSCC, locally advanced cutaneous squamous cell carcinoma; mCSCC, metastatic cutaneous squamous cell carcinoma; Q2W, every 2
weeks; Q3W, every 3 weeks.
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Supplementary Figure 2. Percent Change in Target Lesions from Baseline per RECIST 1.1 per Independent Central Review

laCSCC, locally advanced cutaneous squamous cell carcinoma; mCSCC, metastatic cutaneous squamous cell carcinoma; RECIST 1.1, Response Evaluation Criteria in Solid
Tumors version 1.1; Q2W, every 2 weeks; Q3W, every 3 weeks.
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Supplementary Figure 3. Tumor Response in a) mCSCC Receiving Cemiplimab
3 mg/kg Q2W (Group 1), b) laCSCC Receiving Cemiplimab 3 mg/kg Q2W
(Group 2), and c) mCSCC Receiving Cemiplimab 350 mg/kg Q3W (Group 3)

laCSCC, locally advanced cutaneous squamous cell carcinoma; mCSCC, metastatic cutaneous squamous cell
carcinoma; Q2W, every 2 weeks; Q3W, every 3 weeks.
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Amendment History
Amendment 5 Global
The following table outlines the changes made to the protocol and the affected sections
Change

Sections Changed

In response to health authority guidance, added
an interim analysis for Group 2 and revised the
statistical considerations (ie, secondary
efficacy outcome measures, analysis sets,
definition of the observation period for
treatment-emergent adverse events).

Synopsis – Secondary Variables

Revised footnote “t” in Table 5 and footnote
“s” in Table 6 for clarity to emphasize that all
patients who discontinue study treatment
should enter the follow-up schedule of events,
unless there was a progression of disease or
other factors (eg, withdrawal of consent)

Section 3.2 Planned Interim Analysis
Section 8.2.2 Secondary Outcome Measures
Section 9.3.1 Full Analysis Set
Section 9.3.2. Per Protocol Set (deleted)
Section 9.5.2 Efficacy Analyses
Section 9.5.4.1 Adverse Events
Section 9.7 Interim Analysis
Table 5 Study Schedule (Screening
Treatment) for Groups 1 and 2
Table 6 Study Schedule (Screening
Treatment) for Group 3

Specified that tumor staging (according to Section 8.1 Demographic
AJCC cancer staging manual, 7th edition) will Characteristics
be collected as part of baseline characteristics
Section 20 References

and

and
and

Baseline

Clarified that use of the Canfield tracing Appendix 6 Digital Photographic Procedures
application is optional
Made editorial
consistency

changes

for

clarity and Table 6 Study Schedule (Screening and
Treatment) for Group 3
Section 8.2.1 Primary Efficacy Outcome
Measure
Section 8.2.2 Secondary Outcome Measures
Section 9.5.3 Exploratory Analyses
Appendix 8 Factors to Consider in Assessing
the Relationship of AEs to REGN2810 or
Study Conduct
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Amendment 4 Global
The following table outlines the changes made to the protocol and the affected sections
Change

Sections Changed

An exclusion criterion has been added for the Section 4.2.2 Exclusion Criteria #21
following reason:
Patients who have
previously been treated with idelalisib will be
excluded from treatment with REGN2810 as a
result of the safety findings for 3 patients with
indolent lymphoma previously treated with
idelalisib, a phosphatidylinositol 3-kinase
(PI 3-K) inhibitor, in study R1979-ONC-1504.
Following a single dose of REGN2810
monotherapy in each case, 2 patients
experienced severe stomatitis and/or skin
reactions.
The third patient experienced
myositis and myasthenia gravis after 2 doses of
REGN2810.
Additional safety guidance language added for Section 5.3.2 Study
the management of patients developing Discontinuation
stomatitis or mucositis

Treatment

Hold

or

An adverse event of special interest (AESI) has Section 7.2.3 Other Events that Require
been added to the list of AESIs:
Accelerated Reporting to the Sponsor
An irAE of any grade in a patient previously
treated with a PI 3-K inhibitor.

Amendment 3 Global
Changes to the protocol are summarized in the table below.
Change

Section Affected

The primary purpose of this amendment is to
enroll metastatic (nodal or distant) cutaneous
squamous cell carcinoma (CSCC) patients who
are dosed at 350 mg flat dose every 3 weeks
(Q3W) as Group 3. This cohort opens after the
completion of enrollment to Group 1 and
provides data in support of Q3W dosing in
CSCC patients.
Updated number of patients to up to 182 adult
patients (Group 3: 53 patients).
Primary objective, study description, schedule

Clinical Study Protocol Synopsis: Objectives,
Study Design, Study Duration, Population,
Treatments, Endpoints, Statistical Plan
Section 1.2.1 Rationale For Dose Selection
Section 2.1 Primary Objectives
Section 3.1 Study Description and Duration
Section 3.1.1 Study Groups
Section 4.1 Number of Patients Planned
Section 4.2 Patient Population
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of events, duration, treatment assignment,
primary and secondary variables, secondary
outcomes measure, follow-up, and statistical
plan of the study are revised to include the
additional group.
Additionally,
the
amendment
contains
clarifications and minor revisions suggested at
the external Steering Committee Meeting of 7
April.

Section 4.2.1 Inclusion Criteria, #2, #5
Section 5.1 Investigational Treatment
Section 5.3.1 Dose Modification
Table 2 Dose Reductions
Section 5.5 Method of Treatment Assignment
Table 6 Study Schedule (Screening and
Treatment) for Group 3
Table 7 Study Schedule: Follow-Up (After
Cycle 12 for Group 1 and Group 2 Patients, or
after Cycle 6 for Group 3 Patients)
Section 6.2.1 Unscheduled Visits
Section 6.2.2 Follow-up
Section 6.3.1 Procedures Required Only at the
Screening/Baseline Visit
Section 6.3.2 Efficacy Procedures
Section 6.3.6 Group 3 Only:
Guidance
Regarding Patients who Wish to Continue
Treatment Beyond 54 Weeks
Section 8.2.1 Primary Efficacy Outcome
Measure
Section 8.2.2 Secondary Outcomes Measure
Section 9.1 Statistical hypothesis
Section 9.2 Justification of Sample Size
Table 8 The 95% Binomial Exact Confidence
Intervals for Observed ORR in Group 1 and
Group 3 Given a Sample Size of 50 Patients
(Based on 85% Power)
Section 9.5.2 Efficacy Analyses
Section 9.6 Multiplicity Considerations
Appendix 1 Response Evaluation Criteria in
Solid Tumors: RECIST Guideline (Version
1.1)
Appendix 2 Composite Response Criteria for
Patients with Locally Advanced CSCC
Appendix 3 REGN2810 Pharmacokinetic
Sampling and Assessment Schedule
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regarding
imaging

the 3 Section 3.3.3
review Committees

Independent

Review

Added clarification for procedures if visits are Section 5.3.2
Study Treatment Hold or
missed.
Discontinuation
Removed ADA sample at the end of study Table 5 Study Schedule (Screening and
Treatment) for Groups 1 and 2, footnotes m, n,
visit.
t
Clarify when PK samples will be collected.
End of study definition added.
Updated HBV, HCV, and HIV screening at the Section 6.3.1 Procedures Required Only at the
screening/baseline visit.
Screening/Baseline Visit
Removed language “in triplicate” for ECG Table 5 Study Schedule (Screening and
recordings.
Treatment) for Groups 1 and 2, footnote f
Section 6.3.3.3 Electrocardiogram
Clarified SAEs in event of hospitalization or Section 7.1.2 Serious Adverse Event
death.
Removed the NCI-CTCAE v4.03 and clarified Section 7.2.1 Adverse Events
when AEs should be reported.
Clarified timing in the event an SAE occurs Section 7.2.2 Serious Adverse Events
after last dose of study treatment.
Clarified when to report pregnancy.

Section 7.2.3 Other events that Require
Accelerated Reporting to the Sponsor

Added text about relationship of AEs to study Section 7.3.2 Evaluation of Causality
conduct.
Updated ADA variables definitions.

Section 8.4 Anti-drug Antibody Variables

Updated title of appendix.

Appendix 8 Factors to Consider in Assessing
the Relationship of AEs to REGN2810 or
Study Procedure

Minor editorial/grammatical updates

Throughout document

Appendix 1 EORTC-QLQ-C30 (VERSION 3)
deleted. The study teams are expected to
complete QOL data per Schedules of Events.
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Amendment 2 Global
The primary purpose of this amendment is to revise the text for toxicity management.
In addition, there have been several other changes:
•

To integrate comments raised by regulatory authorities to provide a common global
protocol

•

A new section that outlines the role of study committees has been added

•

Some inclusion/exclusion criteria have been clarified

•

Some footnotes to the Study Schedule Tables have been modified

•

Description of the follow-up period has been revised

•

Clarified time points and research procedures for biopsies

•

Minor edits

Amendment 2DE
The purpose of this amendment was to incorporate the following changes and clarifications
requested by the Paul Ehrlich Institute in Germany:
•

Add baseline testing for hepatitis B virus (HBV), hepatitis C virus (HCV), and human
immunodeficiency virus (HIV)

•

Clarify exclusion criteria for active infection requiring therapy, and for known allergy
to doxycycline or tetracycline

•

Extend post treatment follow up to 5 half-lives (105 days) after the last dose of
REGN2810
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Amendment 1
The purpose of this amendment was to incorporate the following changes and clarifications
requested by the FDA:
•

Provide further justification for including patients with regional nodal metastases in
Group 1 rather than Group 2

•

Clarification of the note for patients with hepatic metastases who wish to enroll in
Group 1 (Inclusion 5, Hepatic Function)

•

Revise Table 3 to require dose reduction for grade 3 nonhematological toxicities,
grade 4 hematological toxicities, and grade 3 thrombocytopenia lasting greater than
seven days or associated with bleeding

•

Additional guidelines for administration of premedication with subsequent treatments
for patients who experience infusion-related hypersensitivity reactions that are less
than grade 3 and who plan to continue treatment

•

Language added to Appendix 3 to clarify the approach to response assessments of
externally visible tumors; a section on criteria for assessing response in extensively
ulcerated lesions has been added.

•

New language added to Appendix 7 on profile view to be obtained at baseline, and at
subsequent visits as appropriate

Other minor modifications include:
•

Clarification that patients who do not experience progressive disease will be followed
for an additional non-treatment period of up to approximately 6 months with scans
performed every 8 weeks

•

Clarification regarding concomitant medications

•

Time window added for vital signs collection

•

Follow-up visit 4 will not require PK sample collection; the list of PK variables has
been updated.
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CLINICAL STUDY PROTOCOL SYNOPSIS
Title

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to
Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell
Carcinoma

Site Locations

Up to 45 sites globally

Objectives

The primary objective of this study is to estimate the clinical benefit of REGN2810
monotherapy for patients with: metastatic (nodal or distant) CSCC, treated every 2
weeks (Group 1); or with unresectable locally advanced CSCC, treated every 2
weeks (Group 2); or with metastatic (nodal or distant) CSCC, treated every 3 weeks
(Group 3); as measured by ORR according to central review in each Group.
The secondary objectives of the study are:

•
•

To estimate ORR according to investigator review
To estimate the duration of response, progression-free survival (PFS), and
overall survival (OS) by central and investigator review

•

To estimate the complete response (CR) rate by central review

•

To assess the safety and tolerability of REGN2810

•

To assess the pharmacokinetics (PK) of REGN2810 (at select sites only)

•

To assess the immunogenicity of REGN2810
−

To assess the impact of REGN2810 on quality of life using European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30)

Exploratory Objectives (Group 2 only)
•

To explore the pharmacodynamic effects of REGN2810 in tumor biopsies
obtained at baseline, during treatment, and at progression in CSCC patients
treated with REGN2810

.
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This is a phase 2, non-randomized, 3-group, multicenter study of REGN2810 at a
dose of 3 mg/kg administered intravenously (IV) every 2 weeks (Groups 1 and 2) or
350 mg administered IV every 3 weeks (Group 3) for patients with advanced CSCC.
The study will have 3 groups. Groups 1 and 3 are for patients with metastatic
CSCC. Group 2 is for patients with unresectable locally advanced CSCC. All
patients will undergo screening procedures to determine eligibility within 28 days
prior to the initial administration of REGN2810. There is no randomization or
placebo control. After Group 1 enrollment is completed, Group 3 opens to enroll
patients who will receive 350 mg REGN2810 flat dose every 3 weeks).
After a screening period of up to 28 days, Group 1 and Group 2 patients will receive
up to twelve 56-day (8-week) treatment cycles for up to 96 weeks of treatment.
Each patient will receive 3 mg/kg REGN2810 IV on days 1, 15±3, 29±3, and 43±3
during each treatment cycle. Tumor assessments will be made at the end of each
treatment cycle. Extensive safety evaluations will occur on day 1 of each cycle, with
routine safety evaluations to be conducted at each REGN2810 dosing visit.
Group 3 patients will receive up to six 63-day (9-week) treatment cycles for up to 54
weeks of treatment. Each patient will receive 350 mg REGN2810 IV on days 1,
22±3, and 43 ±3 during each treatment cycle. Tumor assessments will be made at
the end of each treatment cycle. Extensive safety evaluations will occur on day 1 of
each cycle, with routine safety evaluations to be conducted at each REGN2810
dosing visit.
A patient will receive treatment until the treatment period (96 weeks in Groups 1 and
2; 54 weeks in Group 3) is complete, or until disease progression, unacceptable
toxicity, withdrawal of consent, or confirmed CR. Group 1 and 2 patients with
confirmed CR after a minimum of 48 weeks of treatment may elect to discontinue
treatment and continue with all relevant study assessments (eg, efficacy
assessments). Patients in all groups who do not experience progressive disease (PD)
will be followed for an additional nontreatment period of up to approximately 6
months with scans performed every 8 weeks.

Study Duration

Screening (up to 4 weeks), up to 96 weeks of treatment in Groups 1 and 2 (up to 54
weeks of treatment in Group 3), and up to 6 months of follow-up.

Population
Sample Size:

Up to 182 adult patients (Group 1, 53 patients; Group 2, 76 patients; Group 3, up to
53 patients) are planned to enroll.

Target Population:

Patients with metastatic CSCC or with unresectable locally advanced CSCC.

Treatments
Study Drug
Dose/Route/Schedule:

Groups 1 and 2: REGN2810 3 mg/kg administered IV over 30 minutes every
14 days for up to 96 weeks.
Group 3: REGN2810 350 mg IV over 30 minutes every 21 days for up to 54 weeks.
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Variables
Primary:

The primary efficacy endpoint for this study is ORR according to central review
during the 12 treatment cycles (Groups 1 and 2) or 6 treatment cycles (Group 3).
Overall response rate will be assessed separately for patients with metastatic CSCC
or unresectable locally advanced CSCC:

•

•

Secondary:

For patients in Group 1 and Group 3, RECIST version 1.1 will be used
to determine ORR. For Group 1 and Group 3, patients in which all
response assessments are performed on radiologic scans according to
RECIST 1.1, the determination of the independent radiologic response
assessment committee will serve as the central response assessment.
Clinical or composite response criteria may be used for patients with
externally visible target lesions, if all metastatic lesions are not
measureable by RECIST (such as may occur in patients with bone-only
metastases).
For patients in Group 2, clinical response criteria will be used to
determine ORR, for externally visible tumor(s) require bidimensional
measurements according to World Health Organization (WHO)
criteria. Composite response criteria will be used for patients who
have both target lesions measurable by clinical response criteria and by
RECIST 1.1 to determine ORR. In patients achieving a CR, tumor
biopsies will be used in the final determination of complete versus PR.

The secondary efficacy outcome measures are:

•
•
•
•
•
•
•
•
•

ORR for Group 1, Group 2, and Group 3 by investigator review
Duration of response
PFS
OS
CR rate
Change in scores of patient-reported outcomes on EORTC QLQ-C30
Adverse events (AEs)
REGN2810 concentrations in serum (at select sites)
Anti-REGN2810 antibodies

Exploratory Endpoint
The following exploratory analyses are planned:

•
•

•
•
•

Fold-change in mRNA expression of genes expressed in tumor tissue
Percent change in number of TILs (CD8+ T cells, CD4+ T cells,
T regulatory cells, and tissue permitting, other subtypes such as B cells,
myeloid-derived cells, NK cells, etc) and descriptive change in distribution
of TILs in respect to tumor tissue and stroma
Percent change in expression levels (mRNA and/or protein) of PD-L1,
GITR, and LAG-3, and possibly other check-point modulators
Change in number and type of genetic mutations in known oncogenes and
potential tumor neoantigens
Change in tumor mutation burden
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Tumor imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
and digital medical photography (for externally visible lesions) will be performed to
measure tumor burden and to characterize the efficacy profile of study treatments
using response criteria.
Physical examination, laboratory tests, vital signs, electrocardiogram (ECG),
pregnancy test for women of childbearing potential, and recording of AEs and
concomitant medications will be performed to ensure patient safety and to
characterize the safety profiles of study treatments.
Other assessments will include:

•
•
•
•
Statistical Plan

Peripheral blood samples for PK
Peripheral blood samples to assess anti-REGN2810 antibodies
Tumor biopsies
Quality of life assessments

The sample sizes for each group were selected such that the lower limit of the 95%
confidence intervals of the estimated ORRs will be clinically meaningful. The nonclinically meaningful ORR of 15% for Group 1 and Group 3 will be excluded using
the lower limit of 95% CI if the observed ORR is 28.0% or more. For Group 1 and
for Group 3, 50 patients (in each group) will be required to provide at least 85%
power to reject a null hypothesis. Although Group 1 and 3 have same statistical
assumptions, efficacy in each group is analyzed independently. For Group 2, 72
patients will be required to provide at least 90% power to reject a null hypothesis.
The non-clinically meaningful ORR of 25% for Group 2 will be excluded using the
lower limit of 95% CI if the observed ORR is 36.1% or more. The sample sizes will
be further increased by 5% to account for patients who withdraw prematurely from
the study. Hence, the total sample sizes will be 53 patients for Group 1, 76 patients
for Group 2, and 53 patients for Group 3, for up to 182 patients.
Demographic and baseline characteristics will be summarized descriptively by group
and extent of prior therapy.
The primary endpoint for efficacy analyses is the ORR, by central review. For
Group 1 and Group 3 patients in which all response assessments are done by
RECIST 1.1 analysis of radiologic scans, the independent radiology review is the
central review. For Group 2 patients (and some Group 1 and Group 3 patients),
response assessments include photos and radiologic scans, and the independent
composite review committee will serve as the central review. The investigatorassessed ORR will be considered as a secondary analysis. Patients who are deemed
as not evaluable according to RECIST 1.1 or inevaluable by the composite efficacy
criteria will be considered as not reaching PR/CR for ORR.
The primary analyses of efficacy are based on the exact binomial confidence interval
approach, ie, whether the lower limit of 95% confidence interval will exclude a
historical control ORR that is not deemed clinically meaningful for each group,
respectively. The secondary analyses of efficacy as measured by duration of
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response, duration of disease control, PFS, and OS will be summarized by median
and its 95% confidence interval using the Kaplan-Meier method.
The quality of life of patients will be repeatedly measured by the EORTC QLQ-C30
at the day 1 of each treatment cycle. The change in scores of QLQ-C30 will be
summarized descriptively at each post-baseline time point. The summary scores of
QLQ-C30 will also be graphically depicted by longitudinal plots.
Safety observations and measurements including drug exposure, AEs, laboratory
data, vital signs, and Eastern Cooperative Oncology Group (ECOG) performance
status will be summarized and presented in tables and listings.
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LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
ADA

Anti-drug antibody

ADL

Activities of Daily Living

AE

Adverse event

AESI

Adverse event of special interest

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

ANA

Antinuclear antibody

ANC

Absolute neutrophil count

aPTT

Activated partial thromboplastin time

AST

Aspartate aminotransferase

AUC

Area under the concentration–time curve

BAL

Bronchoalveolar lavage

BCC

Basal cell carcinoma

BUN

Blood urea nitrogen

CR

Complete response

CRC

Central Review Committee

CRF

Case report form (electronic or paper)

CRO

Contract research organization

CRP

C-reactive protein

CSCC

Cutaneous squamous cell carcinoma

CT

Computed tomography

CTLA-4

Cytotoxic T-lymphocyte antigen 4

EC

Ethics committee

ECG

Electrocardiogram

ECOG

Eastern Cooperative Oncology Group

EDC

Electronic data capture

EGFR

Epidermal growth factor receptor

EORTC
QLQ-C30

European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30

EOS

End of study

FAS

Full analysis set

FDG-PET

18

FIH

First-in-human

FFPE

Formalin-fixed, paraffin-embedded

GCP

Good clinical practice

F-fluorodeoxyglucose positron emission tomography
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GITR

Glucocorticoid-induced TNFR family related gene

GnRH

Gonadotropin-releasing hormone

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HIV

Human immunodeficiency virus

HNSCC

Head and neck squamous cell carcinoma

HPV

Human papillomavirus

ICF

Informed consent form

ICH

International Council for Harmonisation

IDMC

Independent Data Monitoring Committee

INR

International Normalized Ratio

irAE

Immune-related adverse event

IRB

Institutional Review Board

irRC

Immune-related response criteria

IUD

Intrauterine device

IV

Intravenous

IWRS

Interactive Web Response System

LAG-3

Lymphocyte activation gene-3

LD

Longest diameter

LDH

Lactate dehydrogenase

LDL

Low-density lipoprotein

LLOQ

Lower limit of quantification

mAb

Monoclonal antibody

MedDRA

Medical Dictionary for Regulatory Activities

MRI

Magnetic resonance imaging

NCCN

The National Comprehensive Cancer Network

NCI-CTCAE

National Cancer Institute-Common Terminology Criteria for Adverse Events

NSCLC

Non–small-cell lung cancer

ORR

Overall response rate

OS

Overall survival

PD

Progressive disease

PD-1

Programmed death-1 (receptor)

PD-L1, PD-L2

Programmed death ligand 1, programmed death ligand 2

PET

Positron-emission tomography

PFS

Progression-free survival

PI 3-K

phosphatidylinositol 3-kinase

PK

Pharmacokinetic
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RCC

Renal cell cancer

RECIST

Response Evaluation Criteria in Solid Tumors

Regeneron

Regeneron Pharmaceuticals, Inc.

RF

Rheumatoid factor

SAE

Serious adverse event

SAF

Safety analysis set

SAP

Statistical analysis plan

SAS

Statistical Analysis Systems (software)

SOC

System organ class

SSC

Study Steering Committee

TEAE

Treatment-emergent adverse event

TIL

Tumor-infiltrating lymphocytes

TSH

Thyroid-stimulating hormone

US

United States

WBC

White blood cell
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1.

INTRODUCTION AND RATIONALE

1.1.

Introduction

Cutaneous squamous cell carcinoma (CSCC) is the second most common malignancy in the
United States (US), with approximately 186,000 to 420,000 individuals diagnosed with CSCC
each year (Karia 2013). Precise incidence and mortality measurements are not available because
these cancers are not included in the Surveillance, Epidemiology, and End Results (SEER)
database. A review of other national databases indicates that incidence of non-melanoma skin
cancers, mostly basal cell carcinoma (BCC) and CSCC, approximately doubled between
1994 and 2006 in the context of an aging population (Rogers 2010). Most CSCC patients have a
favorable prognosis, but annual mortality is approximately 3,900 to 8,800 deaths in the US
(Karia 2013). Risk factors for CSCC include UV exposure, advanced age, and
immunosuppression (Alam 2001, Madan 2010). Although the vast majority of individuals with
diagnosis of CSCC or BCC have a very favorable prognosis, CSCC has a greater propensity for
aggressive recurrences than BCC. Individuals diagnosed with CSCC, unlike those diagnosed
with BCC, have an increased mortality compared with age-matched controls (Rees 2015).
In the American Joint Committee on Cancer 7th Edition Staging System, tumor size less than or
greater than 2 cm is a key distinction between stage 1 and 2, and selected risk factors are also
incorporated in the staging (Farasat 2011). Stage 3 designates CSCC with involvement of a
single lymph node ≤3cm, and stage 4 includes patients with a broad range of locally invasive
tumors and/or distant metastatic disease (Farasat 2011). Limitations of this staging system
include heterogeneity of outcomes in stage I and II tumors; alternative risk-adapted staging has
been proposed but not externally validated (Karia 2014).
Surgical resection is the centerpiece of clinical management of CSCC. The primary goal is
complete resection of cancer, and acceptable cosmetic outcome is a secondary goal
(Madan 2010). The choice of surgical intervention is influenced by a number of factors,
including size and histology of the tumor, expertise of the local clinical team, and comorbidities
of the patient. Factors associated with poor prognosis in CSCC include tumor size >2 cm, tumor
depth >2mm, perineural invasion, host immunosuppression, and recurrent lesions (Madan 2010,
Schmults 2013).
Efficacy for radiation therapy for CSCC has been described in the adjuvant setting in a large
retrospective study of 167 patients with nodal involvement who underwent surgical resection.
Patients undergoing post-operative radiation therapy had a lower rate of locoregional recurrence
compared to those who underwent surgery only (20 vs. 43%), and superior 5-year overall
survival (OS) (73% vs. 54%) of CSCC (Veness 2005). In a small prospective phase 1 study of
15 CSCC patients who received post-operative radiation (60 to 66 Gy for 6 weeks) with
concurrent erlotinib, the 2 year OS was 65% (Heath 2013).
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For the small percentage of patients who develop unresectable locally recurrent or metastatic
disease, treatment options are limited. A phase 2 prospective study of 14 patients with
unresectable or inoperable CSCC treated with platinum based-chemoradiation, reported in
abstract form only, found that OS at 3 years was 54% (Nottage 2012). In a single institution
retrospective case series of 12 patients with unresectable CSCC that were treated with radiation
therapy (median dose 60 Gy in 30 fractions) and concurrent cetuximab, median OS was
8 months (Samstein 2014). Durable disease control was achieved in some patients, and this
retrospective study also reviewed other reports of CSCC treated with chemoradiotherapy (case
reports, case series) in the literature, in which some patients experienced long term disease
control (Samstein 2014). These results underscore that for patients with unresectable advanced
CSCC, the malignancy is a life-threatening condition but some patients may achieve durable
disease control with radiation-based therapy. As such, radiation-based therapy is appropriately
considered for some patients with unresectable CSCC.
Regarding systemic therapies, there have been single-arm studies that often contained
heterogeneous groups of CSCC patients with different stages of disease, but none of these
studies clearly demonstrated therapeutic advantage (Maubec 2011, Nakamura 2013). As a result,
there is a dearth of data to guide clinical decision-making for oncologists who take care of
patients with advanced CSCC. The National Comprehensive Cancer Network (NCCN)
guidelines do not provide firm recommendations. Cisplatin monotherapy, cisplatin plus
5-fluororucacil (5-FU), and cetuximab are discussed only as “possible options,” and participation
in clinical trials is recommended with the caveat that such trials are scarce (Bichakjian 2015).
One factor that has prevented the adoption of a standard-of-care for advanced CSCC is the lack
of an adequate demonstration of safety of any regimen for this patient population. Two
frequently-cited studies of cisplatin + 5-FU-based chemotherapy enrolled 14 and 7 advanced
CSCC patients, respectively, and therefore were unable to provide a meaningful safety
assessment (Sadek 1990, Khansur 1991). A more comprehensive description of the safety profile
of cisplatin + 5-FU was obtained in a large randomized clinical trial for a different patient
population, head and neck squamous cell carcinoma (HNSCC). Among 215 patients with a
median age of 57 years who were treated with cisplatin + 5-FU for advanced HNSCC, 76%
experienced Grade 3 or 4 toxicities. Given that CSCC occurs in an older patient population
(Gray 1997, Diffey 2005, Karia 2014), the lack of optimization of dose and schedule of cisplatin
and 5-FU for older individuals is a practical limitation to the clinical use of these regimens in
CSCC. Advanced age increases the probability of requirement for dose reduction in the first
cycle of chemotherapy among patients with advanced solid tumors (Gajra 2015). As such,
platinum and/or 5-FU-based chemotherapy is not an attractive option for many CSCC patients
due to safety and tolerability concerns associated with advanced age.
Targeting of the epidermal growth factor receptor (EGFR) in CSCC has been explored by several
groups. In a phase 2 study of cetuximab monotherapy for patients with unresectable squamous
cell carcinoma of the skin, median age was 79 years (Maubec 2011). The observed response rate
was 28% (10/36 patients), median progression-free survival (PFS) was 4.1 months, and median
OS was 8.1 months (Maubec 2011). A phase 2 study of panitumumab enrolled 16 patients with
advanced CSCC that was deemed incurable; 2 patients had metastatic disease (Foote 2014).
Overall response rate (ORR) was 31% (95% CI: 11-59%). These studies of EGFR-targeting
monoclonal antibodies share some of the same limitations of the studies of cytotoxic
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chemotherapy that were noted above, including small sample size and lack of demonstration of
benefit in quality of life.
A review of the published literature for systemic therapy for CSCC demonstrates that response
rates appear to be associated with extent of disease. Table 1 includes only studies with a least
20 evaluable patients with advanced CSCC. Response rates for locally advanced (primary site)
tumors are generally higher than response rates for tumors that have metastasized to regional
lymph nodes or distant visceral sites. As such, in prospective clinical research for patients with
advanced CSCC, it is appropriate to evaluate patients with locally advanced CSCC as a distinct
group, and combine patients with nodal or distant visceral metastatic disease as another distinct
group, such as has been done in pivotal trials in basal cell carcinoma (Sekulic 2012,
Migden 2015). Caveats regarding the response rates in Table 1 are that the response assessment
criteria for externally visible lesions were not described in the rigorous manner of contemporary
studies in non-melanoma skin cancer (Sekulic 2012, Migden 2015), and central review was only
applied in the cetuximab study (Maubec 2011). With these caveats, a key observation from these
studies is that patients with disease that has metastasized to lymph nodes or distant sites have
response rates that are lower than those achieved in patients with disease that has remained
localized at the primary site.
Table 1:

Study
1
2
3
4
5
All

Systemic Therapy for Advanced Cutaneous Squamous Cell Carcinoma

Regimen
Peplomycin (Ikeda 1986)
Cis-retinoic acid+ interferon α +
cisplatin (Shin 2002)
Irinotecan (Ikeda 1993)
Cis-retinoic acid + interferon α
(Lippman 1992)
Cetuximab (Maubec 2011)
Total (all patients in Studies 1–
5)

N
86

Response Rate, percent (number of
responses/total evaluable lesions)
Metastatic,
Nodal and
Overall
Primary
Distant
68 (50/73)a
19 (5/26)a
62 (53/86)a

35

34 (12/35)

67 (8/12)

17 (4/23)

34

41 (14/34)

38 (10/26)

50 (4/8)

28

68 (19/28)

93 (13/14)

43 (6/14)

36

28 (10/36)

35 (6/17)

21 (4/19)

219

49 (108/219)

61 (87/142)

26 (23/90)

a

Response was assessed for each individual lesion on the peplomycin study. Some patients had more than 1 lesion
assessed. Therefore, the number of response assessments is greater than the number of patients in the peplomycin
study.
Adapted from Nakumura 2013

1.1.1.

Blockade of the PD-1 Checkpoint with REGN2810

Under chronic stimulation, T cells lose proliferative and effector function capacity, often due to
signal down-modulation via the increased expression of proteins such as programmed cell
death-1 (PD-1), an inhibitory checkpoint receptor of the CD28 receptor family. Blockade of the
PD-1/PD-L1 T-cell checkpoint pathway is an effective and well tolerated approach to stimulating
the immune response, and has achieved significant objective responses in advanced melanoma,
renal cell cancer (RCC), non-small-cell lung cancer (NSCLC), and other solid tumors
(Postow 2015).
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REGN2810 is a high-affinity, fully human, hinge-stabilized IgG4P antibody directed to the
PD-1 receptor that potently blocks the interaction of PD-1with its ligands, PD-L1 and PD-L2
(See the Investigator’s Brochure for further details of nonclinical pharmacology and antitumor
activity of REGN2810). REGN2810 is currently undergoing evaluation in the first-in-human
(FIH) study R2810-ONC-1423 (NCT02383212). It is a phase 1, open-label, multicenter repeatdosing study of REGN2810, alone and in combination with other anti-cancer therapies in
patients with advanced malignancies, and contains both dose escalation and expansion cohorts.

1.2.

Rationale

1.2.1.

Rationale for Dose Selection

For Groups 1 and 2: As of 12 September 2015, 53 patients have been enrolled in study R2810ONC-1423 in 8 dose escalation cohorts, including 3 monotherapy cohorts (1 mg/kg, 3 mg/kg,
10 mg/kg REGN2810 administered intravenously [IV] every 2 weeks [Q2W]) and 5 combination
therapy cohorts (3 mg/kg REGN2810 administered IV Q2W in combination with various
combinations of hypofractionated radiation therapy or cyclophosphamide). No dose-limiting
toxicities have been observed. The dose escalation portion of the study established that 3 mg/kg
REGN2810 administered IV over 30 minutes Q2W is the recommended monotherapy dosing
regimen for the agent in further studies for advanced cancer patients.
For Group 3: This REGN2810 dose of 350 mg every 3 weeks (Q3W) was chosen for Group 3
based on the safety and preliminary anti-tumor activity observed in the ongoing FIH study
R2810-ONC-1423 (NCT02383212), and was supported by modeling of REGN2810 exposure in
serum based on data collected in the FIH study. Simulations of REGN2810 exposure in
1000 patients using population pharmacokinetic (PK) analyses indicated that: 1) the variability in
REGN2810 exposure (CV%) was similar with body weight adjusted as compared to fixed doses;
therefore, supporting the fixed dose selection, and 2) that a 350 mg Q3W dose resulted in similar
(≤20% difference) Ctrough, AUC12W and Cmax as compared to a 3 mg/kg Q2W dose used in the
FIH study. These REGN2810 concentrations exceed those observed at the 1 mg/kg Q2W dose,
and demonstrated clinical efficacy in the FIH study. At the 350 mg Q3W dose, Ctrough values at
steady state generally exceed concentrations of approximately 5 mg/L to 20 mg/L, above which
(based on animal data) saturation of PD-1 target occupancy is expected to occur. Therefore, the
350 mg Q3W dose of REGN2810 is being proposed in Group 3 and in new phase 2 and phase 3
studies across the REGN2810 program.
1.2.2.

Rationale for Study of REGN2810 in CSCC

The central role of sun exposure in the pathogenesis of CSCC is evident at the molecular and
cellular level. Most somatic mutations in CSCC tumors are C > T transitions, consistent with UV
damage (Durinck 2011, Pickering 2014, Li 2015). The total mutation burden of CSCC is
approximately 30 to 60 per megabase, compared with approximately 13 per megabase in
malignant melanoma, which is the tumor type with the highest mutation burden in The Cancer
Genome Atlas (Durinck 2011, Pickering 2014, Li 2015). Pre-clinical studies suggest that UV
light may also be carcinogenic due to incompletely understood immunosuppressive effects
(Fisher 1982, Moodycliffe 2000), in addition to mutagenicity.
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Cutaneous squamous cell carcinoma has several clinical and biological factors that suggest that it
is appropriate for the clinical study of inhibition of the PD-1 immune checkpoint: high mutation
burden (Pickering 2014), presence of tumor-infiltrating lymphocytes (TILs) (Muhleisen 2009,
Freeman 2014), association with immunosuppression as a risk factor (Euvrard 2003), evidence of
direct immunosuppressive effects of UV radiation (Yu 2014), and some clinical efficacy with
interferon α2a-based treatment (Lippman 1992).
The presence of high mutation burden appears to be a shared characteristic of other solid tumors
for which inhibition of the PD-1/PD-L1 axis has been associated with therapeutic efficacy,
including melanoma, NSCLC, and bladder cancer (Alexandrov 2013). Among NSCLC patients
treated with pembrolizumab, emerging clinical data suggest a direct correlation between
mutation burden and clinical efficacy of PD-1 inhibition (Rizvi 2015). Preliminary clinical
results from a phase 2 study of pembrolizumab for patients with advanced solid tumors that are
hypermutated due to mismatch repair deficiency demonstrates that overall radiographic response
rates are approximately 60% (Le 2015).
Taken together, these observations suggest that PD-1 inhibition may also achieve robust efficacy
against CSCC. In the ongoing phase 1 study of REGN2810 for patients with advanced solid
tumors (NCT02383212), evidence of biologic activity has been seen in the first cohort of
REGN2810 monotherapy (1 mg/kg, administered IV every 2 weeks). A partial response (PR)
was observed in a 52-year-old man with unresectable recurrent CSCC at the first tumor
assessment after his first 4 doses of REGN2810, and was confirmed after 8 doses (the patient is
still receiving treatment and PR has been maintained for 20+ weeks as of 18 Sep 2015). This
patient has an extensive prior history of surgery, systemic therapy, and radiation therapy for
recurrent disease for over 13 years. Additionally, a recent case report described a dramatic
response to pembrolizumab (off-label use) in a male with recurrent unresectable CSCC
(Chang 2015).

2.

STUDY OBJECTIVES

2.1.

Primary Objectives

The primary objective of this study is to estimate the clinical benefit of REGN2810 monotherapy
for patients with: metastatic (nodal or distant) CSCC, treated Q2W (Group 1); or with
unresectable locally advanced CSCC, treated Q2W (Group 2); or with metastatic (nodal or
distant) CSCC, treated Q3W (Group 3); as measured by ORR (see Appendix 1 and Appendix 2)
according to central review in each Group.

2.2.

Secondary Objectives

The secondary objectives for Group 1, Group 2, and Group 3 are:
•

To estimate ORR (see Appendix 1 and Appendix 2) according to investigator review

•

To estimate the duration of response, PFS, and OS by central and investigator review

•

To estimate the complete response (CR) rate by central review

•

To assess the safety and tolerability of REGN2810
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•

To assess the PK of REGN2810 (at select sites only)

•

To assess the immunogenicity of REGN2810

•

To assess the impact of REGN2810 on quality of life using European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-C30)

Exploratory Objective (Group 2 only)

To explore the pharmacodynamic effects of REGN2810 in tumor biopsies obtained at baseline,
during treatment, and at progression in CSCC patients treated with REGN2810

3.

STUDY DESIGN

3.1.

Study Description and Duration

This is a phase 2, non-randomized, 3-group, multicenter pivotal trial evaluating the efficacy and
safety of REGN2810 in patients with advanced CSCC. After a screening period of up to
28 days, patients in Groups 1 and 2 will receive up to twelve 56-day (8-week) treatment cycles
for a total of up to 96 weeks of treatment. Each patient will receive 3 mg/kg REGN2810 IV on
days 1, 15±3, 29±3, and 43±3 during each treatment cycle. Tumor assessments will be made at
the end of each treatment cycle. Extensive safety evaluations will occur on day 1 of each cycle;
routine safety evaluations will be conducted at each REGN2810 dosing visit.
Group 1 and Group 2 patients will receive treatment until the 96-week treatment period is
complete, or until disease progression, unacceptable toxicity, withdrawal of consent, or
confirmed CR. Patients with confirmed CR after a minimum of 48 weeks of treatment may elect
to discontinue treatment and continue with all relevant study assessments (eg, efficacy
assessments). Patients who do not experience progressive disease (PD) will be followed for an
additional nontreatment period of up to approximately 6 months (see Table 7) with scans
performed every 8 weeks.
Group 2 patients: Biopsies are obtained at baseline and cycle 1 day 29. Biopsies at progression
are strongly encouraged. Additional biopsies may be obtained at baseline and at response
assessments to clarify malignant versus benign status of indeterminate-appearing tissue, at the
discretion of the investigator (Appendix 5).
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Group 3 patients: This cohort enrolls patients with metastatic CSCC. Group 3 only begins
enrollment after completion of enrollment to Group 1. The regimen is a 350 mg flat dose Q3W
for up to 54 weeks. Patients will receive treatment until the 54-week treatment period is
complete, or until disease progression, unacceptable toxicity or withdrawal of consent. Patients
who do not experience PD will be followed for an additional nontreatment period of up to
approximately 6 months (see Table 6), with scans performed every 8 weeks. No research
biopsies are required.
3.1.1.

Study Groups

There will be 3 study groups:
•

Group 1: Patients with metastatic CSCC. These patients are required to have CSCC
metastases. Group 1 includes patients with both nodal metastatic and distant
metastatic disease.

•

Group 2: Patients with unresectable locally advanced CSCC. These patients are
required to have disease that is considered inoperable or to have medical
contraindication to surgery or radiation, or have not achieved disease control with
these treatments (see Section 4.2.1).

The study populations in Group 1 and Group 2 include patients with both unresectable and
metastatic CSCC, which is conceptually similar to the enrollment of patients with unresectable or
metastatic melanoma in immunotherapy trials (Larkin 2015). The decision to analyze separate
cohorts for patients with locally advanced (Group 2) and metastatic (Group 1) disease is based
on a literature review of the reported experiences with other systemic therapies in CSCC, which
demonstrates that response rates for various chemotherapy regimens generally are higher against
advanced primary tumors that are locally advanced than against tumors that have metastasized to
lymph nodes or distant visceral organs (Nakamura 2013). This observation of higher response
rates in locally advanced versus metastatic patients is also seen in data from studies of
Smoothened inhibitors against basal cell carcinoma, the most common non-melanoma skin
cancer (Sekulic 2012, Migden 2015).
Note in clarification: For patients with in-transit metastases (Carucci 2004), if the baseline
comprehensive work-up confirms that there are no nodal metastases or distant metastases, the
patient will be deemed to have locally advanced disease and would be enrolled in Group 2.
Patients with in-transit metastases are typically managed by a multidisciplinary team
(Carucci 2004), and, therefore, the multidisciplinary review regarding potential surgery or
radiation therapy options that is required prior to study enrolment for all Group 2 patients is
appropriate for patients with in-transit metastases.
•

Group 3: This cohort opens after the completion of enrollment to Group 1, and is for
patients with metastatic CSCC. As was the case for Group 1 patients, Group 3
patients are required to have metastatic disease). As in Group 1, Group 3 includes
patients with both nodal metastatic and distant metastatic disease. Group 3 patients
receive 350 mg REGN2810 Q3W for up to 54 weeks (whereas patients in Groups 1
and 2 received 3 mg/kg REGN2810 Q2W for up to 96 weeks).

Histologic confirmation of CSCC is required for all patients (Groups 1, 2, and 3), as per
inclusion criterion 13 in Section 4.2.1.
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End of Study Definition

The end of study for Group 1 and 2 patients is approximately 6 months from the completion of
96 week treatment period. The end of study for Group 3 patients is approximately 6 months
from the completion of 54 week treatment period.

3.2.

Planned Interim Analysis

At the time of the planned efficacy analysis for Group 1 (6 months after last patient, first dose),
an interim analysis of Group 2 patients will be performed in order to assess the risks and benefits
of REGN2810 in unresectable locally advanced CSCC. This analysis will be restricted to Group
2 patients with potential for adequate follow-up, defined as patients who have the opportunity to
receive approximately 9 months of study treatment at the time of the interim analysis. This
analysis will provide an ORR (with 95% confidence interval) for Group 2 patients with adequate
follow-up.

3.3.

Study Committees

3.3.1.

Independent Data Monitoring Committee

An Independent Data Monitoring Committee (IDMC) composed of members who are
independent from the sponsor and the study sites will be established to monitor patient safety by
conducting formal reviews of accumulated safety data.
The IDMC will provide the sponsor with appropriate recommendations on the conduct of the
clinical study to ensure the protection and safety of the patients enrolled in the study, per IDMC
charter.
3.3.2.

Study Steering Committee

A Study Steering Committee (SSC) will be appointed by Regeneron Pharmaceuticals, Inc.
(Regeneron), comprising approximately 3 to 7 investigators participating in the trial and
Regeneron representatives from the study team. The SSC will ensure transparent management of
the study according to the protocol through recommending and approving modifications as
circumstances require. The SSC will review protocol amendments as appropriate. Together with
the study team, the SSC will also develop recommendations for publications of study results
including authorship rules. The details of the role of the steering committee will be defined in a
steering committee charter.
3.3.3.

Independent Review Committees

Three Independent Review Committees will be established to assess the primary endpoint of
response rate by central review: independent radiologic response assessment committee,
independent photographic response assessment committee, and independent composite response
assessment committee. Committee members will follow charters that are established for each of
these committees.
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4.

SELECTION, WITHDRAWAL, AND REPLACEMENT OF
PATIENTS

4.1.

Number of Patients Planned

Up to 182 adult patients (Group 1, 53 patients; Group 2, 76 patients; Group 3, 53 patients) are
expected to be enrolled at approximately 45 sites globally.

4.2.

Study Population

The study will include eligible patients with metastatic (nodal and/or distant) CSCC (Group 1
and Group 3) and unresectable locally advanced CSCC (Group 2). Group 3 for metastatic CSCC
opens only after enrollment to Group 1 is complete.
4.2.1.

Inclusion Criteria

A patient must meet the following criteria to be eligible for inclusion in the study:
1. Histologically confirmed diagnosis of invasive CSCC.
Notes on tumor primary site: Patients for whom the primary site of squamous cell
carcinoma was the dry red lip (vermillion) are not eligible. Patients with tumors arising
on the cutaneous hairbearing (non-glabrous) lip with extension onto dry red lip
(vermillion) may be eligible after communication with and approval from medical
monitor. Patients for whom the primary site of squamous cell carcinoma was the
anogenital area (penis, scrotum, and perianal region) are not eligible. Patients for whom
the primary site is nose are only eligible if the investigator is able to establish
unambiguously that the primary site was skin, not nasal mucosa with outward extension
to skin.
Notes on tumor histology: Patients with mixed histologies (eg, sarcomatoid,
adenosquamous) generally will not be eligible. Patients with mixed histology in which
the predominant histology is invasive CSCC (with only a minimal component of mixed
histology) may be eligible, after communication with and approval from medical
monitor.
2. At least 1 lesion that is measurable by study criteria.
If a previously radiated lesion is to be followed as a target lesion, progression must be
confirmed by biopsy after radiation therapy. Previously radiated lesions may be followed
as non-target lesions if there is at least 1 other measurable target lesion.
Group 1 and Group 3: There must be at least 1 baseline measurable lesion ≥10 mm in
maximal diameter (1.5 cm for lymph nodes) according to Response Evaluation Criteria in
Solid Tumors (RECIST) 1.1 criteria (Appendix 1; Eisenhauer 2009)
Group 2: There must be at least 1 measureable baseline lesion in which the longest
diameter (LD) and the perpendicular diameter are both ≥10 mm if followed by digital
medical photography (see Appendix 2). Non-measurable disease for Group 2 is defined
as either unidimensionally measurable lesions, tumors with margins that are not clearly
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defined, or lesions with maximum perpendicular diameters less than 10 mm. Patients
without measureable disease at baseline are not eligible for the study.
Note: In the case of a Group 1 or Group 3 patient with metastatic disease that does not
meet target lesion criteria by RECIST 1.1 (eg, bone only lesions, perineural disease;
Appendix 1) and with externally visible CSCC target lesion(s), Appendix 2 may be used,
in which bi-dimensional measurements are required (at baseline, perpendicular diameters
must both be ≥10 mm). The patient would then be enrolled in Group 1 with the plan to
measure externally visible target lesion(s) by photography with bi-dimensional
measurements; the metastatic lesions that are not measurable by RECIST 1.1 criteria
would be followed as non-target lesions on scans.
In the case of a Group 2 patient with a deeply invasive lesion that the investigator deems
is best measured by magnetic resonance imaging (MRI) or computed tomography (CT),
measurement for that target lesion will be done according to RECIST 1.1 criteria
(Appendix 1). The requirement for a lesion to be measurable by RECIST 1.1 is that it
must be ≥10 mm in longest dimension.
3. Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (ECOG PS 1
definition: Restricted in physically strenuous activity but ambulatory and able to carry out
work of a light or sedentary nature, eg, light house work, office work; Appendix 7).
Note: Patients with ECOG PS >1 are ineligible.
4. ≥18 years old
5. Hepatic function:
a. Total bilirubin ≤1.5 x upper limit of normal (ULN; if liver metastases ≤3 x ULN).
Patients with Gilbert’s Disease and total bilirubin up to 3 x ULN may be eligible after
communication with and approval from the medical monitor.
b. Transaminases ≤3 x ULN (or ≤5.0 x ULN, if liver metastases)
c. Alkaline phosphatase (ALP) ≤2.5 x ULN (or ≤5.0 x ULN, if liver or bone metastases)
Note for patients with hepatic metastases who wish to enroll in Group 1 or Group 3: If
transaminase levels (AST and/or ALT) are >3 x but ≤5 x ULN, total bilirubin must be ≤1.5 x
ULN. If total bilirubin is >1.5 x but ≤3 x ULN, both transaminases (AST and ALT) must be
≤3 x ULN.
6. Renal function: Serum creatinine ≤1.5 x ULN or estimated creatinine clearance (CrCl)
>30 mL/min
7. Bone marrow function:
a. Hemoglobin ≥9.0 g/dL
b. Absolute neutrophil count (ANC) ≥1.5 x 109/L
c. Platelet count ≥75 x 109/L
8. Ability to provide signed informed consent
9. Ability and willingness to comply with scheduled visits, treatment plans, laboratory tests,
and other study-related procedures
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10. Anticipated life expectancy >12 weeks
11. Group 2 only: Surgery must be deemed contraindicated in the opinion of a Mohs
dermatologic surgeon, a head and neck surgeon, or plastic surgeon. A copy of the
surgeon’s consultation note from a clinical visit within 60 days of enrollment must be
submitted.
Acceptable contraindications in the surgeon’s note include:
•

CSCC that has recurred in the same location after 2 or more surgical procedures and
curative resection is deemed unlikely

•

CSCCs with significant local invasion that precludes complete resection

•

CSCCs in anatomically challenging locations for which surgery may result in severe
disfigurement or dysfunction (eg, removal of all or part of a facial structure, such as
nose, ear, or eye; or requirement for limb amputation)

•

Other conditions deemed to be contraindicating for surgery must be discussed with
the medical monitor before enrolling the patient.

12. Group 2 only: Patients must be deemed as not appropriate for radiation therapy.
Specifically, patients must meet at least 1 of the following criteria:
a. A patient previously received radiation therapy for CSCC, such that further radiation
therapy would exceed the threshold of acceptable cumulative dose, per the radiation
oncologist. A copy of the radiation oncologist’s consultation note, from a clinical visit
within 60 days of enrollment, must be submitted.
b. Judgment of radiation oncologist that such tumor is unlikely to respond to therapy. A
copy of the radiation oncologist’s consultation note, from a clinical visit within
60 days of enrollment, must be submitted.
c. A clinic note from the investigator indicating that an individualized benefit:risk
assessment was performed by a multidisciplinary team (consisting of, at minimum, a
radiation oncologist AND EITHER a medical oncologist with expertise in cutaneous
malignancies OR a dermato-oncologist, OR a head and neck surgeon) within 60 days
prior to enrollment in the proposed study, and the radiation therapy was deemed to be
contraindicated.
Acceptable contraindications to radiation therapy in the investigator’s note for patients
who have not received any prior radiation include:
•

CSCCs in anatomically challenging locations for which radiation therapy would be
associated with unacceptable toxicity risk in the context of the patient’s overall
medical condition in the opinion of the multidisciplinary team (eg, a neck tumor for
which radiation therapy would result in potential need for a percutaneous gastrostomy
tube). A copy of the investigator’s consultation note documenting the
multidisciplinary assessment must be submitted.

•

Other conditions deemed to be contraindicating for radiation therapy must be
discussed with the medical monitor before enrolling the patient.
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13. All patients in either group must consent to provide archived or newly obtained tumor
material (either formalin-fixed, paraffin-embedded [FFPE] block or 10 unstained or
stained slides) for central pathology review for confirmation of diagnosis of CSCC. This
material must be confirmed as received by the central lab prior to enrollment.
14. Group 2 only: Patients must consent to undergo biopsies of externally visible CSCC
lesions at baseline, cycle 1 day 29 (±3 business days), at time of tumor progression, and
at other time points that may be clinically indicated in the opinion of the investigator.
15. Group 2 only: An investigator note which states that the natural history of the patient’s
advanced CSCC would likely be life-threatening within 3 years with currently available
management options outside of a clinical trial.
4.2.2.

Exclusion Criteria

A patient who meets any of the following criteria will be excluded from the study:
1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
required treatment with systemic immunosuppressive treatments, which may suggest risk
for immune-related adverse events (irAEs). The following are not exclusionary: vitiligo,
childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism that
required only hormone replacement, or psoriasis that does not require systemic treatment.
2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
3. Prior treatment with other immune modulating agents that was (a) within fewer than 4
weeks (28 days) prior to the first dose of REGN2810, or (b) associated with immunemediated adverse events that were ≥ grade 1 within 90 days prior to the first dose of
REGN2810, or (c) associated with toxicity that resulted in discontinuation of the
immune-modulating agent. Examples of immune modulating agents include therapeutic
anti-cancer vaccines, cytokine treatments (other than G-CSF or erythropoietin), or agents
that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), 4-1BB (CD137), PI 3-K-delta, or
OX-40.
4. Untreated brain metastasis(es) that may be considered active. (Note: patients with brain
involvement of CSCC due to direct extension of invading tumor, rather than metastasis,
may be allowed to enroll if they do not require greater than 10 mg prednisone daily, after
discussion and approval of the medical monitor). Patients with previously treated brain
metastases may participate provided that the lesion(s) is (are) stable (without evidence of
progression for at least 6 weeks on imaging obtained in the screening period), and there is
no evidence of new or enlarging brain metastases, and the patient does not require any
immunosuppressive doses of systemic corticosteroids for management of brain
metastasis(es) within 4 weeks of first dose of REGN2810.
5. Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within
4 weeks prior to the first dose of REGN2810.
Note: Patients who require brief course of steroids (eg, as prophylaxis for imaging
studies due to hypersensitivity to contrast agents) are not excluded.
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6. Active infection requiring therapy, including infection with human immunodeficiency
virus, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
7. History of pneumonitis within the last 5 years
8. Grade ≥ 3 hypercalcemia at time of enrollment
9. Any systemic anticancer treatment (chemotherapy, targeted systemic therapy,
photodynamic therapy), investigational or standard of care, within 30 days of the initial
administration of REGN2810 or planned to occur during the study period (Patients
receiving bisphosphonates or denosumab are not excluded), radiation therapy within 14
days of initial administration of REGN2810 or planned to occur during the study period.
Note: For patients with multiple CSCCs at baseline that are not designated by the
investigator as target lesions, treatment of these non-target CSCCs with surgery may be
permitted but must be discussed with the medical monitor prior to any surgical procedure.
10. History of documented allergic reactions or acute hypersensitivity reaction attributed to
antibody treatments.
11. Patients with allergy or hypersensitivity to REGN2810 or to any of the excipients must be
excluded. Specifically, because of the presence of trace components in REGN2810,
patients with allergy or hypersensitivity to doxycycline or tetracycline are excluded.
12. Breast feeding
13. Positive serum pregnancy test (a false positive pregnancy test, if demonstrated by serial
measurements and negative ultrasound, will not be exclusionary, upon communication
with and approval from the medical monitor).
14. Concurrent malignancy other than CSCC and/or history of malignancy other than CSCC
within 3 years of date of first planned dose of REGN2810, except for tumors with
negligible risk of metastasis or death, such as adequately treated BCC of the skin,
carcinoma in situ of the cervix, or ductal carcinoma in situ of the breast, or low-risk early
stage prostate adenocarcinoma (T1-T2aN0M0 and Gleason score ≤6 and PSA ≤10
ng/mL) for which the management plan is active surveillance, or prostate
adenocarcinoma with biochemical-only recurrence with documented PSA doubling time
of > 12 months for which the management plan is active surveillance (D’Amico 2005,
Pham 2016). Patients with hematologic malignancies (eg, chronic lymphocytic leukemia,
CLL) are excluded.
15. Any acute or chronic psychiatric problems that, in the opinion of the investigator, make
the patient ineligible for participation.
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16. Continued sexual activity in men** or women of childbearing potential*** who are
unwilling to practice highly effective contraception during the study and until 6 months
after the last dose of study drug (highly effective contraceptive measures include stable
use of oral contraceptives such as combined estrogen and progestogen and progestogen
only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or
more menstrual cycles prior to screening; intrauterine device [IUD]; intrauterine
hormone-releasing system (IUS); bilateral tubal ligation; vasectomy, and sexual
abstinence).
** Contraception is not required for men with documented vasectomy.
*** Postmenopausal women must be amenorrheic for at least 12 months in order not to
be considered of childbearing potential. Pregnancy testing and contraception are not
required for women with documented hysterectomy or tubal ligation.
17. Patients with a history of solid organ transplant (patients with prior corneal transplant(s)
may be allowed to enroll after discussion with and approval from the medical monitor).
18. Prior treatment with a BRAF inhibitor
19. Any medical co-morbidity, physical examination finding, or metabolic dysfunction, or
clinical laboratory abnormality that, in the opinion of the investigator, renders the patient
unsuitable for participation in a clinical trial due to high safety risks and/or potential to
affect interpretation of results of the study.
Note in clarification: For Group 2 patients, the investigator must contact the sponsor’s
medical monitor regarding any patients that the investigator feels cannot provide the
required baseline tumor biopsies.
20. Inability to undergo any contrast-enhanced radiologic response assessment.
Notes regarding imaging options: A patient who is unable to undergo CT with
iodinated contrast (eg, due to contrast allergy) would not be excluded if his/her disease
can be measured by MRI with gadolinium. A patient who is unable to undergo MRI with
gadolinium would not be excluded if his/her disease can be measured by CT scan with
contrast.
Note regarding Group 2 patients: In selected cases, a patient in Group 2 who is unable
to undergo any contrast enhanced radiographic imaging (neither CT with iodinated
contrast nor MRI with gadolinium) may be eligible if the patient’s disease can be
comprehensively assessed with digital medical photography, after communication with
and approval from medical monitor.
21. Prior treatment with idelalisib
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4.3.

Premature Withdrawal from the Study or from Study Treatment

4.3.1.

Reasons for Premature Withdrawal or Discontinuation of Study Treatment

A patient has the right to voluntarily discontinue study treatment or withdraw from the study at
any time, for any reason, and without repercussion.
The investigator and sponsor have the right to discontinue a patient from study treatment or
withdraw a patient from the study at any time.
Reasons for discontinuation of study treatment or withdrawal from the study may include, but
are not limited to:

4.3.2.

•

Patient withdrawal of consent at any time

•

Any medical condition that the investigator or sponsor determines may jeopardize the
patient’s safety if he or she continues in the study or continues treatment with study
drug

•

The investigator or sponsor determines it is in the best interest of the patient

•

Patient noncompliance (eg, not complying with protocol required visits, assessments,
and dosing instructions)

•

Pregnancy
Discontinuation of Study Treatment

A patient who permanently discontinues study treatment will be followed as detailed in
Section 6.2.2.
4.3.3.

Withdrawal from Study Participation

During the treatment period and follow-up period, a patient who withdraws consent to continue
participation in the study will not be followed for any reason after consent has been withdrawn.
An excessive rate of withdrawals would render the study uninterpretable; therefore, unnecessary
withdrawal of patients should be avoided.

4.4.

Replacement of Patients

Patients prematurely discontinued from the study who had received at least 1 treatment with
REGN2810 will not be replaced.

5.

STUDY TREATMENTS

5.1.

Investigational Treatment

REGN2810 will be supplied as a liquid in sterile, single-use vials.
Instructions on dose preparation are provided in the
pharmacy manual.
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REGN2810 will be administered in an outpatient setting as an approximately 30 minute
(±10 minutes) IV infusion. Each patient’s dose will depend on individual body weight, with the
exception of Group 3 patients who will receive a flat dose. The dose of REGN2810 must be
adjusted each cycle for changes in body weight of ≥ 10%. Dose adjustments for changes in body
weight of < 10% will be at the discretion of the investigator.

5.2.

Pretreatments

Appropriate premedication for study treatments may be administered at the investigator’s
discretion as per usual clinical practice and in accordance with institutional guidelines. No
premedications are to be administered for the first dose of REGN2810.

5.3.

Dose Modification and Study Drug Discontinuation Rules

5.3.1.

Dose Modification

For Groups 1 and 2, the planned dose and schedule is 3 mg/kg REGN2810 IV over
approximately 30 minutes every 14 days. For Group 3, the planned dose and schedule is 350 mg
REGN2810 IV over approximately 30 minutes every 21 days. Patients will generally remain on
the assigned dosage of REGN2810 throughout the course of study treatment. Dose reduction of
REGN2810 may be allowed, based on the guidelines below, and only after discussion and
agreement between the investigator and sponsor.
5.3.2.

Study Treatment Hold or Discontinuation

Adverse events (AEs) are to be reported according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Patients who experience
grade ≥3 treatment-related toxicity (excluding laboratory abnormalities that are considered
clinically insignificant) that is not otherwise specified in the protocol will be required to
temporarily discontinue treatment with REGN2810. Such patients may be considered for
resumption of treatment once the toxicity resolves to grade 1 or baseline, or when the toxicity is
stable and manageable through supportive/medical therapy (eg, grade 3 hypertension that can be
controlled with addition of a second anti-hypertensive agent).
Note in clarification on scheduling after missed visits/assessments: The general approach
regarding missed treatments of REGN2810 (eg, due to AEs or other reasons) is “time marches
on.” Missed doses of REGN2810 will not be made up, unless missed doses occur ≤ 3 calendar
days from the scheduled date.
Study visits cannot be performed outside of the scheduled visit. As such, if a patient misses a
dose by more than 3 days for any reason, the next dose would be at the subsequent every 2 week
dose (which could be given 3 days early if need be). If an investigator deems that re-scheduling
a missed dose of REGN2810 outside of the 3 day window is in the best interest of the patient,
this should be discussed with the medical monitor.
Holding of treatment due to an AE or a missed visit if a patient is hospitalized is not a violation.
If a patient is able to come in for a study visit according to the visit schedule, but does not
receive REGN2810, the visit should be entered into the database. The protocol assessments
required at the visit (ie, labs, physical exam) should still be completed as far as possible and the
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data entered at the appropriate visit in the electronic case report form (CRF). If the patient is not
able to come in for a study visit, according to the study schedule, the visit should be skipped.
Upon occurrence of a study treatment-related event at any time on the study, resumption of
treatment after resolution or stabilization of the condition is allowed at the discretion of the
investigator and sponsor if resuming treatment is thought to be in the best interest of the patient,
with the exception of the following categories:
•

Patients with events that require REGN2810 to be discontinued for more than 84 days
from last scheduled dose.

•

Patients with grade ≥2 uveitis. Patients with grade 2 uveitis will generally be
discontinued from study treatment, unless there is resolution to grade ≤1 as outlined
in Appendix 4 AND discussion with and approval by the medical monitor. All
patients with grade ≥3 uveitis will be permanently discontinued from study treatment.

After other AEs, resumption of treatment may be at the initial dose level, or at 1 dose level
reduced based upon the discretion of the investigator and the sponsor (Table 2).
Table 2:

Dose Reductions

For Groups 1 and 2:
Dose Level

Reduction Order

Dose

Dose Level -1

First dose reduction

1 mg/kg REGN2810 every 14 days

Dose Level -2

Second dose reduction

0.3 mg/kg REGN2810 every 14 days

Dose Level

Reduction Order

Dose

Dose Level -1

First dose reduction

120 mg REGN2810 Q3W

Dose Level -2

Second dose reduction

60 mg REGN2810 Q3W

For Group 3:

A patient who requires dose reduction below dose level -2 will be removed from the study.
Guidelines for study treatment temporary discontinuations, including delays and interruptions,
and permanent discontinuations for toxicity are outlined in Table 3.
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Study Treatment Dose Modifications or Discontinuations

Toxicity

Grade

Hold
Treatment?

Restarting
Criteria

Restarting
Dose/Schedule

Discontinuation
Criteria

Hematological Toxicity
(other than grade 3
thrombocytopenia greater
than 7 days or associated
with bleeding)

1, 2, 3

No

N/A

N/A

N/A

4

Yes

Toxicity
resolves to
Grade ≤1 or
baseline

Decrease REGN2810
dosage to the next lower
dosing level (see
Table 2)

Toxicity does not
resolve within 84 days
of last infusion
Permanent
discontinuation should
be considered for any
severe or lifethreatening event

Grade 3 thrombocytopenia
greater than 7 days or
associated with bleeding

3

Yes

Toxicity
resolves to
Grade ≤1 or
baseline

Decrease REGN2810
dosage to the next lower
dosing level (see
Table 2)

Toxicity does not
resolve within 84 days
of last infusion
Permanent
discontinuation should
be considered for any
severe or lifethreatening event

Nonhematological Toxicity

1

No

N/A

N/A

Note: Exceptions to be treated
as for Grade 1 toxicity:

2

Consider
withholding
for persistent
symptoms

Toxicity
resolves to
Grade 0–1
or baseline

Clinical AE resolves
within 4 weeks: Same
dose and schedule
Clinical AE does not
resolve within 4 weeks:
May decrease
REGN2810 dosage to
the next lower dosing
level (see Table 2)

Toxicity does not
resolve within 84 days
of last infusion

3

Yes

Toxicity
resolves to
Grade 0–1
or baseline

Decrease REGN2810
dosage to the next lower
dosing level (see
Table 2)

Toxicity does not
resolve within 84 days
of last infusion

4

Yes

N/A

N/A

Patient must be
discontinued

•

Grade 2 alopecia

•

Grade 2 fatigue

•

Clinically
insignificant lab
abnormality not
meeting AE criteria

N/A

For additional information regarding AEs with a potential for irAEs, reference Table 4 and Appendix 4.

Any patient currently receiving REGN2810 who was previously treated with a
phosphatidylinositol 3-kinase (PI 3-K) inhibitor and who develops stomatitis or mucositis should
temporarily suspend study treatment. If this or any other immune-related AE occurs among
these patients, the sponsor should be informed as soon as possible to discuss further management
of the patient. An irAE of any grade in a patient previously treated with a PI 3-K inhibitor
should be reported as an adverse event of special interest (AESI).
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Immune-Related Adverse Events

Case report forms (CRFs) for this study are designed to capture AEs that may be suggestive of
potential irAEs. Attribution of AEs in the CRFs will require not only the investigator’s
assessment regarding whether the AE was related to REGN2810, but also whether the AE was an
irAE. Please see the CRF completion guidelines for information about attribution of irAEs.
Investigators must be extremely vigilant and be ready to intervene early in the
management of irAEs, as the onset of symptoms of irAEs (eg, pneumonitis) may be subtle.
Detailed guidance of management of irAEs is provided in Appendix 4. In the event of irAEs that
are not addressed in Appendix 4, general guidance is provided in Table 4. The recommendations
in Table 4 and Appendix 4 should be seen as guidelines, and the treating physician should
exercise clinical judgment based on the symptoms and condition of the individual patient.
Table 4:

General Treatment Hold Guidelines for Immune-Related Adverse Events

Severity

Withhold/Discontinue Treatment?

Supportive Care

Grade 1

No action

Provide symptomatic treatment

Grade 2

May withhold treatment

Consider systemic corticosteroids in addition to
appropriate symptomatic treatment

Grade 3
Grade 4

Withhold treatment
Discontinue if unable to reduce
corticosteroid dose to < 10 mg per day
prednisone equivalent within 12 weeks of
toxicity

Systemic corticosteroids are indicated in addition to
appropriate symptomatic treatment. May utilize 1 to
2 mg/kg prednisone or equivalent per day.
Steroid taper should be considered once symptoms
improve to Grade 1 or less and tapered over at least
4 weeks.
For any severe (Grade 3-4) irAE, if symptoms worsen or
do not improve on adequate corticosteroids within 48 to 72
hours, consider adding additional immunosuppressive
agents (to be selected from agents such as infliximab,
cyclophosphamide, cyclosporine, mycophenolate-mofetil).
Referral of the patient to a specialized unit for assessment
and treatment should be considered.

Note: These recommendations should be seen as guidelines, and the treating physician should
exercise clinical judgment based on the symptoms and condition of the individual patient.
Note regarding irAEs: For any AE that is of a type known to be potentially immune-related (eg,
rash, colitis, elevated transaminases, endocrine), but is deemed not to be an irAE by the
investigator, the sponsor may request additional information.
5.3.2.2.

Permanent Discontinuation of Study Treatment

In the event of an infusion reaction of grade ≥ 3 severity during or directly following
REGN2810 infusion, dosing should be stopped and the patient must permanently discontinue
REGN2810 treatment.
Study treatment will be permanently stopped in the event of evidence of pregnancy.
In addition, study treatment for any patient may be discontinued for other safety reasons or
compliance issues at the discretion of the investigator or sponsor. A patient may choose to
discontinue study treatment or study participation at any time for any reason.
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A patient who permanently discontinues REGN2810 treatment should continue follow-up in the
study without additional treatment until progression of disease, completion of all study
assessments, or closure of the study (Section 4.3).

5.4.

Management of Infusion/Allergic/Hypersensitivity Reactions

Acute infusion reactions are defined as any AE that occurs during the infusion or within 2 hours
after the infusion is completed. Emergency equipment and medication for the treatment of these
potential adverse effects (eg, antihistamines, bronchodilators, IV saline, corticosteroids,
acetaminophen, and/or epinephrine) must be available for immediate use. Infusion reactions
must be reported as AEs (Section 7.2.1) and graded according to the NCI-CTCAE version 4.03
grading scale (Section 7.3.1).
In the event of an infusion reaction of Grade 3 or greater severity during or directly following
REGN2810 infusion, dosing should be stopped and the patient must be permanently
discontinued from REGN2810 treatment.
5.4.1.

Interruption of the Infusion

The infusion should be interrupted if any of the following AEs are observed:
•

cough

•

rigors/chills

•

rash, pruritus (itching)

•

urticaria (hives, welts, wheals)

•

diaphoresis (sweating)

•

hypotension

•

dyspnea (shortness of breath)

•

vomiting

•

flushing

The reaction(s) should be treated symptomatically, and the infusion may be restarted at 50% of
the original rate.
If investigators feel there is a medical need for treatment or discontinuation of the infusion other
than described above, they should use clinical judgment to provide the appropriate response
according to typical clinical practice.
For patients who experience infusion-related hypersensitivity reactions that are less than grade 3
and who plan to continue treatment, premedication will be required for re-treatment.
For grade 1 symptoms (mild reaction; infusion interruption not indicated; intervention not
indicated), the following prophylactic medications are recommended for future infusions:
diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol 325 mg to 1000 mg
at least 30 minutes prior to subsequent REGN2810 infusions.
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For grade 2 symptoms (moderate reaction that requires therapy or infusion interruption, but for
which symptoms resolve promptly with appropriate treatment such as antihistamines,
nonsteroidal anti-inflammatory drugs, narcotics, corticosteroids, and/or IV fluids; prophylactic
medications indicated ≤24 hours), the following prophylactic medications are recommended for
future infusions: diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol
325 mg to 1000 mg at least 30 minutes prior to subsequent REGN2810 infusions. If necessary,
corticosteroids (up to 25 mg of hydrocortisone or equivalent) may be used.
5.4.2.

Termination of the Infusion

The infusion should be terminated and NOT restarted if any of the following AEs occur:
•

anaphylaxis

•

laryngeal/pharyngeal edema

•

severe bronchospasm

•

chest pain

•

seizure

•

severe hypotension

5.5.

Method of Treatment Assignment

Each patient who signs the informed consent form (ICF) will be assigned a patient number and
tracked centrally as described in the Interactive Web Response System (IWRS) manual.
Eligible patients will be enrolled sequentially as confirmed and tracked by the sponsor, until each
group is filled per protocol criteria. Details on treatment assignment can be found in the IWRS
manual.
Patients can only be enrolled in Group 3 after enrollment in Group 1 is complete.
5.5.1.

Blinding

This is an open-label study; no blinding will be employed.

5.6.

Treatment Logistics and Accountability

5.6.1.

Packaging, Labeling, and Storage

Open-label REGN2810 will be supplied as a liquid in sterile, single-use vials that will display the
product lot number on the label.

Further storage instructions will be provided in the pharmacy
manual.
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A pharmacist or other qualified individual will be identified at each site to prepare REGN2810
for administration.
Detailed preparation and administration
instructions will be provided to the sites in the pharmacy manual.
5.6.2.

Supply and Disposition of Treatments

Study drug will be shipped
intervals or as needed during the study. At specified
site monitoring visits), at the site close-out visit,
documentation by the site monitor, all opened
destroyed -or- returned to the sponsor or designee.
5.6.3.

to the investigator or designee at regular
time points during the study (eg, interim
and following drug reconciliation and
and unopened study drug will be

Treatment Accountability

All drug accountability records must be kept current.
The investigator must be able to account for all opened and unopened study drug. These records
should contain the dates, quantity, and study medication dispensed to each patient, returned from
each patient (if applicable), and disposed of at the site or returned to the sponsor or designee.
All accountability records must be made available for inspection by the sponsor and regulatory
agency inspectors; photocopies must be provided to the sponsor at the conclusion of the study.
5.6.4.

Treatment Compliance

REGN2810 will be administered at the study site and recorded on the electronic CRF. All
dosing records for each patient will be kept by the site. All drug compliance records must be
kept current and must be made available for inspection by the sponsor and regulatory agency
inspectors.

5.7.

Concomitant Medications and Procedures

5.7.1.

Concomitant Medications

Any treatment administered from the time of informed consent until 30 days after the last study
treatment will be considered concomitant treatment. This includes medications and other
therapies for which administration started before the study and will continue during the study, as
well as any therapies started in the follow-up period (approximately 6 months [Table 7]) to treat
a study-drug–related AE. All concomitant treatments must be recorded in the study CRF with
the generic name, dose, dose unit, frequency, indication, and start/stop date, as appropriate.
5.7.2.

Prohibited Medications and Concomitant Treatments

While participating in this study, a patient may not receive any standard or investigational agent
for treatment of a tumor other than REGN2810 as monotherapy. After communication with
the sponsor, focal palliative treatment (eg, radiation) would be allowed for local control of a
tumor once a patient has completed 24 weeks of study treatment. Any other medication
which is considered necessary for the patient’s welfare, and which is not expected to interfere
with the evaluation of the study drug, may be given at the discretion of the investigator.
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Patients using immunosuppressive doses (> 10 mg per day of prednisone or equivalent) of
systemic corticosteroids other than for corticosteroid replacement will not be eligible for the
study. It is recommended that patients do not receive systemic corticosteroids such as
hydrocortisone, prednisone, prednisolone (Solu-Medrol®) or dexamethasone (Decadron®) at any
time throughout the study except in the case of a life-threatening emergency and/or to treat an
irAE. Physiologic replacement doses of systemic corticosteroids are permitted, even if
>10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg,
contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type
hypersensitivity reaction caused by contact allergen) is permitted.
Note: Bisphosphonates and denosumab are not prohibited.
5.7.3.

Surgery

For patients with locally advanced target lesions that are considered unresectable at baseline, but
are subsequently deemed resectable during the course of the study due to tumor response to
REGN2810, curative intent surgery may be allowed but must be discussed with the medical
monitor prior to any surgical procedure. (This statement does not apply to patients in emergency
life-threatening situations that require immediate surgery). Patients with inoperable CSCC at
baseline who are rendered operable with clear margins will be deemed to have experienced PR.
If during the course of the study a patient develops new cutaneous lesions that are suspected to
be a non-melanoma skin cancer other than CSCC (eg, BCC), removal of the lesion and continued
treatment on study may be allowed after discussion with the medical monitor.
5.7.4.

Radiation Therapy

Radiation therapy is not part of the study regimen. Patients for whom radiation therapy is
planned are not eligible. If during the course of the study, a patient develops a symptomatic
lesion for which palliative radiation therapy is deemed appropriate by the investigator, this will
be deemed PD and generally the patient would be removed form study. Palliative radiation
therapy may be allowed in certain circumstances in patients who have been on study for at least
24 weeks (see Section 5.7.2). Such cases must be discussed with the medical monitor prior to
any radiation therapy if the investigator feels that restarting REGN2810 after radiation is in the
best interest of the patient. The patient will be deemed to have experienced disease progression
if radiation therapy is instituted, but will be followed for OS.

6.

STUDY SCHEDULE AND VISIT DESCRIPTIONS

6.1.

Study Schedule

Study assessments and procedures are presented by study period and visit in Table 5 for Groups
1 and 2, and Table 6 for patients in Group 3; Table 7 presents study assessments and procedures
for all groups during the follow-up period. Study visits can be scheduled so as not to fall on
weekends or holidays, after discussion and approval by the Sponsor.
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Study Schedule (Screening and Treatment) for Groups 1 and 2

Study Procedure

Cycles 2 - 12a

Cycle 1

Screening

End of Study
t

b

Visit Days

–28 to –1

1

15±3

29±3

43±3 56±3

1

15±3 29±3 43±3 56± 3 30 days after last dose of REGN2810

Clinical Assessments and Study Treatment
c

Informed Consent

X

Genomics Substudy Informed Consent (optional)

X

Medical/Oncology History

X
d

Complete Physical Examination and ECOG PS

X

e

X
-

Physical Examination, Limited
f

X
X

X

X

X
X

X

X

X

X

Vital Signs and Weight

X

X

X

X

X

X

X

X

X

Height

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

12-Lead ECG
g

h

X

X
X

X

Brain MRI
3 mg/kg REGN2810 IV
Laboratory Tests
i

j

Hematology and Blood Chemistry
k

Serum HCG ≤72 Hour Predose

X

X

X

Urine Pregnancy Test

X

X

X

X

X

Serum IgG, IgM, IgE

X

X

X

aPTT; INR

X

X

RF and ANA

X

X

X

TSH and CRP

X

X

X

X

X

l

X

Urinalysis

HBV, HCV, HIV

X

Immune Safety and PK Blood Samples

m

ADA
n

REGN2810 PK/Drug Conc. Sample

X

X

X

X
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Study Procedure

Cycles 2 - 12a

Cycle 1

Screening

End of Study
t

b

Visit Days

–28 to –1

1

15±3

29±3

43±3 56±3

1

15±3 29±3 43±3 56± 3 30 days after last dose of REGN2810

Pathology and Research Samples
o

Archived tissue for histological confirmation of CSCC

X

Optional blood DNA for genomics substudy
p

Tumor biopsies for Group 2

X
X

X

X

X (only
photography
for Group 2
patients)

As needed to clarify response status

Response Imaging and other assessments
q

CT/MRI and/or digital photography
EORTC QLQ-C30
r

Concomitant medications

X

X

X

X

X

X

X

X

X

s

← continuous monitoring→

Adverse Events

ADA=anti-drug antibody; AE=adverse event; ANA=antinuclear antibody; aPTT=activated partial thromboplastin time; CRP=C-reactive protein; CT=computed
tomography; ECG=electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group Performance Status; EOS=end of study; HCG=human chorionic
gonadotropin; INR=International Normalized Ratio; MRI=magnetic resonance imaging; RF= rheumatoid factor; TSH=thyroid-stimulating hormone;
HBV=hepatitis B virus; HCV=hepatitis C virus: HIV=human immunodeficiency virus
a
The maximum number of treatment cycles is 12 (planned 96 weeks total). See Section 6.2 regarding treatment discontinuation.
b
Should occur at least 53 days from day 1 of previous cycle, and no sooner than 11 days after the previous dose.
c
Informed consent must be provided before the initiation of screening procedures and must be obtained within 45 days prior to cycle1/day1. All screening
assessments must be performed within 28 days prior to cycle 1/day 1 (with the exception of brain MRI according to footnote h ). Assessments performed as
part of standard of care that fall within the screening window but before informed consent is obtained may be used for screening, and need not be repeated for
enrollment eligibility.
d
Complete physical examination includes head and neck, lungs, heart, abdomen, lymph nodes, extremities, and skin. A brief neurologic examination should
also be performed. The exam may be performed ≤72 hours prior to study treatment. Complete physical exam must be accompanied by assessment and
documentation of ECOG Performance Status (Appendix 7).
e
Limited physical exam includes lungs, heart, abdomen, and skin.
f
A 12-lead electrocardiogram should be recorded at screening, and 30±10 minutes after end of infusion at day 1 visits during cycle 1 and cycle 3.
g
Vital signs include temperature, resting blood pressure, pulse, and respiration. Vital signs will be assessed and documented prior to the REGN2810 infusion,
and then approximately 15 minutes after the completion of the REGN2810 infusion. The allowable window for each specified time point is ±10 minutes.
h
Brain MRI with gadolinium is required at screening if not performed in the prior 60 days. Brain scans during the treatment and follow-up periods are required
if there is a prior history of lesions present at screening or as clinically indicated. A brain CT with iodinated contrast may be performed if an MRI with
gadolinium is contraindicated.
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Hematology includes: WBC count, 3-cell differential (ANC, monocyte count, lymphocyte count), hemoglobin, and platelet count. Samples may be collected
≤72 hours prior to study treatment.
Chemistry includes: sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorous, glucose, albumin, creatinine, blood urea nitrogen (BUN),
ALT, AST, total bilirubin, alkaline phosphatase (ALP), uric acid, and LDH. Samples may be collected ≤72 hours prior to study treatment.
Predose β-HCG (serum) at screening up to 72 hours prior to first administration. Subsequent pregnancy tests may be urine β-HCG. Serum pregnancy test and
urine pregnancy test are requirements for women of child bearing potential only.
Urinalysis: glucose, blood, pH, specific gravity, ketones, and spot urine protein. Samples may be collected ≤72 hours prior to study treatment.
ADA samples are collected prior to treatment on day 1 of cycles 1, 3, 5, 7, and 11.
Blood samples for PK will be collected (at select sites) at pre-infusion and end of infusion on days 1, 15, 29, and 43 of cycle 1, on day 1 of cycles 2 through 6,
7, 9, and 11. The final PK sample will be collected either at the EOS visit (for patients who discontinue treatment due to progression or toxicity during cycles
1 through 12) or at the follow-up visit 1 in Table 7 (for patients who complete cycles 1 through 12). See Appendix 3 for details on PK collection schedule.
See Section 6.3.1 regarding requirements for documentation of histologic confirmation of diagnosis of CSCC.
For Group 2 patients only: Tumor biopsies are required at baseline and on cycle 1 day 29 (±3 business days). Tumor biopsies should be performed at any
response assessment in which there is indeterminate-appearing skin regarding malignant versus benign status. Tumor biopsies should also be collected for
histologic confirmation of complete response in any patient for whom the clinical impression is complete response, as well as at progression. Biopsies must
be annotated and photographed. Guidelines for tumor biopsies are provided in Appendix 5.
The same method (CT with iodinated contrast or MRI with gadolinium) and/or digital medical photography used at baseline should be used throughout the
study. For patients with locally advanced CSCC, guidelines for digital photography are provided in Appendix 6 . Imaging requirements differ for patients in
Group 1 and Group 2; see Sections 6.3.1 and 6.3.2 for further details. For day 29 photos for Group 2 patients, the intent of the photography is to show
locations of the biopsies; formal response assessments are not planned for day 29 photos.
Concomitant medication recording will be done at the start of each cycle, at a minimum. Concomitant medications should be recorded from the date of
signing the ICF through follow-up visit 1 (post-treatment;Table 7).
Adverse event recording will be ongoing throughout the course of the study, using NCI-CTCAE v4. See Section 7.2.
(1) The EOS visit is for patients who experience PD requiring study discontinuation in cycles 1 through 12. This visit should occur 30 days (allowed window:
21 to 42 days) after the last dose of REGN2810. The only post-treatment assessment that can occur outside of this timeframe is the post-treatment biopsy
(required in Group 2) that can be obtained at any time within 28 days of last dose of REGN2810. (2) Patients who complete the required events in Table 5
(excluding the EOS visit) with any status other than PD (eg, CR, PR, or SD), or who discontinue treatment during cycles 1- 12 for any reason other than PD,
should go on to complete the assessments in Table 7 (unless not possible, due to factors such as clinical decline or withdrawal of consent). These patients do
not need to complete the EOS visit at end of cycle 12 as they will be assessed per Table 7. After treatment and follow-up are completed or patients
prematurely discontinue treatment and follow-up, patients will be followed quarterly for survival and tumor treatment status, if available.
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Study Schedule (Screening and Treatment) for Group 3

Study Procedure

Cycles 2 – 6a

Cycle 1

Screening

End Of study
30 days after last dose of
s

b

Visit Days

–28 to –1

1

22±3

43±3

63±3

1

22±3

43±3

63±3

REGN2810

Clinical Assessments and Study Treatment
c

Informed Consent

X

Genomics Substudy Informed Consent (optional)

X

Medical/Oncology History

X
d

Complete Physical Examination and ECOG PS

X

e

X
-

Physical Examination, Limited
f

X
X

X

X
X

X

X

X

Vital Signs and Weight

X

X

X

X

X

X

X

Height

X

X

X

X

X

X

X

X

X

X

X

X

X

12-Lead ECG
g

h

X

X
X

X

Brain MRI
350 mg REGN2810 IV
Laboratory Tests
i

j

Hematology and Blood Chemistry
k

Serum HCG ≤72 Hour Predose

X
X

Urine Pregnancy Test
l

Urinalysis

X

Serum IgG, IgM, IgE
aPTT; INR
HBV, HCV, HIV

X

X

X

X

X

X

X

X

X

X

X

X

Immune Safety and PK Blood Samples
RF and ANA

X

X

X

TSH and CRP

X

X

X

X

X

m

ADA
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Study Procedure

Cycles 2 – 6a

Cycle 1

Screening

End Of study
30 days after last dose of

b

Visit Days

–28 to –1
n

REGN2810 PK/Drug Conc. Sample

1

22±3

43±3

X

X

X

63±3

1

s

22±3

43±3

63±3

X

REGN2810
X

Pathology and Research Samples
o

Archived tissue for histological confirmation of CSCC

X

Optional blood DNA for genomics substudy

X

Response Imaging and other assessments
p

CT/MRI and/or digital photography
EORTC QLQ-C30
q

Concomitant medications

X

X

X

X

X

X

X

X

X

X

r

← continuous monitoring→

Adverse Events

ADA=anti-drug antibody; AE=adverse event; ANA=antinuclear antibody; aPTT=activated partial thromboplastin time; CRP=C-reactive protein; CT=computed
tomography; ECG=electrocardiogram; ECOG PS=Eastern Cooperative Oncology Group Performance Status; EOS=end of study; HCG=human chorionic
gonadotropin; INR=International Normalized Ratio; MRI=magnetic resonance imaging; RF= rheumatoid factor; TSH=thyroid-stimulating hormone;
HBV=hepatitis B virus; HCV=hepatitis C virus: HIV=human immunodeficiency virus
a
The maximum number of treatment cycles is 6 (planned 54 weeks total). See Section 6.2 regarding treatment discontinuation.
b
Should occur at least 60 days from day 1 of previous cycle, and no sooner than 18 days after the previous dose.
c
Informed consent must be provided before the initiation of screening procedures and must be obtained within 45 days prior to cycle1/day1. All screening
assessments must be performed within 28 days prior to cycle 1/day 1 (with the exception of brain MRI according to footnote h ). Assessments performed as
part of standard of care that fall within the screening window but before informed consent is obtained may be used for screening, and need not be repeated for
enrollment eligibility.
d
Complete physical examination includes head and neck, lungs, heart, abdomen, lymph nodes, extremities, and skin. A brief neurologic examination should
also be performed. The exam may be performed ≤72 hours prior to study treatment. Complete physical exam must be accompanied by assessment and
documentation of ECOG Performance Status (Appendix 7).
e
Limited physical exam includes lungs, heart, abdomen, and skin.
f
A 12-lead electrocardiogram should be recorded at screening, and 30±10 minutes after end of infusion at day 1 visits during cycle 1 and cycle 3.
g
Vital signs include temperature, resting blood pressure, pulse, and respiration. Vital signs will be assessed and documented prior to the REGN2810 infusion,
and then approximately 15 minutes after the completion of the REGN2810 infusion. The allowable window for each specified time point is ±10 minutes.
h
Brain MRI with gadolinium is required at screening if not performed in the prior 60 days. Brain scans during the treatment and follow-up periods are required
if there is a prior history of lesions present at screening or as clinically indicated. A brain CT with iodinated contrast may be performed if an MRI with
gadolinium is contraindicated.
i
Hematology includes: WBC count, 3-cell differential (ANC, monocyte count, lymphocyte count), hemoglobin, and platelet count. Samples may be collected
≤72 hours prior to study treatment.
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j

Chemistry includes: sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorous, glucose, albumin, creatinine, blood urea nitrogen (BUN),
ALT, AST, total bilirubin, alkaline phosphatase (ALP), uric acid, and LDH. Samples may be collected ≤72 hours prior to study treatment.
k
Predose β-HCG (serum) at screening up to 72 hours prior to first administration. Subsequent pregnancy tests may be urine β-HCG. Serum pregnancy test and
urine pregnancy test are requirements for women of child bearing potential only.
l
Urinalysis: glucose, blood, pH, specific gravity, ketones, and spot urine protein. Samples may be collected ≤72 hours prior to study treatment.
m
ADA samples are collected prior to treatment on day 1 of cycles 1, 3, and 5.
n
Blood samples for PK will be collected (at select sites) at pre-infusion and end of infusion on days 1, 22, and 43 of cycle 1, and on day 1 of cycles 2 through
6. The final PK sample will be collected either at the EOS visit (for patients who discontinue treatment due to progression or toxicity during cycles 1 through
6) or at the follow-up visit 1 in Table 7 (for patients who complete cycles 1 through 6). See Appendix 3 for details on PK collection schedule.
o
See Section 6.3.1 regarding requirements for documentation of histologic confirmation of diagnosis of CSCC.
p
The same method (CT with iodinated contrast or MRI with gadolinium) and/or digital medical photography used at baseline should be used throughout the
study. See Sections 6.3.1 and 6.3.2 for further details regarding imaging requirements for Group 3.
q
Concomitant medication recording will be done at the start of each cycle, at a minimum. Concomitant medications should be recorded from the date of
signing the ICF through follow-up visit 1 (post-treatment; Table 7).
r
Adverse event recording will be ongoing throughout the course of the study, using NCI-CTCAE v4. See Section 7.2.
s
(1) The EOS visit is for patients who experience PD requiring study discontinuation in cycles 1 through 6. This visit should occur 30 days (allowed window: 21
to 42 days) after the last dose of REGN2810. (2) Patients who complete the required events in Table 6 (excluding the EOS visit) with any status other than PD
(eg, CR, PR, or SD), or who discontinue treatment during cycles 1-6 for any reason other than PD, should go on to complete the assessments in Table 7 (unless
not possible, due to factors such as clinical decline or withdrawal of consent). These patients do not need to complete the EOS visit at end of cycle 6 as they
will be assessed per Table 7. After treatment and follow-up are completed or patients prematurely discontinue treatment and follow-up, patients will be
followed quarterly for survival and tumor treatment status, if available.
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Study Schedule: Follow-Up (After Cycle 12 for Group 1 and 2 Patients, or after Cycle 6 for Group 3 Patients)

Study Procedure
Visit

Time point (Day)
Physical examination (complete)a
ECOG Status
Vital Signsb
Weight

k

Follow-up 1
Cycle 12 (Gp1 and 2) or
Cycle 6 (Gp 3) visit +
28 ± 7 days
X
X
X
X

Laboratory Tests
Hematologyc, g
Blood Chemistry, d, g
Urine Pregnancy Teste,g
Urinalysisf, g
Serum IgG, IgM, IgEg

X
X
X
X
X

Immune Safety Assays
RFg
ANAg
TSHg
CRPg

X
X
X
X

PK Drug Conc/ADA Sample
REGN2810 PK/Drug Conc. Sample
ADA sample

X
X

Follow-up 2

Follow-up 3

Follow-up 4

Follow-up 1 +
28 ± 7 days
X
X
X
X

Follow-up 2
+ 28 ± 7 days
X
X
X
X

Follow-up 3 + 28 ± 7
days
X
X
X
X

Follow-up 5

Follow-up 6

Follow-up 7

Follow-up 4 Follow-up 5 + Follow-up 6 +
+ 28 ± 7 days 28 ± 7 days
28 ± 7 days
X
X
X
X
X
X
X
X
X
X
X
X

X
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Study Procedure
Visit

Time point (Day)
Pathology Samples
Tumor biopsyg
Tumor Assessments
CT/MRI (chest/abdomen/pelvis)
And/or digital photographyh
Other Clinical Assessments
Concomitant medicationsi
Adverse eventsj
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k

Follow-up 1
Cycle 12 (Gp1 and 2) or
Cycle 6 (Gp 3) visit +
28 ± 7 days

Follow-up 2

Follow-up 3

Follow-up 4

Follow-up 1 +
28 ± 7 days

Follow-up 2
+ 28 ± 7 days

Follow-up 3 + 28 ± 7
days

Follow-up 5

Follow-up 6

Follow-up 7

Follow-up 4 Follow-up 5 + Follow-up 6 +
+ 28 ± 7 days 28 ± 7 days
28 ± 7 days

=================================== At Time of Progression =====================

X

X
===========

============= ===========

X

============

X

=========== ============ ==========

ADA=anti-drug antibody; AE=adverse event; ANA=antinuclear antibody; CRP=C-reactive protein; CT=computed tomography; ECOG=Eastern Cooperative
Oncology Group; MRI=magnetic resonance imaging; RF= rheumatoid factor; TSH=thyroid-stimulating hormone.
a
Complete physical examination includes head and neck, lungs, heart, abdomen, lymph nodes, extremities, and skin. A brief neurologic examination should also
be performed. Complete physical exam must be accompanied by assessment and documentation of ECOG Performance Status (Appendix 7).
b
Vital signs include temperature, resting blood pressure, pulse, and respiration.
c
Hematology includes: WBC count, 3-cell differential (ANC, monocyte count, lymphocyte count), hemoglobin, and platelet count.
d
Chemistry includes: sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorous, glucose, albumin, creatinine, blood urea nitrogen (BUN),
ALT, AST, total bilirubin, alkaline phosphatase (ALP), uric acid, and LDH.
e
Pregnancy tests may be urine β-HCG.
f
Urinalysis: glucose, blood, pH, specific gravity, ketones, and spot urine protein.
g
At time of progression, the EOS tumor biopsy should be obtained for all patients in Group 2 (see Section 6.2.2 and Appendix 5). Blood samples for laboratory
tests (hematology, blood chemistry, urine pregnancy test, urinalysis, serum IgG, IgM, and IgE) and immune safety (RF, ANA, TSH, CRP) are also obtained at
time of progression (within 28 days of the imaging study that documented progression) according to the EOS assessment schedule in Table 5 and Table 6.
h
The same method (CT/MRI) and/or digital medical photography used at baseline should be used throughout the study. Scans linked to follow-up visits are
required only if PD has not been confirmed previously while on study. CT/MRI imaging will be obtained within 14 days prior to the follow-up visit (per
Table 7), so that the disease status is known at the time of the visit. Digital medical photography may be obtained within 14 days prior to visit, or on the day of the
visit, and response status (CR, PR, SD, PR) will guide whether the visit is to be treated as a follow-up visit or as the EOS visit.
i
Concomitant medications should be recorded from the date of informed consent through 30 days after last dose of study drug. Any drug started to treat a study
drug-related AE during the follow-up will also be recorded. In addition, any cancer treatments should be recorded from the day of informed consent until
105 days (5 half-lives) after the administration of the last dose of REGN2810. Any AE assessed as related to study treatment and persisting after 105 days
(5 half-lives) post-last dose should be reported until resolution to baseline or grade ≤1.
j
Nonserious AE and SAE data will be collected from the day of informed consent until 105 days (5 half-lives) after the last dose of REGN2810. Any AE
assessed as related to study treatment and persisting after 105 days (5 half-lives) post-last dose should be reported until resolution to baseline or grade ≤1.
k
After treatment and follow-up are completed or patients prematurely discontinue treatment and follow-up, patients will be followed quarterly for survival and
tumor treatment status, if available. See Section 6.2.2.
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6.2.

Study Follow-Up and Treatment Discontinuation

6.2.1.

Unscheduled Visits

All attempts should be made to keep patients on the study schedule as specified in Table 5 and
Table 6. Unscheduled visits may be necessary to repeat testing following abnormal laboratory
results, for follow-up of AEs, or for any other reason, as warranted.
6.2.2.

Follow-up

Patients who discontinue study treatment due to PD should return to the clinic 30 days (range:
28 to 42 days) after the last study treatment to complete the EOS assessments indicated in
Table 5,Table 6. After the EOS visit, patients should be followed for survival status until death,
loss to follow-up, or study termination by the sponsor.
For all patients in Group 2, tumor biopsies (Appendix 5) should be obtained at time of
progression, whether progression occurs in cycles 1 through 12 or during follow-up (after
cycle 12).
Patients who discontinue study treatment due to reasons other than PD (eg, toxicity, confirmed
CR after 48 weeks) should continue follow-up to complete all assessments in Table 5 and
Table 6 until PD or completion of follow-up visit 7.
For patients in Group 1 or Group 2 who complete 12 cycles of treatment or for patients in Group
3 who complete 6 cycles of treatment without disease progression and subsequently experience
disease progression without any intervening systemic anticancer therapy, resumption of
treatment with 3 mg/kg REGN2810 IV every 2 weeks will be allowed (with 350 mg IV every 3
weeks, for Group 3). Prior to resumption of REGN2810 treatment, patients must be reconsented and repeat all screening activities (with the exception of providing new archived
pathology material, or research biopsies), and the investigator must confirm that the patient still
meets all eligibility criteria (other than the exclusion regarding prior treatment with anti-PD-1).
Such patients will resume 3 mg/kg REGN2810 monotherapy treatment every 2 weeks for up to
96 weeks if originally enrolled in Group 1 or 2 (maximum 12 re-treatment cycles), or
350 mg REGN2810 monotherapy treatment every 3 weeks for up to 54 weeks if enrolled in
Group 3 (maximum 6 re-treatment cycles). The re-treatment visit schedule will follow the study
schedule in Table 5 (Group 1 and Group 2) or Table 6 (Group 3). However, PK, research blood
samples, and research tumor biopsies (exploratory “Tumor Biopsies for Group 2) are not
required for these patients during re-treatment.
After treatment and follow-up are completed or if patients prematurely discontinue from
treatment and follow-up, patients will be followed quarterly for survival and tumor treatment
status, if available, until death. Follow-up status may be determined at clinic visits or via
telephone contact with the patient, a family member of the patient, or the physician.
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6.3.

Study Procedures

6.3.1.

Procedures Required Only at the Screening/Baseline Visit

The following procedures will be performed at screening for the purpose of determining study
eligibility or characterizing the baseline population:
•

Serum β-HCG (result must be ≤72 hours before first dose).

•

HBV, HCV, and HIV screening. The required serologies are: hepatitis B surface
antigen, hepatitis C antibody test (if positive, obtain hepatitis C RNA PCR to rule out
active infection), HIV-1 and HIV-2 serum antibody

•

Documentation of pathologic confirmation of CSCC by a pathologist at the study site
(see Section 4.2.1, Inclusion 1). The pathology report that documents the diagnosis of
CSCC should be from the most recent biopsy that documented CSCC. Pathology
material (FFPE block or 10 unstained slides from the sample in the submitted
pathology report) must be provided to the sponsor prior to enrollment.

•

Group 2 only: Baseline/screening research biopsy is required (see Appendix 5 for
guidelines). This baseline biopsy is intended for exploratory assessments, but will
only be used for this purpose after central pathology confirmation of diagnosis of
CSCC is obtained on archived material. If the archived material is not sufficient for
confirmation of diagnosis of CSCC by central review, baseline biopsy material will
be used for central pathologic confirmation; remaining baseline tumor material can
only be used for exploratory assessments after central pathology confirmation of
diagnosis of CSCC has been established.

•

Brain MRI: Brain MRI is required at screening if not performed in the prior 60 days.
Brain scans during the treatment and follow-up periods are required if there is a prior
history of lesions present at screening or as clinically indicated. A brain CT may be
performed if an MRI is contraindicated.

•

Group 1 and Group 3 – Baseline imaging should include all known target lesions.
Baseline scans must evaluate extent of disease, including imaging of chest, abdomen,
and pelvis. This may be accomplished with CT chest, abdomen, and pelvis with
contrast, or CT chest with contrast and MRI abdomen/pelvis with gadolinium. The
imaging modality for metastatic lesions may be either CT with iodinated contrast or
MRI with gadolinium, per investigator discretion. Magnetic resonance imaging with
gadolinium is generally preferred for bone lesions, perineural lesions, abdomen,
pelvis, extremity, and head and neck. Computed tomography with contrast is
generally preferred for chest. For Group 1 patients who also have externally visible
lesions, digital medical photography will be used, and these lesions generally will be
followed as non-target lesions. Note: In the case of a Group 1 or Group 3 patient with
metastatic disease that is not measurable by RECIST criteria (eg, bone only lesions,
perineural disease) and with externally visible CSCC target lesions, digital medical
photography may be used to follow the externally visible lesions as target lesions.
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Group 2 – Externally visible lesions will be followed by digital medical
photography. Baseline assessments will include radiologic imaging of all target
lesions (preferably MRI with gadolinium for all anatomic sites except lung, but CT
with iodinated contrast allowed at any anatomic site, per investigator discretion) to
assess for deep invasion. Baseline radiologic assessment will also include CT chest,
preferably with contrast (If CT chest identifies a metastatic lesion, the patient should
be assigned to Group 1 if open for enrollment, or Group 3, if open for enrollment).
Efficacy Procedures

For patients with disease that can be measured radiologically according to RECIST 1.1 criteria
(Appendix 1; Eisenhauer 2009), a CT or MRI for tumor assessment will be performed as detailed
in Table 5 and Table 6. The choice of whether the imaging is by CT or MRI is an investigator
decision, but preferred imaging choices are provided in Section 6.3.1. Once the choice of CT
scan or MRI has been made, subsequent assessments should be made using the same modality
whenever possible. For patients whose CSCC lesions are evaluable on the skin, composite
response criteria (Appendix 2) should be used on the same schedule (every 8 weeks for Groups 1
and 2, every 9 weeks for Group 3), in combination with radiologic imaging if appropriate.
•

Group 1 and Group 3: Whole-body imaging – as performed at the baseline
assessment – is strongly recommended at each response assessment. At a minimum,
all radiologically measureable target lesions (RECIST 1.1) should be imaged at each
response assessment. The same radiologic imaging modality should be used at each
response assessment. Additionally, radiologic imaging of anatomic area of externally
visible target lesions should be performed at each response assessment (MRI with
gadolinium is preferred for all anatomic sites except lung). Externally visible CSCC
lesions noted at baseline should be photographed at each response assessment
(Appendix 6), and will generally be deemed non-target. New externally visible
lesions that are clinically suspicious for malignancy should be photographed
(Appendix 6) and biopsied. Note: In the case of a Group 1 or Group 3 patient with
metastatic disease that is not measurable by RECIST criteria (eg, bone only lesions,
perineural disease) and with externally visible CSCC target lesions, digital medical
photography may be used to follow the externally visible lesions as target lesions.

•

Group 2: All externally visible CSCC lesions should be photographed in a consistent
manner at each response assessment as described in Appendix 6. Radiologic imaging
(MRI with gadolinium preferred) of anatomic area of externally visible target lesions
should be performed at each response assessment. In cases in which it is the opinion
of the investigator that no significant added information was provided by baseline
radiologic imaging of the lesion (beyond the information that was provided by
baseline digital medical photography), it is allowed to use digital medical
photography only (without radiologic imaging) at subsequent response assessments of
that lesion, at the discretion of the investigator.

To account for the possibility of unconventional immune responses, immune-related response
criteria (irRC) (Nishino 2013) can inform the decision regarding whether to continue treatment
for an individual patient if the investigator believes it is in the best clinical interest of the patient,
after discussion and approval from the medical monitor. Reasons for any such decision to
Regeneron Pharmaceuticals, Inc.

Page 55 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Clinical Study Protocol

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

treat beyond the protocol definitions of progression must be documented in the CRFs.
However, irRC are currently deemed a surrogate endpoint (Postow 2015), and irRC data are not
included in the primary endpoint of this study. Any patient who experiences best response (PR
or CR) after initial progression (per Appendix 1 or Appendix 2, as appropriate) in the context of
continued treatment (according to principles of irRC in after sponsor approval) will not have that
best response (partial or complete) counted towards the primary endpoint of this study.
In Group 1 and Group 3, patients will generally be followed by RECIST 1.1 criteria
(Appendix 1). It is possible that some patients in Group 1 and Group 3 may also have externally
visible lesions that are measurable by digital medical photography. Generally, it will be
clinically appropriate to follow these externally visible lesions as non-targets. However, for
Group 1 and Group 3 patients with externally visible lesions that are deemed clinically
significant by the investigator, the clinical and composite response criteria in Appendix 2 may be
used in selected cases. However, it is anticipated that most patients in Group 1 and Group 3 will
be followed by RECIST 1.1 only.
For Group 2, response assessment is according to the clinical and composite response criteria in
Appendix 2.
For externally visible lesions that are indeterminate-appearing regarding presence of CSCC, see
Appendix 5 for guidelines on tumor biopsies. Annotation of tumor measurements and biopsies
should adhere to the guidelines in Appendix 5. If annotation of the full perimeter of a lesion is
deemed not clinically appropriate by the investigator (eg, an ulcerated lesion), the priority
annotation will be the axes delimiters. The perimeter of the lesion should be annotated as fully
as possible without causing undue discomfort to the patient.
All radiology, photography and biopsy results will be independently reviewed. A blinded central
review committee will be formed to determine overall response for each patient based on the
integration of these modalities.
6.3.3.

Safety Procedures

6.3.3.1.

Vital Signs

Vital signs, including temperature, resting blood pressure, pulse, and respiration, will be
collected at time points according to Table 5, Table 6 and, Table 7.
Note: blood pressure should be measured after the patient has been resting quietly for at least
5 minutes.
At cycle 1 day 1 and on all subsequent treatment days, vital signs will be collected prior to
infusion, and approximately 15 minutes after the completion of the infusion. The allowable
window for each specified time point is ±10 minutes.
6.3.3.2.

Physical Examination

A thorough complete or limited physical examination will be performed at visits specified in
Table 5, Table 6 and, Table 7. Care should be taken to examine and assess any abnormalities
that may be present, as indicated by the patient’s medical history.
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Complete physical examination will include examination of head and neck, lungs, heart,
abdomen, lymph nodes, extremities, and skin. A brief neurologic examination also should be
performed. Complete physical exam must be accompanied by assessment and documentation of
ECOG Performance Status (Appendix 7).
Limited physical examination will include lungs, heart, abdomen, and skin.
6.3.3.3.

Electrocardiogram

A standard 12-lead ECG will be performed at time points according to Table 5, Table 6 and
Table 7.
The patient should be relaxed and in a recumbent or semi-recumbent position at least 5 minutes
before recording an ECG. The ECG strips or reports will be retained with the source. The ECG
will be reviewed by the investigator (paper or electronic tracing) and will be available for
comparison with subsequent ECGs by the investigator. The following will be recorded on the
CRF:
•

PR Interval (msec)

•

QRS Interval (msec)

•

QT Interval (msec)

•

Heart Rate (BPM; recorded from the ventricular rate).

Any ECG finding that is judged by the investigator as a clinically significant change (worsening)
compared to the baseline value will be considered an AE, recorded, and monitored.
6.3.3.4.

Immune Safety Assays

Immune safety assays consist of rheumatoid factor (RF), thyroid-stimulating hormone (TSH),
C-reactive protein (CRP), and antinuclear antibody (ANA) titer and pattern.
If, during the course of the study, a 4-fold or greater increase from baseline in RF or ANA or
abnormal levels of TSH or CRP are observed, the following tests may also be performed:
anti-DNA antibody, anti-Sjögren’s syndrome A antigen (SSA) antibody (Ro), anti-Sjögren’s
syndrome B antigen (SSB) antibody (La), antithyroglobulin antibody, anti-LKM antibody,
antiphospholipid antibody, anti-islet cell antibody, antineutrophil cytoplasm antibody, C3, C4,
CH50.
6.3.3.5.

Immunoglobulin Levels

Serum IgG, IgM, and IgE will be measured at timepoints according to Table 5, Table 6, and
Table 7.
6.3.3.6.

Coagulation Tests

Activated partial thromboplastin time (aPTT) and International Normalized Ratio (INR) will be
analyzed by the site’s local laboratory.
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Laboratory Testing

Hematology, chemistry, urinalysis, and pregnancy testing samples will be analyzed by the site’s
local laboratory.
Detailed instructions for blood sample collection are in the laboratory manual provided to study
sites.
Samples for laboratory testing will be collected at time points according to Table 5, Table 6, and
Table 7.
Tests will include:
Blood Chemistry
Sodium

Phosphorus

ALT

Potassium

Glucose

AST

Chloride

Albumin

Total bilirubin

Bicarbonate*

Creatinine

Alkaline phosphatase (ALP)

Calcium

Blood urea nitrogen (BUN)

Magnesium

Uric acid

**

Lactate dehydrogenase (LDH)

Hematology
Hemoglobin

Differential (absolute, percent if absolute not performed):

WBCs

Neutrophils

Platelet count

Lymphocytes
Monocytes

Urinalysis
Glucose

pH

Ketones

Blood
Specific gravity
Spot urine protein
At ex-US centers where the bicarbonate test is not performed as part of the routine chemistry panel, it may be
omitted.
**
At ex-US centers where Urea assay is performed instead of Blood Urea Nitrogen (Urea), the Urea assay will be
acceptable.
*

Abnormal Laboratory Values and Laboratory Adverse Events
•

All laboratory values must be reviewed by the investigator or authorized designee.

•

Significantly abnormal tests must be repeated to confirm the nature and degree of the
abnormality. When necessary, appropriate ancillary investigations should be initiated.
If the abnormality fails to resolve or cannot be explained by events or conditions
unrelated to the study medication or its administration, the medical monitor must be
consulted.

•

The clinical significance of an abnormal test value, within the context of the disease
under study, must be determined by the investigator.

Criteria for reporting laboratory values as an AE are provided in Section 7.2.5.
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6.3.4.

Pharmacokinetic and Antibody Procedures

6.3.4.1.

Drug Concentration Measurements and Samples

REGN2810 PK parameters will be determined by measuring REGN2810 concentrations in
serum samples using a validated assay at visits and time points indicated in Table 5, Table 6, and
Table 7, and listed in Appendix 3. Actual time of each blood draw must be recorded. “Predose”
is defined as before the start of the first REGN2810 infusion. Predose samples may be collected
≤ 72 hours prior to day 1 dosing. Subsequent PK sampling times will be based on the
REGN2810 dosing time that precedes the PK sampling. Pre-infusion is defined as before the
start of the REGN2810 infusion and “0 hour” is defined as immediately after the end of the
REGN2810 infusion.
Any unused samples collected for drug concentration measurements may be used for exploratory
biomarker research or to investigate unexpected AEs.
6.3.4.2.

Anti-drug Antibody Measurements and Samples

Samples for ADA assessment will be collected prior to dosing at time points listed in Table 5,
Table 6 and, Table 7.
Any unused samples collected for ADA assessment may be used for exploratory biomarker
research or to investigate unexpected AEs.
6.3.5.

Biomarker Measurements and Samples

Speculated pharmacodynamic,
biomarkers related to
REGN2810 treatment exposure, clinical activity, or underlying disease will be investigated in
tumor biopsy tissue collected at baseline, after treatment with REGN2810, and at progression, if
available.

Biomarker results will be reported separately from the
clinical study report.
6.3.5.1.

Tumor Biomarker Procedures

For patients with locally advanced CSCC (Group 2), tumor biopsies will be collected per the
timepoints and methodology in Appendix 5.
Expression levels (mRNA and/or protein) of PD-L1, GITR, and LAG-3, as well as the number
and distribution of TILs (defined by lineage markers CD4, CD8, CD25, FoxP3) will be assessed
in tumor biopsy samples. Additional biomarkers may be measured tissue permitting.

Tumor tissue, as well as RNA and DNA isolated from tumor tissue, will be used to assess
changes in potential pharmacodynamic biomarkers induced by REGN2810 treatment from
baseline.
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Main exploratory potential biomarkers of interest include, but are not limited to:
•
•
•
•
•

Tumor RNA expression
Number and distribution of TILs (CD8+ T cells, CD4+ T cells, T regulatory cells, and
tissue permitting, other subtypes such as B cells, myeloid-derived cells, NK cells,
etc.)
Expression levels (mRNA and/or protein) of PD-L1, GITR, and LAG-3, and possibly
other check-point modulators
Mutations in known oncogenes and potential tumor neoantigens
Tumor mutation burden

Additional biomarkers may be measured (for example, exome sequencing, single cell RNA
analysis, microsatellite instability, T cell clonality) tissue permitting.

6.3.5.2.

Genomics Sub-Study – Optional

Patients who agree to participate in the genomics sub-study will be required to sign a separate
genomics sub-study ICF before collection of the samples. Blood for genomic DNA extraction
should be collected on day 1/baseline (predose), but may be collected at any study visit. Patients
are not required to participate in the genomics sub-study in order to enroll in the primary study.
DNA samples for the genomics sub-study will be double-coded as defined by the International
Council for Harmonisation (ICH) guideline E15. Sub-study samples may be stored for up to 15
years after the final date of the clinical study report and may be used for research purposes. The
purpose of the genomic analyses is to identify genomic associations with clinical or biomarker
response to target modulation, disease prognosis and progression, or other clinical outcome
measures.

6.3.6.

Group 3 Only: Guidance Regarding Patients who Wish to Continue Treatment
Beyond 54 Weeks

The intent of Group 3 is that patients who have completed 54 weeks of treatment without PD
will enter post-treatment follow-up. The potential risks and benefits of continued treatment
beyond 54 weeks are not known, but risks may include cumulative toxicities with cytotoxic
chemotherapy and late immune-related toxicities with PD-1 inhibition. The Group 3 design of
up to 54 weeks of planned treatment, with an option for re-treatment as set forth in Section 6.2.2,
must be discussed with Group 3 patients during the informed consent process.
Some patients who are experiencing clinical benefit may be hesitant to stop treatment at
54 weeks. It is important that study teams remind patients of the treatment duration as they
Regeneron Pharmaceuticals, Inc.

Page 60 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Clinical Study Protocol

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

approach the completion of 54 weeks. Patients who are experiencing durable responses or stable
disease (>6 months) should be reminded that study treatment ends at 54 weeks, with a plan for
follow-up and potential re-treatment in the event of PD.
Patients are strongly encouraged to adhere to the study plan. However, it is anticipated that some
Group 3 patients who have experienced clinical benefit may be unwilling to discontinue
treatment at 54 weeks. In such cases, the investigator will contact the medical monitor. Patients
who have not experienced PD and who are unwilling to stop study treatment will be allowed to
continue study treatment if the investigator deems that there are not unacceptable safety risks
with continued treatment, after notification of medical monitor. After 54 weeks, such patients
may continue on the same dose and schedule of study treatment (350 mg REGN2810 every 3
weeks, unless there has been dose reduction) that they have been receiving. The schedule of
events will follow Table 6, but cycles will be counted as 7 - 12 (instead of 1 – 6). The patient
will not repeat screening assessments before beginning cycle 7.

7.

SAFETY DEFINITIONS, REPORTING, AND MONITORING

7.1.

Definitions

7.1.1.

Adverse Event

An AE is any untoward medical occurrence in a patient administered a study drug which may or
may not have a causal relationship with the study drug. Therefore, an AE is any unfavorable and
unintended sign (including abnormal laboratory finding), symptom, or disease which is
temporally associated with the use of a study drug, whether or not considered related to the study
drug.
An AE also includes any worsening (ie, any clinically significant change in frequency and/or
intensity) of a pre-existing condition that is temporally associated with the use of the study drug.
Progression of underlying malignancy will not be considered an AE if it is clearly consistent
with the typical progression pattern of the underlying cancer (including time course, affected
organs, etc.). Clinical symptoms of progression may be reported as AEs if the symptom cannot
be determined as exclusively due to the progression of the underlying malignancy, or does not fit
the expected pattern of progression for the disease under study.
If there is any uncertainty about an AE being due only to progression of the underlying
malignancy, it should be reported as an AE or SAE as outlined in Section 7.2.
NCI-CTCAE version 4.03 terms should be used.

Regeneron Pharmaceuticals, Inc.

Page 61 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

Clinical Study Protocol
7.1.2.

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

Serious Adverse Event

An SAE is any untoward medical occurrence that at any dose:
•

Results in death – includes all deaths, even those that appear to be completely
unrelated to study drug (eg, a car accident in which a patient is a passenger), within
30 days of last dose of REGN2810.

•

Is life-threatening – in the view of the investigator, the patient is at immediate risk of
death at the time of the event. This does not include an AE that had it occurred in a
more severe form, might have caused death.

•

Requires in-patient hospitalization or prolongation of existing hospitalization.
In-patient hospitalization is defined as admission to a hospital or an emergency room
for longer than 24 hours. Prolongation of existing hospitalization is defined as a
hospital stay that is longer than was originally anticipated for the event, or is
prolonged due to the development of a new AE as determined by the investigator or
treating physician. Hospitalization or prolongation of existing hospitalization due to
the progression of underlying malignancy will not be considered an SAE, if it is
clearly consistent with the typical progression pattern of the underlying cancer.

•

Results in persistent or significant disability/incapacity (substantial disruption of
one’s ability to conduct normal life functions).

•

Is a congenital anomaly/birth defect

•

Is an important medical event – Important medical events may not be immediately
life-threatening or result in death or hospitalization, but may jeopardize the patient or
may require intervention to prevent 1 of the other serious outcomes listed above
(eg, intensive treatment in an emergency room or at home for allergic bronchospasm;
blood dyscrasias or convulsions that do not result in hospitalization; or development
of drug dependency or drug abuse).

Hospitalization or death due solely to manifestations consistent with typical progression of
underlying malignancy will not be considered an SAE in this study.
Serious adverse events must be reported as directed in Section 7.2.
7.1.3.

Adverse Events of Special Interest

An AESI (serious or non-serious) is one of scientific and medical interest specific to the
sponsor’s product or program, for which ongoing monitoring and rapid communication by the
investigator to the sponsor can be appropriate. Such an event might warrant further investigation
in order to characterize and understand it. Depending on the nature of the event, rapid
communication by the trial sponsor to other parties (eg, regulators) might also be warranted
(Section 7.2.3).
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7.2.

Recording and Reporting Adverse Events

7.2.1.

Adverse Events

The investigator (or designee) will seek information on AEs at each patient contact, and record
all AEs that occur from the time the informed consent is signed until 105 days (5 half-lives) after
the end of study treatment. After informed consent has been obtained but prior to initiation of
study treatment, only the following categories of AEs should be reported on the AE electronic
CRF:
•

SAEs

•

Nonserious AEs associated with a protocol-mandated intervention (eg, AEs related to
an invasive procedure such as a biopsy)

(Other AEs that occur prior to first treatment should be reported on the medical history CRF.)
All AEs after initiation of study treatment and until 105 days (5 half-lives) after the last study
treatment, regardless of relationship to study treatment, will be reported on the AE electronic
CRF. Additionally, any SAE or other AE of concern that the investigator believes may be
related to study treatment and that occurs later than 105 days (5 half-lives) after last study
treatment should be reported.
Information on follow-up for AEs is provided in Section 7.2.6. Laboratory, vital signs, or ECG
abnormalities are to be recorded as AEs as outlined in Section 7.2.5.
7.2.2.

Serious Adverse Events

All SAEs, regardless of assessment of causal relationship to study treatment must be reported to
the sponsor (or designee) within 24 hours. Refer to the safety reporting guidelines for the
procedure to be followed.
Information not available at the time of the initial report must be documented in a follow-up
report. Substantiating data such as relevant hospital or medical records and diagnostic test
reports may also be requested.
In the event the investigator is informed of an SAE that occurs more than 105 days (5 half-lives)
after the last dose of study treatment, only those SAEs or other AEs of concern deemed by the
investigator to be related to study treatment will be reported to the sponsor. The investigator
should make every effort to obtain follow-up information on the outcome of a treatment-related
SAE until the event is considered chronic and/or stable.
7.2.3.

Other Events that Require Accelerated Reporting to the Sponsor

The following events also require reporting to the sponsor (or designee) within 24 hours of
learning of the event:
Symptomatic Overdose of Study Drug:
Accidental or intentional overdose of at least 2 times the intended dose of study drug within the
intended therapeutic window, if associated with an AE.
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Pregnancy:
Although pregnancy is not considered an AE, it is the responsibility of the investigator to report
to the sponsor (or designee), within 24 hours of identification, any pregnancy occurring in a
female patient or female partner of a male patient, during the study or within 105 days of the last
dose of study drug. Any complication of pregnancy affecting a female study patient or female
partner of a male study patient, and/or fetus and/or newborn must be reported as an SAE.
Outcomes for all pregnancies should be reported to the sponsor.
Adverse Events of Special Interest:
An AESI must be reported within 24 hours of identification. Adverse events of special interest
for this study include:
•

Grade 2 or greater infusion-related reactions

•

Grade 2 or greater allergic/hypersensitivity reactions

•

Grade 3 or higher irAEs.

•

An irAE of any grade in a patient previously treated with a PI 3-K inhibitor
Note: An irAE can occur shortly after the first dose or several months after the last
dose of treatment. All AEs of unknown etiology associated with drug exposure
should be evaluated to determine possible immune etiology. If an irAE is suspected,
efforts should be made to rule out neoplastic, infectious, metabolic, toxin or other
etiologic causes prior to labeling an AE as an irAE.

Refer to the safety reporting guidelines for the reporting procedures to be followed.
If any SAE or unusual AE is judged related to study treatment, and as possible and practical,
obtain a blood sample from the patient to permit measurement of plasma drug levels.
7.2.4.

Reporting Adverse Events Leading to Withdrawal from the Study

All AEs that lead to a patient’s withdrawal from study treatment or from the study must be
reported to the sponsor’s medical monitor within 30 days.
Refer to the safety reporting guidelines for the procedures to be followed.
7.2.5.

Abnormal Laboratory, Vital Signs, or Electrocardiogram Results

The criteria for determining whether an abnormal objective test finding should be reported as an
AE include:
•

the test result is associated with accompanying symptoms, and/or

•

the test result requires additional diagnostic testing or medical/surgical intervention,
and/or

•

the test result leads to a change in dosing (outside of protocol-stipulated dose
adjustments), and/or

•

the test result leads to discontinuation from the study, significant additional
concomitant medication, or other therapy
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Contact the medical monitor in the event the investigator feels that an abnormal test finding
should be reported as an AE, although it does not meet any of the above criteria.
Repeating an abnormal test, in the absence of any of the above conditions, does not constitute an
AE. Any abnormal test result that is determined to be an error does not require reporting as an
AE.
Evaluation of severity of laboratory abnormalities will be assessed according to the scale
outlined in Section 7.3.1.
7.2.6.

Follow-up

Information for any nonserious AE that starts during the treatment period or within 105 days (5
half-lives) after last treatment will be collected from the time of the event until resolution of the
event, or until the patient’s last study visit, whichever comes first.
Serious adverse event information will be collected until the event is considered chronic and/or
stable.

7.3.

Evaluation of Severity and Causality

7.3.1.

Evaluation of Severity

The severity of AEs (including test findings classified as AEs) will be graded using the current
version of the NCI-CTCAE grading system. Adverse events not listed in the NCI-CTCAE will
be graded according to the following scale:
1 (Mild):

Mild; asymptomatic or mild symptoms; clinical or diagnostic
observations only; intervention not indicated.

2 (Moderate):

Moderate; minimal, local or noninvasive intervention indicated;
limiting age-appropriate instrumental ADL*.

3 (Severe):

Severe or medically significant but not immediately life-threatening;
hospitalization or prolongation of hospitalization indicated; disabling;
limiting self-care ADL**.

4 (Life–threatening):

Life-threatening consequences; urgent intervention indicated.

5 (Death):

Death related to AE

* Instrumental Activities of Daily Living (ADL) refer to preparing meals, shopping for groceries or clothes, using
the telephone, managing money, etc.
** Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and
not bedridden.

7.3.2.

Evaluation of Causality

Relationship of AEs to Study Drug:
The relationship of AEs to study drug will be assessed by the investigator, and will be a clinical
decision based on all available information. The following question will be addressed:
Is there a reasonable possibility that the AE may have been caused by the study drug?
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The possible answers are:
Not Related: There is no reasonable possibility that the event may have been caused by the
study drug
Related:

There is a reasonable possibility that the event may have been caused by the study
drug

The investigator should justify the causality assessment of each reported SAE.
Appendix 8 lists factors to consider in assessing the relationship of AEs to REGN2810.
Relationship of Adverse Events to Study Conduct:
The relationship of AEs or SAEs to study conduct will be assessed by the investigator, and will
be a clinical decision based on all available information. The following question will be
addressed:
Is there a reasonable possibility that the AE or SAE may have been caused by study conduct?
The possible answers are:
Not Related: There is no reasonable possibility that the event may have been caused by study
conduct
Related:

There is a reasonable possibility that the event may have been caused by study
conduct.

A list of factors to consider when assessing the relationship of AEs or SAEs to study conduct is
provided in Appendix 8.
The investigator should justify the causality assessment of each SAE.

7.4.

Safety Monitoring

The investigator will monitor the safety of study patients at his/her site(s) as per the requirements
of this protocol and consistent with current Good Clinical Practice (GCP). Any questions or
concerns should be discussed with the sponsor in a timely fashion. The sponsor will monitor the
safety data from across all study sites. The medical monitor will have primary responsibility for
the emerging safety profile of the compound. The study monitor will be supported by other
departments (eg, Pharmacovigilance and Risk Management; Biostatistics and Data
Management). Safety monitoring will be performed on an ongoing basis (eg, individual review
of SAEs) and on a periodic cumulative aggregate basis.

7.5.

Investigator Alert Notification

Regeneron (or designee) will inform all investigators participating in this clinical trial, as well as
in any other clinical trial using the same investigational drug, of any SAE that meets the relevant
requirements for expedited reporting (an AE that is serious, unexpected based on the
Investigator’s Brochure, and has a reasonable suspected causal relationship to the
medicinal/study drug).
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8.

STUDY VARIABLES

8.1.

Demographic and Baseline Characteristics

Baseline characteristics will include standard demography (eg, age, race, weight, height), disease
characteristics including medical history, cancer stage (Edge 2010), and medication history for
each patient.

8.2.

Primary and Secondary Variables

8.2.1.

Primary Efficacy Outcome Measure

The primary efficacy endpoint for this study is ORR according to central review during the
12 treatment cycles (Groups 1 and 2) or 6 treatment cycles (Group 3). Overall response rate will
be assessed separately for patients with metastatic CSCC or unresectable locally advanced
CSCC:
•

For patients in Group 1 and Group 3, RECIST version 1.1 will be used to determine
ORR (Eisenhauer 2009) (Appendix 1). For Group 1 and Group 3, patients in which
all response assessments are performed on radiologic scans according to RECIST 1.1,
the determination of the independent radiologic response assessment committee will
serve as the central response assessment. Clinical or composite response criteria
(Appendix 2) may be used for patients with externally visible target lesions, if all
metastatic lesions are not measureable by RECIST (such as may occur in patients
with bone-only metastases).

•

For patients in Group 2, clinical response criteria (Appendix 1 ) will be used to
determine ORR, for externally visible tumor(s) require bidimensional measurements
according to World Health Organization (WHO) criteria. Composite response criteria
will be used for patients who have both target lesions measurable by clinical response
criteria and by RECIST 1.1 to determine ORR (Appendix 2). In patients achieving a
CR, tumor biopsies will be used in the final determination of complete versus PR.

Patients who are deemed not evaluable (NE) by RECIST version 1.1 (Group 1 and Group 3;
Appendix 1) or inevaluable by the clinical or composite response criteria (Group 2; Appendix 2)
will be considered as not reaching PR/CR for ORR.
8.2.2.

Secondary Outcome Measures

The secondary efficacy outcome measures are:
•

ORR for Group 1, Group 2, and Group 3 by investigator assessments
− For Group 1 and Group 3 patients in which all response assessments are
performed on radiologic scans according to RECIST 1.1, the term “composite
response assessment” is not applicable. The investigator’s response assessment
for such patients will be RECIST 1.1 assessment.
− For Group 2 patients in which all response assessments are performed on
photographs according to Clinical Response Criteria for Externally Visible
Tumors (in Appendix 2), the term “composite response assessment” is not
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applicable. The investigator’s response assessment for such patients will be
according to Clinical Response Criteria for Externally Visible Tumors.
− For patients in which target lesion response assessments are performed with both
scans (according to RECIST 1.1) and photographs (according to Clinical
Response Criteria for Externally Visible Tumors), the investigator’s response
assessment will be according to Composite Response Criteria (in Appendix 3 ).
•
•
•
•
•
•
•
•
8.2.3.

Duration of response
PFS
OS
CR rate
Change in scores of patient-reported outcomes on EORTC QLQ-C30
AEs
REGN2810 concentrations in serum (Appendix 3; at select sites)
Anti-REGN2810 antibodies
Exploratory Outcome Measures

The following exploratory analyses are planned:
•

8.3.

Pharmacokinetic Variables

Serum concentration of REGN2810 will be assessed at multiple time points throughout the study
treatment and follow-up periods, and the PK will be analyzed.
Pharmacokinetic variables may include, but are not limited to, the following:
•
•
•

Ceoi – concentration at end-of-infusion
Ctrough – pre-infusion concentration
teoi – time of end-of-infusion
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Anti-drug Antibody Variables

Regeneron plans to evaluate the impact of the immunogenicity of REGN2810.
Anti-drug antibody variables include status (positive or negative) and titer as follows:
•
•
•

9.

Treatment emergent – defined as any positive post-dose ADA assay response when
baseline results are negative
Treatment boosted – defined as any post-dose ADA response that is at least 4-fold
over baseline titer levels
Titer values (Titer value category):
− Low (titer < 1,000)
− Moderate (1,000≤ titer ≤10,000)
− High (titer > 10,000)

STATISTICAL PLAN

This section provides the basis for the statistical analysis plan (SAP) for the study. The SAP may
be revised during the study to accommodate amendments to the clinical study protocol and to
make changes to adapt to unexpected issues in study execution and data that may affect the
planned analyses. The final SAP will be issued before the database is locked.
Analysis variables are listed in Section 8.

9.1.

Statistical Hypothesis

For the primary endpoint of ORR, the following null hypothesis and alternative will be tested for
Group 1, 3 and Group 2, respectively.
Group 1: H0: ORR = 15% vs. H1: ORR ≠ 15%
Group 2: H0: ORR = 25% vs. H1: ORR ≠ 25%
Group 3: H0: ORR = 15% vs. H1: ORR ≠ 15%

9.2.

Justification of Sample Size

Patients will be enrolled into 3 separate groups according to the stage of disease: metastatic
CSCC (Group 1 and Group 3) or locally advanced CSCC (Group 2). A single-stage exact
binomial design is adopted for each group, respectively, for the primary endpoint of ORR. After
completion of enrollment in Group 1, up to 53 additional patients with metastatic CSCC will be
enrolled in Group 3.
Published clinical studies for CSCC patients have had relatively small sample sizes and often
include a wide range of disease stages (Nakamura 2013). Clinical studies of CSCC patients have
been predominantly composed of patients with locally advanced disease (primary site). The
NCCN guidelines for CSCC, cisplatin monotherapy, cisplatin plus 5-FU, and cetuximab are
described as “possible options” (Bichakjian 2015). In the only study of cisplatin-based therapy
for advanced CSCC reported in the last 15 years, the ORR was 34% (Shin 2002). Cetuximab
yielded a response rate of 28% in a phase 2 study for patients with advanced CSCC
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(Maubec 2011). Most patients in these studies had locoregionally advanced disease. There
hasn’t been a publication of a clinical study specifically for patients with metastatic CSCC. The
aggregate experience of patients enrolled in trials of systemic therapy indicates that a clinically
meaningful ORR for an investigational agent would be >15% for patients with metastatic disease
or >25% for patients with unresectable locally/regionally advanced CSCC (Khansur 1991,
Lippman 1992, Nakamura 2013, Shin 2002).
Hence, the sample sizes for Group 1, Group 2, and Group 3 were selected such that the lower
limit of the 95% confidence intervals of the estimated ORRs will be clinically meaningful. The
non-clinically meaningful ORR of 15% for Group 1 and Group 3 (evaluated independently) will
be excluded using the lower limit of 95% CI if the observed ORR is 28.0% or more; ie, the ORR
for Group 1 and/or Group 3 (evaluated independently) is significantly different from 15%. The
non-clinically meaningful ORR of 25% for Group 2 will be excluded using the lower limit of
95% CI if the observed ORR is 36.1% or more; ie, the ORR for Group 2 is significantly different
from 25% (see Table 8 and Table 9).
Table 8:

The 95% Binomial Exact Confidence Intervals for Observed ORR in
Group 1 and Group 3 Given a Sample Size of 50 Patients (Based on 85%
Power)

Number of Responders

Observed ORR

95%CI – lower

95% CI – upper

7

0.14

0.058

0.267

8

0.16

0.072

0.291

9

0.18

0.086

0.314

10

0.20

0.100

0.337

11

0.22

0.115

0.360

12

0.24

0.131

0.382

13

0.26

0.146

0.403

14

0.28

0.162

0.425

15

0.30

0.179

0.446

16

0.32

0.195

0.467

17

0.34

0.212

0.488
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The 95% Binomial Exact Confidence Intervals for Observed ORR in
Group 2 Given a Sample Size of 72 Patients (Based on 90% Power)

Number of Responders

Observed ORR

95%CI – lower

95% CI – upper

18

0.250

0.155

0.366

19

0.264

0.167

0.381

20

0.278

0.179

0.396

21

0.292

0.190

0.411

22

0.306

0.202

0.425

23

0.319

0.214

0.440

24

0.333

0.227

0.454

25

0.347

0.239

0.469

26

0.361

0.251

0.483

27

0.375

0.264

0.497

28

0.389

0.276

0.511

29

0.403

0.289

0.525

30

0.417

0.302

0.539

31

0.431

0.314

0.553

32

0.444

0.327

0.566

For Group 1 and Group 3, 50 patients (in each group) will be required to provide at least 85%
power to reject a null hypothesis of an ORR of 15% at a 2-sided significance level of no more
than 5% if the true ORR is 34%. For Group 2, 72 patients will be required to provide at least
90% power to reject a null hypothesis of an ORR of 25% at a 2-sided significance level of no
more than 5% if the true ORR is 44%. The sample sizes will be further increased by 5% to
account for patients who withdraw prematurely from the study. Hence, the total sample sizes
will be 53 patients for Group 1, 76 patients for Group 2, and 53 patients in Group 3, for a total of
182 patients.

9.3.

Analysis Sets

9.3.1.

Full Analysis Set

The full analysis set (FAS) includes all patients who have passed screening and deemed to be
eligible for this study. All efficacy endpoints will be analyzed using FAS.
9.3.2.

Safety Analysis Set

The safety analysis set (SAF) includes all enrolled patients who received any study drug for each
group. Treatment compliance/administration and all clinical safety variables will be analyzed or
summarized using the SAF.
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Pharmacokinetic Analysis Set

The PK analysis set will include all patients who had received REGN2810 and had at least
1 qualified (non-missing) post-baseline measurement of REGN2810 concentration in serum.
9.3.4.

Anti-drug Antibody Set

The ADA population includes all treated patients who had at least 1 post-dose ADA result.
9.3.5.

Biomarker Analysis Set

The biomarker analysis set (BAS) includes all treated patients who had at least 1 sample assayed.

9.4.

Patient Disposition

The following will be provided by group and overall:
•
•
•
•

9.5.

The number of screened patients
The number of patients included in the FAS and the SAF
The number of patients who discontinued study participation, and the reasons for
discontinuation from the study
The number of patients who discontinued treatment, and the reasons for treatment
discontinuation

Statistical Methods

In general, the descriptive summary for continuous data will include the number of observations
(n), mean, standard deviation (SD), median, minimum and maximum.
In addition,
25% percentile and 75%-percentile will also be provided.
The descriptive summary for categorical data will include counts (n) and percentages calculated
in each group. The denominator will be determined by the analysis population used for the
summary. Non-evaluable outcome or missing data will be handled based on the data handling
strategy.
The descriptive summary for time-to-event data will include the median time-to-event and its
95% confidence intervals using the Kaplan-Meier method.
9.5.1.

Demography and Baseline Characteristics

Demographic and baseline characteristics will be summarized descriptively for each group by
extent of prior therapy (no prior systemic therapy versus having received any prior systemic
therapy).
9.5.2.

Efficacy Analyses

The primary endpoint for efficacy analyses is the ORR, by central review. For Group 1 and
Group 3 patients in which all response assessments are done by RECIST 1.1 (Eisenhauer 2009)
analysis of radiologic scans, the independent radiology review is the central review. For Group 2
patients (and some Group 1 and Group 3 patients), response assessments include photos and
radiologic scans, and the independent composite review committee will serve as the central
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review. The investigator-assessed ORR will be considered as a secondary analysis. Patients
who are deemed as not evaluable according to RECIST 1.1 or inevaluable by the composite
efficacy criteria will be considered as not reaching PR/CR for ORR (see Section 6.3.2).
The primary analyses of efficacy are based on the binomial exact confidence interval approach,
ie, whether the lower limit of 95% confidence interval will exclude a historical control ORR that
is not deemed clinically meaningful. The 95% binomial exact confidence intervals using
Clopper-Pearson method (Clopper 1934) for observed ORRs are listed for Group 1 (Table 8) and
Group 2 (Table 9) and Group 3 (Table 8).
The secondary analyses of efficacy as measured by duration of response, PFS, and OS will be
summarized by median and its 95% confidence interval by the Kaplan-Meier method.
The CR rate will be summarized descriptively with 95% confidence interval. Absence of
residual CSCC in patients with locally advanced CSCC achieving a clinical response to
REGN2810, as measured by central review, will be summarized descriptively.
9.5.3.

Exploratory Analyses

Subgroup analyses: Subgroup efficacy analyses may be performed based on the number of
prior systemic therapy regimens, the degree of differentiation of the tumor (well, moderate, or
poor), the presence or absence of human papillomavirus (HPV) in the tumor, and the presence or
absence of use of immune suppressive medications (eg, high dose steroids) to manage irAEs that
may arise during the study. However, such analyses may not have enough power for hypothesis
tests, and in that case will serve only for hypothesis-generating purpose.
Quality of life analysis: The quality of life of patients will be repeatedly measured by the
EORTC QLQ-C30 at the day 1 of each treatment cycle. The change scores of QLQ-C30 will be
summarized descriptively at each post-baseline time point. The summary scores of QLQ-C30
will also be graphically depicted by longitudinal plots.
9.5.4.

Safety Analysis

Safety observations and measurements including drug exposure, AEs, laboratory data, vital
signs, and ECOG performance status will be summarized and presented in tables and listings.
9.5.4.1.

Adverse Events

Definitions
For safety variables, 3 observation periods are defined:
•

The pre-treatment period is defined as the time from signing the ICF to before the
first dose of study drug.

•

The treatment period is defined as the day from first dose of study drug to follow-up
visit 1

•

The post-treatment period is defined as the time after follow-up visit 1.

Treatment-emergent adverse events (TEAEs) are defined as those not present at baseline or
represent the exacerbation of a condition present at baseline during the on-treatment period or
within 105 days after the last study dose.
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Analysis
All AEs reported in this study will be coded using the currently available version of the Medical
Dictionary for Regulatory Activities (MedDRA®). Coding will be to lowest level terms. The
verbatim text, the preferred term (PT), and the primary system organ class (SOC) will be listed.
Summaries of all TEAEs by group will include:
•

The number (n) and percentage (%) of patients with at least 1 TEAE by SOC and PT

•

TEAEs by severity (NCI-CTCAE, version 4.03 grade), presented by SOC and PT

•

TEAEs by outcome

•

TEAEs by relationship to experimental treatment (related, not related), presented by
SOC and PT

Deaths and other SAEs will be listed and summarized by group.
Events of NCI-CTCAE Grade 3 and Grade 4 severity will be summarized by group.
Treatment-emergent adverse events leading to permanent treatment discontinuation will be listed
and summarized by group.
9.5.4.2.

Other Safety

Vital Signs
Vital signs (temperature, pulse, blood pressure, and respiration rate) will be summarized by
baseline and change from baseline to each scheduled assessment time with descriptive statistics.
Laboratory Tests
Laboratory test results will be listed, and number and percentage of patients with NCI-CTCAE
Grade 3 or Grade 4 lab values will be summarized by lab test and by group.
9.5.4.3.

Treatment Exposure

Duration of exposure, number of dose administered and dose intensity will be summarized by
group. Dose intensity will be calculated by dividing actual dose by body weight for REGN2810.
9.5.4.4.

Treatment Compliance

Patients will be administered IV study drug and treatment compliance will be defined in detail in
the SAP and summarized by group.
9.5.5.

Analysis of Drug Concentration Data

9.5.5.1.

Descriptive Analysis of Drug Concentrations

Summaries of study drug concentrations will be presented by nominal time point (ie, the time
points specified in the protocol) and group.
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Analysis of Anti-Drug Antibody Data

Formation of ADA will be assessed in individual patients and per treatment group as follows:
•

Possible correlation between changes in PK profile and the presence/absence of
anti-REGN2810 antibodies will be evaluated to identify a potential impact of
anti-REGN2810 antibodies on drug exposure.

•

Possible correlation between AEs and the presence/absence of anti-REGN2810
antibodies may be evaluated to identify a potential impact of anti-REGN2810
antibodies on the incidence of Grade 3 and 4 AEs, atypical AEs, and SAEs.

Cases of ADA positivity will be listed and summarized as appropriate.
9.5.7.

Analysis of Biomarker Data

Biomarker data will be analyzed using standard scientific methods and summarized by
descriptive statistics and plot. Comparative analysis of biomarker data with parent study may be
performed using paired t-test or nonparametric Wilcoxon signed rank test or Chi-square test.
Correlative analysis with clinical response may be performed using correlation coefficient, box
plot and scatter plot, and basic regression models. Both comparative analysis and correlative
analysis will be exploratory in nature and will be described in a separate report.
9.5.7.1.

Sample Size Justification for Biomarker Measurements in Tumor Tissue
Biopsies

Although many biomarkers may be assayed in tumor biopsy tissues, CD274 (PD-L1) was
selected to illustrate the power analysis as an example. PD-L1 expression level, as defined by
percent tumor cells with membranous staining by immunohistochemistry, was reported to be
associated with clinical activity of Nivolumab (Borghaei 2015).
The prevalence of
PD-L1 expression levels ≥1%, ≥5%, ≥10% were 53%, 41%, and 37%, respectively, and the
ORRs were reported as 9% vs. 31%, 10% vs. 36%, 11% vs. 37% for each categorization of
PD-L1 expression level, respectively. In the following power analysis, the following variations
are considered (Table 10):
1. Actual number of tumor biopsy obtained and deemed evaluable are 60, 50, or 40.
2. The PD-L1 expression level categorization results in PD-L1 negative / positive ratio as
1:1 or 3:2.
3. Objective response rates of 10% (PD-L1 negative) vs. 30% (PD-L1 positive) results an
odds ratio of 3.857 and 10% (PD-L1 negative) vs. 25% (PD-L1 positive) results an odds
ratio of 3.0
The power analysis was based on the one-sided Chi-square test with type I error of 20% due to
the exploratory nature of biomarker analysis, performed in nQuery Advisor 7.0 (Elashoff 2007).
The power may be overestimated for some configurations as the large sample approximation
may not be adequate for a Chi-square test with small sample sizes.
In summary, requiring each patient enrolled in this study to provide tumor biopsy provides
moderate power for exploratory biomarker analysis.
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Power Analysis for PD-L1 Biomarkers from Tumor Biopsies

Number of
Tumor Biopsies
60

PD-L1
Neg/Pos
1:1

50

1:1

40

1:1

60

3:2

50

3:2

40

3:2

Tumor Response
Odds Ratio
3.857
3.0
3.857
3.0
3.857
3.0
3.857
3.0
3.857
3.0
3.857
3.0

Power (%)
87
75
83
71
77
66
86
75
82
70
76
65

Multiplicity Considerations

Adjustments to the significance level for the purposes of multiple testing are not applicable for
this study. Statistical analyses for Group 1 and Group 2 will be conducted and reported
separately; ie, efficacy results and clinical conclusions from Group 1 will not affect those of
Group 2, and vice versa. Therefore, statistical control of overall type I error for the whole study
is not planned.
Group 3 is a 53 patient cohort that opens after Group 1 completes enrollment. Efficacy results
and clinical conclusions from Group 3 will not affect those of Group 1 or Group 2. Efficacy
results and clinical conclusions from Group 1 or Group 2 will not affect those of Group 3.

9.7.

Interim Analysis

For regions where alpha spending is not required: For this planned interim analysis, the ORR
and associated 95% confidence interval will be summarized. As the primary objective of this the
interim analysis is point estimation on ORR and characterizing the precision of point estimation,
there is no hypothesis testing associated with this interim analysis. Also, no decisions will be
made regarding study conduct associated with the interim analysis. Therefore, Type I error
adjustment is not applicable for this planned interim analysis.
For regions where alpha spending is required: For this interim analysis on Group 2 patients,
2-sided alpha of 0.0001 will be allocated for interim analysis, and 2-sided alpha of 0.0499 will be
preserved for the final analysis. Correspondingly, for the interim analysis of the primary
endpoint of ORR in Group 2 patients, the precision of ORR will be estimated by adjusted and
2-sided 99.99% exact confidence interval. The un-adjusted and 2-sided 95% exact confidence
interval will also be reported at the time of interim analysis. At the time of the final analysis for
Group 2 patients, both adjusted 95.01% and un-adjusted 95% exact confidence interval will be
reported.

Regeneron Pharmaceuticals, Inc.

Page 76 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

Clinical Study Protocol

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

For other efficacy endpoints in Group 2 patients, only 2-sided 95% exact confidence interval will
be presented both at the interim and at the final analysis.

9.8.

Additional Statistical Data Handling Conventions

The following analysis and data conventions will be followed:
Definition of baseline:
•

Unless otherwise specified, the last assessment before the initial administration of
REGN2810 will be considered the baseline evaluation

General rules for handling missing data:
•

Unless otherwise specified, there will be no imputations for the missing data

•

If the start date of an AE or concomitant medication is incomplete or missing, it will
be assumed to have occurred on or after the intake of study medication except if an
incomplete date (eg, month and year) clearly indicates that the event started prior to
treatment. If the partial date indicates the same month or year of the intake of study
medication date, then the start date by the study medication intake date will be
imputed, otherwise, the missing day or month by the first day or the first month will
be imputed.

•

Patients who are deemed NE by RECIST version 1.1 (Group 1; Appendix 1) or
inevaluable by the composite response criteria (Group 2; Appendix 2) will be
considered as not reaching PR/CR for ORR. Their disease progression will be
censored at the date of baseline tumor assessment + 1 day. Duration of response and
PFS will be censored at the last tumor assessment date for patients without disease
progression.

•

Missing data in quality of life analysis will be presented as missing in changes scores.

Visit windows:
•

9.9.

Assessments taken outside of protocol allowable windows will be displayed
according to the case report form (CRF) assessment recorded by the investigator.

Statistical Considerations Surrounding the Premature Termination
of a Study

If the study is terminated prematurely, only those parameters required for the development
program and/or reporting to regulatory authorities will be summarized. Investigator and sponsor
responsibilities surrounding the premature termination of a study are presented in Section 15.1.
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10.

DATA MANAGEMENT AND ELECTRONIC SYSTEMS

10.1.

Data Management

A data management plan specifying all relevant aspects of data processing for the study
(including data validation, cleaning, correcting, releasing) will be maintained and stored at
Regeneron.
A medical coding plan will specify the processes and the dictionary used for coding. All data
coding (eg, AEs, baseline findings, medication, medical /surgical history) will be done using
internationally recognized and accepted dictionaries.
The CRF data for this study will be collected with electronic data capture (EDC) tool. User
training must be documented before the user is granted access to the EDC system.

10.2.

Electronic Systems

Electronic systems that may be used to process and/or collect data in this study will include the
following:
•

EDC system – data capture

•

Statistical Analysis Systems (SAS) (Software)– statistical review, analysis and
reporting

•

Pharmacovigilance safety database

•

IWRS

11.

STUDY MONITORING

11.1.

Monitoring of Study Sites

The study monitor and/or designee (eg, contract research organization [CRO] monitor) will visit
each site prior to enrollment of the first patient, and periodically during the study. In accordance
with ICH guidelines, the monitor will compare the CRF entries with the appropriate source
documents. Additional review may include, but is not limited to, patient ICFs, documentation of
patient recruitment and follow-up, AEs, SAEs, and concomitant therapy; as well as records of
study drug dispensing, compliance, and accountability. A copy of the drug dispensing log must
be provided to the sponsor upon request.

11.2.

Source Document Requirements

Investigators are required to prepare and maintain adequate and accurate patient records (source
documents).
The investigator must keep all source documents on file with the CRF (throughout this protocol,
CRF refers to either a paper CRF or an eCRF). Case report forms and source documents must be
available at all times for inspection by authorized representatives of the sponsor and regulatory
authorities.
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Case Report Form Requirements

Study data obtained in the course of the clinical study will be recorded on electronic CRFs by
trained site personnel. A CRF must be completed for each and every patient enrolled in the
study. After review of the clinical data for each patient, the investigator must provide an
electronic signature. A copy of each CRF page is to be retained by the investigator as part of the
study record and must be available at all times for inspection by authorized representatives of the
sponsor and regulatory authorities.
Corrections to the CRF will be entered in the CRF by the investigator or an authorized designee.
All changes, including date and person performing corrections, will be available via the audit
trail, which is part of the system. For corrections made via data queries, a reason for any
alteration must be provided.

12.

AUDITS AND INSPECTIONS

This study may be subject to a quality assurance audit or inspection by the sponsor or regulatory
authorities. Should this occur, the investigator is responsible for:
•

Informing the sponsor of a planned inspection by the authorities as soon as
notification is received, and authorizing the sponsor’s participation in the inspection

•

Providing access to all necessary facilities, study data, and documents for the
inspection or audit

•

Communicating any information arising from inspection by the regulatory authorities
to the sponsor immediately

•

Taking all appropriate measures requested by the sponsor to resolve the problems
found during the audit or inspection

Documents subject to audit or inspection include but are not limited to all source documents,
CRFs, medical records, correspondence, ICFs, Institutional Review Board (IRB) files,
documentation of certification and quality control of supporting laboratories, and records
relevant to the study maintained in any supporting pharmacy facilities. Conditions of study
material storage are also subject to inspection. In addition, representatives of the sponsor may
observe the conduct of any aspect of the clinical study or its supporting activities both within and
outside of the investigator’s institution.
In all instances, the confidentiality of the data must be respected.

13.

ETHICAL AND REGULATORY CONSIDERATIONS

13.1.

Good Clinical Practice Statement

It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study
will be conducted in accordance with the ethical principles that have their origin in the
Declaration of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable
regulatory requirements.
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Informed Consent

The principles of informed consent are described in ICH Guidelines for GCP.
The ICF used by the investigator must be reviewed and approved by the sponsor prior to
submission to the appropriate IRB. A copy of the IRB-approved ICF and documentation of
approval must be provided to the sponsor before study drug will be shipped to the study site.
It is the responsibility of the investigator or designee (if acceptable by local regulations) to obtain
written informed consent from each patient prior to his/her participation in the study and after the
aims, methods, objectives, and potential hazards of the study have been explained to the patient
in language that he/she can understand. The ICF should be signed and dated by the patient and
by the investigator or authorized designee who reviewed the ICF with the patient.
•

Patients who can write but cannot read will have the ICF read to them before signing
and dating the ICF.

•

Patients who can understand but who can neither write nor read will have the ICF
read to them in presence of an impartial witness, who will sign and date the ICF to
confirm that informed consent was given.

The original ICF must be retained by the investigator as part of the patient’s study record, and a
copy of the signed ICF must be given to the patient.
If new safety information results in significant changes in the risk/benefit assessment, the ICF
must be reviewed and updated appropriately. All study patients must be informed of the new
information and provide their written consent if they wish to continue in the study. The original
signed revised ICF must be maintained in the patient’s study record and a copy must be given to
the patient.

13.3.

Patient Confidentiality and Data Protection

The investigator must take all appropriate measures to ensure that the anonymity of each study
patient will be maintained. Patients should be identified by a patient identification number, only,
on CRFs or other documents submitted to the sponsor. Documents that will not be submitted to
the sponsor (eg, signed ICF) must be kept in strict confidence.
The patient’s and investigator’s personal data, which may be included in the sponsor database,
will be treated in compliance with all applicable laws and regulations. The sponsor shall take all
appropriate measures to safeguard and prevent access to this data by any unauthorized third
party.

Regeneron Pharmaceuticals, Inc.

Page 80 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

Clinical Study Protocol

13.4.

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

Institutional Review Board/Ethics Committee

An appropriately constituted IRB/Ethics Committee (EC), as described in ICH Guidelines for
GCP, must review and approve:
•

The protocol, ICF, and any other materials to be provided to the patients
(eg, advertising) before any patient may be enrolled in the study

•

Any amendment or modification to the study protocol or ICF before implementation,
unless the change is necessary to eliminate an immediate hazard to the patients, in
which case the IRB/EC should be informed as soon as possible

•

Ongoing studies on an annual basis or at intervals appropriate to the degree of risk

In addition, the IRB/EC should be informed of any event likely to affect the safety of patients or
the continued conduct of the clinical study.
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their
functions must be received by the sponsor prior to shipment of drug supplies to the investigator.
The approval letter should include the study number and title, the documents reviewed, and the
date of the review.
Records of the IRB/EC review and approval of all study documents (including approval of
ongoing studies) must be kept on file by the investigator.

14.

PROTOCOL AMENDMENTS

The sponsor may not implement a change in the design or operation of the protocol or ICF
without an IRB/EC-approved amendment.

15.

PREMATURE TERMINATION OF THE STUDY OR
CLOSE-OUT OF A SITE

15.1.

Premature Termination of the Study

The sponsor has the right to terminate the study prematurely. Reasons may include efficacy,
safety, or futility, among others. Should the sponsor decide to terminate the study, the
investigator(s) will be notified in writing.

15.2.

Close-out of a Site

The sponsor and the investigator have the right to close-out a site prematurely.
Investigator’s Decision
The investigator must notify the sponsor of a desire to close-out a site in writing, providing at
least 30 days’ notice. The final decision should be made through mutual agreement with the
sponsor. Both parties will arrange the close-out procedures after review and consultation.

Regeneron Pharmaceuticals, Inc.

Page 81 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

Clinical Study Protocol

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

Sponsor’s Decision
The sponsor will notify the investigator(s) of a decision to close-out a study site in writing.
Reasons may include the following, among others:
•
•

•

The investigator has received all items and information necessary to perform the
study, but has not enrolled any patient within a reasonable period of time
The investigator has violated any fundamental obligation in the study agreement,
including but not limited to, breach of this protocol (and any applicable amendments),
breach of the applicable laws and regulations, or breach of any applicable ICH
guidelines
The total number of patients required for the study are enrolled earlier than expected

In all cases, the appropriate IRB/EC and Health Authorities must be informed according to
applicable regulatory requirements, and adequate consideration must be given to the protection
of the patients’ interests.

16.

STUDY DOCUMENTATION

16.1.

Certification of Accuracy of Data

A declaration assuring the accuracy and content of the data recorded on the CRFs must be signed
by the investigator. This certification form accompanies each set of CRFs. The signed form will
be provided to the sponsor with the final set of CRFs for each patient.

16.2.

Retention of Records

The investigator must retain all essential study documents, including ICFs, source documents,
investigator copies of CRFs, and drug accountability records for at least 15 years following the
completion or discontinuation of the study, or longer if a longer period is required by relevant
regulatory authorities. The investigator must consult with the sponsor before discarding or
destroying any essential study documents following study completion or discontinuation.
Records must be destroyed in a manner that ensures confidentiality.
If the investigator’s personal situation is such that archiving can no longer be ensured, the
investigator must inform the sponsor and the relevant records will be transferred to a mutually
agreed-upon destination.

17.

CONFIDENTIALITY

Confidentiality of information is provided as a separate agreement.

18.

FINANCING AND INSURANCE

Financing and insurance information is provided as a separate agreement.

19.

PUBLICATION POLICY

The publication policy is provided as a separate agreement.
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INVESTIGATOR’S AGREEMENT

I have read the attached protocol: A Phase 2 Study of REGN2810, a Fully Human Monoclonal
Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell
Carcinoma, and agree to abide by all provisions set forth therein.
I agree to comply with the current International Council for Harmonisation Guideline for Good
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country,
state, or locality relating to the conduct of the clinical study.
I also agree that persons debarred from conducting or working on clinical studies by any court or
regulatory agency will not be allowed to conduct or work on studies for the sponsor or a
partnership in which the sponsor is involved. I will immediately disclose it in writing to the
sponsor if any person who is involved in the study is debarred, or if any proceeding for
debarment is pending, or, to the best of my knowledge, threatened.
This document contains confidential information of the sponsor, which must not be disclosed to
anyone other than the recipient study staff and members of the IRB/EC. I agree to ensure that
this information will not be used for any purpose other than the evaluation or conduct of the
clinical investigation without the prior written consent of the sponsor.

(Signature of Investigator)

(Date)

(Printed Name)
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RESPONSE EVALUATION CRITERIA IN SOLID
TUMORS: RECIST GUIDELINE (VERSION 1.1)

For the purposes of this study, patients should be re-evaluated for response every 8 weeks
(Group 1 and Group 2) or every 9 weeks (Group 3). Confirmatory scans should also be obtained
4 weeks following initial documentation of objective response or progressive disease.
Response and progression will be evaluated in this study using the international criteria proposed
by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1;
Eisenhauer 2009). Changes in the largest diameter (unidimensional measurement) of the tumor
lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST
criteria.
Selection of Lesions
•

Measurable disease: Measurable lesions are defined as those that can be accurately
measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm
(≥2 cm) by chest x-ray or as ≥ 10 mm (≥ 1 cm) with CT scan, MRI, or calipers by
clinical exam. All tumor measurements must be recorded in millimeters (or decimal
fractions of centimeters).
Note:

•

Malignant lymph nodes: To be considered pathologically enlarged and measurable,
a lymph node must be ≥ 15 mm (≥ 1.5 cm) in short axis when assessed by CT scan
(CT scan slice thickness recommended to be no greater than 5 mm [0.5 cm]). At
baseline and in follow-up, only the short axis will be measured and followed.

•

Non-measurable disease: All other lesions (or sites of disease), including small
lesions (longest diameter < 10 mm [< 1 cm] or pathological lymph nodes with ≥ 10 to
< 15 mm [≥ 1 to < 1.5 cm] short axis), are considered non-measurable disease. Bone
lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis
cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed
by CT or MRI), are considered as non-measurable.
Note: Cystic lesions that meet the criteria for radiographically defined simple cysts
should not be considered as malignant lesions (neither measurable nor
non-measurable) since they are, by definition, simple cysts. ‘Cystic lesions’ thought
to represent cystic metastases can be considered as measurable lesions, if they meet
the definition of measurability described above. However, if non-cystic lesions are
present in the same patient, these are preferred for selection as target lesions.

•

Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and
5 lesions in total, representative of all involved organs, should be identified as target
lesions and recorded and measured at baseline. Target lesions should be selected on
the basis of their size (lesions with the longest diameter), be representative of all
involved organs, but in addition should be those that lend themselves to reproducible
repeated measurements. It may be the case that, on occasion, the largest lesion does
not lend itself to reproducible measurement in which circumstance the next largest
lesion which can be measured reproducibly should be selected. A sum of the
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diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes
are to be included in the sum, then only the short axis is added into the sum. The
baseline sum diameters will be used as reference to further characterize any objective
tumor regression in the measurable dimension of the disease.
•

Non-target lesions: All other lesions (or sites of disease) including any measurable
lesions over and above the 5 target lesions should be identified as non-target lesions
and should also be recorded at baseline. Measurements of these lesions are not
required, but the presence, absence, or in rare cases unequivocal progression of each
should be noted throughout follow-up.

Methods for Evaluation of Measurable Disease
All measurements should be taken and recorded in metric notation using a ruler or calipers. All
baseline evaluations should be performed as closely as possible to the beginning of treatment and
never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be
imaged but are assessable by clinical exam.
•

Clinical lesions. Clinical lesions will only be considered measurable when they are
superficial (eg, skin nodules and palpable lymph nodes) and ≥10 mm (≥1 cm)
diameter as assessed using calipers (eg, skin nodules). In the case of skin lesions,
documentation by color photography, including a ruler to estimate the size of the
lesion, is recommended.

•

Chest x-ray. Lesions on chest x-ray are acceptable as measurable lesions when they
are clearly defined and surrounded by aerated lung. However, CT is preferable.

•

Conventional CT and MRI. This guideline has defined measurability of lesions on
CT scan based on the assumption that CT slice thickness is 5 mm (0.5 cm) or less. If
CT scans have slice thickness greater than 5 mm (0.5 cm), the minimum size for a
measurable lesion should be twice the slice thickness. MRI is also acceptable in
certain situation.

•

PET-CT. At present, the low dose or attenuation correction CT portion of a
combined PET-CT is not always of optimal diagnostic CT quality for use with
RECIST measurements. However, if the site can document that the CT performed as
part of a PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and
oral contrast), then the CT portion of the PET-CT can be used for RECIST
measurements and can be used interchangeably with conventional CT in accurately
measuring cancer lesions over time. Note, however, that the PET portion of the CT
introduces additional data which may bias an investigator if it is not routinely or
serially performed.

•

Ultrasound. Ultrasound is not useful in assessment of lesion size and should not be
used as a method of measurement. Ultrasound examinations cannot be reproduced in
their entirety for independent review at a later date and, because they are operator
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dependent, it cannot be guaranteed that the same technique and measurements will be
taken from one assessment to the next. If new lesions are identified by ultrasound in
the course of the study, confirmation by CT or MRI is advised. If there is concern
about radiation exposure at CT, MRI may be used instead of CT in selected instances.
•

Endoscopy, Laparoscopy. The utilization of these techniques for objective tumor
evaluation is not advised. However, such techniques may be useful to confirm
complete pathological response when biopsies are obtained or to determine relapse in
trials where recurrence following complete response (CR) or surgical resection is an
endpoint.

•

Tumor markers. Tumor markers alone cannot be used to assess response. If markers
are initially above the upper normal limit, they must normalize for a patient to be
considered in complete clinical response.

•

Cytology, Histology. These techniques can be used to differentiate between partial
responses (PR) and complete responses (CR) in rare cases (eg, residual lesions in
tumor types, such as germ cell tumors, where known residual benign tumors can
remain).
The cytological confirmation of the neoplastic origin of any effusion that appears or
worsens during treatment when the measurable tumor has met criteria for response or
stable disease is mandatory to differentiate between response or stable disease (an
effusion may be a side effect of the treatment) and progressive disease

•

FDG-PET. While FDG-PET response assessments need additional study, it is
sometimes reasonable to incorporate the use of FDG-PET scanning to complement
CT scanning in assessment of progression (particularly possible ‘new’ disease). New
lesions on the basis of FDG-PET imaging can be identified according to the following
algorithm:
a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of
PD based on a new lesion.
b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive
FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this
is PD. If the positive FDG-PET at follow-up is not confirmed as a new site of
disease on CT, additional follow-up CT scans are needed to determine if there is
truly progression occurring at that site (if so, the date of PD will be the date of the
initial abnormal FDG-PET scan). If the positive FDG-PET at follow-up
corresponds to a pre-existing site of disease on CT that is not progressing on the
basis of the anatomic images, this is not PD.
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a
biopsy in cases where a residual radiographic abnormality is thought to represent
fibrosis or scarring. The use of FDG-PET in this circumstance should be
prospectively described in the protocol and supported by disease-specific medical
literature for the indication. However, it must be acknowledged that both
approaches may lead to false positive CR due to limitations of FDG-PET and
biopsy resolution/sensitivity.
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Note: A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake
greater than twice that of the surrounding tissue on the attenuation corrected image.
Response Criteria
Evaluation of Target Lesions
•

Complete Response (CR): Disappearance of all target lesions. Any pathological
lymph nodes (whether target or non-target) must have reduction in short axis to
<10 mm (<1 cm).

•

Partial Response (PR): At least a 30% decrease in the sum of the diameters of target
lesions, taking as reference the baseline sum diameters.

•

Progressive Disease (PD): At least a 20% increase in the sum of the diameters of
target lesions, taking as reference the smallest sum on study (this includes the
baseline sum if that is the smallest on study). In addition to the relative increase of
20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm).
(Note: the appearance of one or more new lesions is also considered progressions).

•

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient
increase to qualify for PD, taking as reference the smallest sum diameters while on
study.

Evaluation of Non-Target Lesions
•

Complete Response (CR): Disappearance of all non-target lesions and normalization
of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm
[<1 cm] short axis).
Note: If tumor markers are initially above the upper normal limit, they must
normalize for a patient to be considered in complete clinical response.

•

Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or
maintenance of tumor marker level above the normal limits.

•

Progressive Disease (PD): Appearance of one or more new lesions and/or
unequivocal progression of existing non-target lesions. Unequivocal progression
should not normally trump target lesion status. It must be representative of overall
disease status change, not a single lesion increase.

Although a clear progression of “non-target” lesions only is exceptional, the opinion of the
treating physician should prevail in such circumstances, and the progression status should be
confirmed at a later time by the review panel (or Principal Investigator).
Evaluation of Overall Response Criteria
The best overall response is the best response recorded from the start of the treatment until
disease progression/recurrence (taking as reference for progressive disease the smallest
measurements recorded since the treatment started). The patient’s best response assignment will
depend on the achievement of both measurement and confirmation criteria. Revised Response
Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Eisenhauer 2009) are summarized in
the table:
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Response According to Revised Response Evaluation Criteria in Solid Tumors
(Version 1.1)
Target
Lesions

Non-Target Lesions

New
Lesions

Overall
Response

Best Overall Response when
Confirmation is Requireda

CR

CR

No

CR

>4 weeks confirmation

CR

Non-CR/Non-PD

No

PR

>4 weeks confirmation

CR

Not evaluated

No

PR

PR

Non-CR/Non-PD/not evaluated

No

PR

SD

Non-CR/Non-PD/not evaluated

No

SD

Documented at least once
>4 weeks from baseline

PD

Any

Yes or No

PD

no prior SD, PR or CR

Any

PD*

Yes or No

PD

Any

Any

Yes

PD

CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease.
In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as PD.

a
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COMPOSITE RESPONSE CRITERIA FOR PATIENTS
WITH LOCALLY ADVANCED CSCC

These criteria are designed primarily for patients in Group 2. This appendix describes clinical
response criteria for externally visible lesions that can be measured bi-dimensionally using
digital medical photography. This appendix also provides composite response criteria for disease
that is measureable by both clinical response criteria and RECIST 1.1.
Group 2 patients will be followed by digital medical photography. Group 2 patients will also
undergo radiologic imaging (typically, MRI with gadolinium) at baseline, and this will also be
performed serially at each response assessment unless the investigator deems that baseline
radiologic imaging was uninformative. Radiologic imaging (preferably, MRI with gadolinium)
will be essential in the evaluation of tumors that have subdermal components that cannot be
adequately assessed by digital medical photography. See protocol Section 6.3.1 and 6.3.2 for
further information on imaging requirements for Group 2 patients.
Response assessments occur every 8 weeks (except for Group 3, in which response assessments
occur every 9 weeks). Standardized digital photographs of the externally visible component of all
target lesions must be obtained at baseline and at the time of each subsequent tumor assessment.
Guidelines for digital medical photography are provided in Appendix 6. Investigators will also
provide a clinical description of the externally visible target lesion(s) at baseline and at each
tumor assessment, as well as comments on any changes in the lesion(s) since the previous
assessment.
SPECIAL ISSUES FOR EXTERNALLY VISIBLE TUMORS:
1) Anatomic Defects
Regarding tumor around a surgical cavity/anatomic defect (eg, rhinectomey), such lesions should
be considered non-measureable unless there is a nodular lesion measuring ≥10 mm in maximal
bi-dimensional perpendicular diameters. The surgical cavity or anatomic defect should not be
considered in measuring the lesion.
2) Indeterminate-Appearing Tissue
If there is uncertainty about whether a given lesion or area of a lesion represents malignancy
versus benign process (eg, scarring, fibrosis), biopsies should be obtained.
Indeterminate-appearing areas (eg, scarring, fibrosis) are included in the tumor measurements
unless biopsies are obtained to establish benign status.
To reduce risk of sample error, biopsy of only a single area on the tumor is not allowed. Biopsy
of at least two separate areas of the lesion are required when biopsy is indicated. Each biopsy
will be performed in a pairwise manner (approximately adjacent) so that there will be one sample
for local review and one for central review for each biopsy, as per Appendix 5.
As such, when the decision is made to perform biopsy, at least 4 biopsy samples are obtained
(biopsy of two separate areas, with two biopsies in each area: one for central, one for local from
each area). Biopsy samples will not be bisected or split in half for local and central review;
rather, separate adjacent samples will be obtained. See Appendix 5 for biopsy details.
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Note on timeline for finalization of measurement/response assessment: Generally, baseline
disease measurements and response assessments should be completed on the day of the visit at
which digital medical photography was performed. However, for visits in which tumor biopsies
are performed, it is understood that the local pathology report may not be available for up to
5 business days after the biopsy.
When biopsies are performed to distinguish between benign versus malignant tissue, the
annotated photograph for that visit should clearly indicate the region of the tumor that was
biopsied to distinguish benign versus malignant tissue. Within one week of the date of biopsies,
the investigator should finalize the tumor measurements for that visit with the benefit of the local
pathology report.
For circumstances in which the intent of the biopsy is to distinguish between disease stability and
response, it is not necessary to hold study treatment while the local pathology report is pending.
For circumstances in which the biopsy, if positive, would result in discontinuation of study
treatment due to progression, treatment should be held until biopsy results are finalized and
progression has been ruled out.
3) Local Versus Central Review
An independent photographic review committee, with access to de-identified digital medical
photography results and biopsy results, will provide response assessments as required by the
sponsor to address study objectives (Section 2). Independent photographic reviews will be
scheduled by the sponsor in coordination with vendor, but will not be “real-time.” Clinical
management decisions generally will be as per investigator response assessments and local
pathology review. In the unlikely event that independent review yields major differences with the
local response assessment that could have implications for the ongoing management of an active
patient on study, the situation will be discussed between the sponsor and the investigator in order
to determine patient management.
4) Confirmation of Responses
After any objective response, confirmatory digital photography (and radiologic imaging, if
performed as part of the initial response assessment) will be obtained at least 4 weeks following
initial documentation of objective response.
For any complete responses observed in digital medical photography of externally visible target
lesions, confirmatory biopsies are required to establish status of complete response.
5) Patients in Group 1 and Group 3 with Externally Visible Tumors
Regarding Group 1 and Group 3 (metastatic CSCC), these patients will generally be followed by
RECIST 1.1 criteria (Appendix 1). It is possible that some patients in Group 1 or Group 3 may
also have externally visible lesions that are measurable by digital medical photography. In such
circumstances, the externally visible lesions generally will be followed as non-target lesions. The
exception to this rule would be a patient with externally visible lesions in whom the only M1
lesions are not measurable by RECIST (eg, a patient with bone-only metastases), in which case
the externally visible lesions (lesion size ≥10 mm in baseline dimensional perpendicular axes)
would be target lesions and followed as per clinical response criteria in this appendix, and the
non-measureable metastatic lesions (eg, bone metastases) would be followed as non-target
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lesions. For any target lesions in Group 2 or Group 1 or Group 3 that are measured by digital
medical photography, measurements will be bi-dimensional.
6) Patients in Group 2 with Deeply Invasive Tumors
Regarding Group 2 (unresectable locally advanced CSCC), tumor measurements for these
patients will generally be performed with digital medical photography (bi-dimensional
measurements). However, some patients in Group 2 may have deeply invasive target lesions in
which tumor measurements can better be obtained with cross-sectional imaging (eg, MRI with
gadolinium or CT with contrast). For any target lesions in Group 2 (as in Group 1 or Group 3)
that are measured by cross-sectional imaging (MRI gadolinium or CT with contrast),
measurements will unidimensional according to RECIST 1.1.
Clinical Response Criteria for Externally Visible Tumors (for Group 2 patients with
locally advanced CSCC, and selected Group 1 and Group 3 patients in which target lesions are
followed by digital medical photography)
A. Externally Visible Tumor Dimension
The externally visible component of target lesion(s) will be measured using bi-dimensional
WHO criteria as the sum of the products (of individual target lesions) in the longest dimension
and perpendicular second longest dimension at each tumor assessment and will be documented
using standardized digital photography (Appendix 6). In the absence of substantial change in
lesion geometry, subsequent visit measurements should be performed in the same axes and the
investigator should refer to the previous visit’s annotated photographs as a starting point to
identify axis for measurement when making subsequent assessments.
Clinical response criteria for externally visible tumor(s) require bidimensional measurements
according to WHO criteria (reference), and are as follows:
•

Complete response of externally visible disease (vCR): all target lesion(s) and nontarget lesion(s) no longer visible, maintained for at least 4 weeks. Documentation of
vCR requires confirmation by biopsies of site(s) of externally visible target lesion(s)
with histologic confirmation of no residual malignancy, per central pathology review
(Appendix 5). In the absence of such histologic confirmation, a patient cannot be
deemed to have experienced vCR and the best response would be partial response.

•

Partial response of externally visible disease (vPR): decrease of 50% (WHO criteria)
or greater in the sum the products of perpendicular longest dimensions of target
lesion(s), maintained for at least 4 weeks

•

Stable externally visible disease (vSD): not meeting criteria for vCR, vPR, or
progressive disease

•

Progression of visible disease (vPD): increase of ≥ 25% (WHO criteria) in the sum of
the products of perpendicular longest dimensions of target lesion(s). In rare cases,
unequivocal progression of a non-target lesion may be accepted as vPD.
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B. New Lesions
A new cutaneous lesion consistent with CSCC will be considered as cPD if the lesion is ≥10 mm
in both maximal perpendicular diameters, and can be clearly documented as not being previously
present, unless it is confirmed on biopsy not to be consistent with CSCC. If a new cutaneous
lesion is not biopsied or if the histology is inconclusive, it should be considered CSCC and
deemed cPD.
Overall Clinical Responses For Locally Advanced CSCC Lesions that are Measured by
Digital Medical Photography

a
b
c
d
e
f

a

Clinical Response

Externally Visible
Tumor Dimensiona

New Lesions

vCR

No

cCRb,c

vPR

No

cPRd

vSD

No

cSDe

vPD

Yes or No

cPDf

Any

Yes

cPD

f

See above for definitions
Clinical Complete Response
Negative biopsy showing no residual malignant cells is required for any lesion be deemed cCR
Clinical Partial Response
Clinical Stable Disease
Clinical Progression of Disease

Composite Response Criteria
These criteria are for patients who have locally advanced or metastatic CSCC (any Group) that is
measurable by BOTH clinical response criteria by digital medical photography and RECIST 1.1
using radiologic imaging. The “Clinical Response” column in this table will be based on the
results of the “Clinical Response” (far-right) column of the table above. RECIST 1.1
response is according to Appendix 1. The determinations of the Independent Composite
Response Committee will serve as the central reviews for these patients.
Clinical Response
(Digital Medical
Photography)

RECIST 1.1 Response
(Radiology)

Composite (Overall):
Clinical + RECIST
Response

cCR

CR or NAa

CR

NA

CR

CR

cCR

PR or SD

PR

cPR

CR, PR, or SD, or NA

PR

NA

PR

PR

cSD

CR or PR

PR

Regeneron Pharmaceuticals, Inc.

Page 96 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

Clinical Study Protocol

a

J Immunother Cancer

R2810-ONC-1540 Amendment 5 Global

Clinical Response
(Digital Medical
Photography)

RECIST 1.1 Response
(Radiology)

Composite (Overall):
Clinical + RECIST
Response

cSD

SD or NA

SD

NA

SD

SD

cPD

Any

PD

Any

PD

PD

NA indicates “Not applicable” (eg, because the assessment was not done).

In addition, if all previously inoperable target lesions are rendered operable with clear margins
obtained at the time of surgery, this will be considered a PR. If the investigator deems a
previously unresectable lesion to be potentially resectable due to response to REGN2810, the
Medical Monitor should be consulted prior to any surgical procedure being performed. A
decision will be rendered by the sponsor as to whether the planned surgical intervention is
compatible with study requirements. (This statement does not apply to patients in emergency
life-threatening situations that require immediate surgery).
C. Ulcerated Lesions
This section only pertains to target lesions that have extensive ulceration at baseline that prevents
measurement by the above methods in this appendix. Response criteria are as follows:
•

Complete response: re-epithelialization of the entire baseline area of ulceration of
target lesion(s), maintained over at least 4 weeks.

•

Partial response: there are no criteria for partial response

•

Stable disease: not meeting criteria for complete response or progressive disease

•

Progressive disease: new ulceration of target lesion(s) not related to (ie, in a location
separate from) tissue biopsy or other known trauma, persistent without evidence of
healing for at least 2 weeks
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REGN2810 PHARMACOKINETIC SAMPLING AND
ASSESSMENT SCHEDULE

For Groups 1 and 2:
Study Visit

PK Sampling Time

Cycle 1, day 1

•
•

Preinfusion
Within 10 minutes after end of infusion

Cycle 1: day 15 ± 3, day 29 ± 3, day 43 ±
3

•
•

Preinfusion
Within 10 min after end of infusion

Cycles 2–6: day 1

•
•

Preinfusion
Within 10 min after end of infusion

Cycles 7, 9, 11: day 1

•
•

Preinfusion
Within 10 min after end of infusion

End of study (if progression during
cycles 1-12) or Follow-up Visit 1

Anytime during the visit

For Group 3:
Study Visit

PK Sampling Time

Cycle 1, day 1

•
•

Preinfusion
Within 10 minutes after end of infusion

Cycle 1: day 22 ± 3, day 43 ± 3

•
•

Preinfusion
Within 10 min after end of infusion

Cycles 2-6: day 1

•

Preinfusion

•

Within 10 min after end of infusion

End of study (if progression during
cycles 1-6) or Follow-up Visit 1

Anytime during the visit
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RECOMMENDED DOSE MODIFICATION OR DISCONTINUATION AND
SUPPORTIVE CARE GUIDELINES FOR SPECIFIC STUDY DRUG-RELATED
ADVERSE EVENTS

Section 5.3.2 provides the dose level reductions.
Event(s)

CTCAE
Management/
v4.03 Grade REGN2810 Dosing

≤ Grade 1
Colitis events
• Bowel obstruction
• Colitis
• Colitis
microscopic
Grade 2
• Enterocolitis
hemorrhagic
• Gastrointestinal
(GI) perforation
• Necrotizing
colitis
Diarrhea:
All patients who
experience diarrhea
should be advised to
drink liberal
quantities of clear
fluids. If sufficient
oral fluid intake is
not feasible, fluid
and electrolytes
should be
substituted via IV
infusion.

Action/Supportive Care Guidelines

• For diarrhea, treat symptomatically (loperamide, oral hydration, electrolyte
substitution and ADA colitis diet). Endoscopy is recommended if symptoms
persist.
• Grade 1 diarrhea that persist for >1 week should be treated with the addition
of oral diphenoxylate hydrochloride and atropine sulfate four times daily and
budesonide 9 mg daily.
Hold until ≤Grade 1. • GI consultation and endoscopy is recommended to confirm or rule out colitis
Resume at same
for grade 2 diarrhea that persists >1 week or grade 1-2 diarrhea with rectal
dose level. May
bleeding (additional guidelines for the treatment of persistent colitis are
increase dosing
provided below).
interval by 1 week if • Grade 2 diarrhea should be treated with the addition of oral diphenoxylate
it takes more than
hydrochloride and atropine sulfate four times daily and budesonide 9 mg
4 weeks for
daily.
toxicities to resolve. • Grade 2 diarrhea with diffuse ulceration and bleeding seen on endoscopy
may require oral steroids with prolonged taper and represent an increased risk
for the development of bowel perforation. Consider prophylactic antibiotics
for opportunistic infections.
• When symptoms improve to Grade 1 or less, steroid taper should be started
and continued over no less than 4 weeks.
• In patients with Grade 2 enterocolitis, REGN2810 should be withheld and
antidiarrheal treatment should be started. If symptoms are persistent for more
than one week, systemic corticosteroids should be initiated (eg,
0.5 mg/kg/day of prednisone or equivalent). When symptoms improve to
Grade 1 or less, corticosteroid taper should be started and continued over at
least 1 month.
No change in dose

Regeneron Pharmaceuticals, Inc.

Symptoms

Differential
Diagnosis

a

Symptoms may
include (but are
not limited to):
• Abdominal
pain, cramping
and/or bloating
• Blood and/or
mucus in stool
with or without
fever
• Constipation
• Diarrhea
• Ileus
• Nausea and/or
vomiting
• Peritoneal
signs
consistent with
bowel
perforation
• Rectal bleeding
• With or
without fever
Patients with
diarrhea should be

All attempts
should be made
to rule out other
causes such as
metastatic
disease, bacterial
or parasitic
infection, viral
gastroenteritis,
or the first
manifestation of
an inflammatory
bowel disease by
examination for
stool leukocytes,
stool cultures,
and a
Clostridium
difficile titer.
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(continued)
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing
Grade 3–4

J Immunother Cancer

Withhold
REGN2810
Discontinue if
unable to reduce
corticosteroid dose
to < 10 mg per day
prednisone
equivalent within
12 weeks of toxicity

Action/Supportive Care Guidelines
• In patients with Grade 3 enterocolitis, REGN2810 will be permanently
discontinued and treatment with systemic corticosteroids should be initiated
at a dose of 1–2 mg/kg/day of prednisone or equivalent. When symptoms
improve to Grade 1 or less, corticosteroid taper should be started and
continued over at least 1 month. Consider prophylactic antibiotics for
opportunistic infections.
For Grade 3–4 diarrhea (or Grade 2 diarrhea that persists after initial steroid
treatment),
• Rule out bowel perforation. Imaging with plain films or computed
tomography (CT) can be useful.
• Consider consultation with gastroenterologist and confirmation biopsy with
endoscopy.
• Treat with intravenous (IV) steroids (methylprednisolone 125 mg) followed
by high-dose oral steroids (prednisone 1–2 mg/kg once per day or
dexamethasone 4 mg every 4 hours). When symptoms improve to Grade 1 or
less, steroid taper should be started and continued over no less than 4 weeks.
Taper over 6–8 weeks in patients with diffuse and severe ulceration and/or
bleeding.
• If IV steroids followed by high-dose oral steroids does not reduce initial
symptoms within 48–72 hours, consider treatment with infliximab at 5 mg/kg
once every 2 weeks. Discontinue infliximab upon symptom relief and initiate
a prolonged steroid taper over 45–60 days. If symptoms worsen during
steroid reduction, initiate a retapering of steroids starting at a higher dose of
80 or 100 mg followed by a more prolonged taper and administer infliximab.
CAUTION: infliximab is contraindicated in patients with bowel perforation
b
or sepsis .
• If symptoms persist despite the above treatment a surgical consult should be
obtained.
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Symptoms

Differential
Diagnosis

a

carefully
monitored for
signs and
symptoms of
enterocolitis (such
as diarrhea,
abdominal pain,
blood or mucus in
stool, with or
without fever) and
of bowel
perforation (such
as peritoneal signs
and ileus). In
symptomatic
patients,
infectious
etiologies should
be ruled out, and
if symptoms are
persistent and/or
severe,
endoscopic
evaluation should
be considered.

Page 100 of 117
CONFIDENTIAL

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

Clinical Study Protocol

Event(s)
Endocrine events
• Hyperthyroidism
• Hypophysitis
• Hypopituitarism
Endocrine events
• Hypothyroidism
• Thyroid disorder
• Thyroiditis
Endocrine events
• Adrenal
insufficiency
• Hypophysitis
• Panhypopituitarism

J Immunother Cancer
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing
Grade 1-2

No change in dose

Grade 3-4

Hold until on stable
replacement dose

Grade 1-4

Hold until on stable
replacement dose

Action/Supportive Care Guidelines

Symptoms

Differential
Diagnosis

a

• Monitor thyroid function or other hormonal level tests and serum chemistries Symptoms may
include (but not
more frequently until returned to baseline values.
limited to):
• Abdominal
pain
• Consider endocrine consultation.
• Abnormal
• Rule out infection and sepsis with appropriate cultures and imaging.
thyroid
• Replacement of appropriate hormones as required.
function tests
and/or serum
• Thyroid hormone and/or steroid replacement therapy to manage adrenal
chemistries
insufficiency.
(Thyroid• If Grade 1–2 hypophysitis is considered, pituitary gland imaging should be
stimulating
considered (magnetic resonance imaging [MRIs] with gadolinium and
hormone
selective cuts of the pituitary can show enlargement or heterogeneity and
increased
confirm the diagnosis).
[decreased],
• Grade 3–4 hypophysitis with clinically significant adrenal insufficiency and
Free thyroxine
hypotension, dehydration, and electrolyte abnormalities (such as
increased, Trihyponatremia and hyperkalemia) constitutes adrenal crisis. Hospitalization
iodothyronine
and IV methylprednisolone should be initiated.
increased.)
c
• Arrhythmias
• Cold or heat
intolerance
• Fatigue
• Fever
• Headache
• Hypotensionc
• Loss of
appetite
• Mental status
and/or
behavior
changes
• Nausea and/or
vomiting
• Unusual bowel
habits
• Vision
disturbances
• Weakness

Regeneron Pharmaceuticals, Inc.

All attempts
should be made
to rule out other
causes such as
brain metastases,
sepsis, and/or
infection. An
endocrinology
consultation is
recommended.
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Event(s)
Eye event:
Uveitis
(iritis, iridocyclitis)
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing
Grade 1

Grade 2

Grade 3–4

J Immunother Cancer

Discontinue
REGN2810 if
symptoms persist
despite treatment
with topical
immunosuppressive
therapy
Discontinue
REGN2810 if
symptoms persist
despite treatment
with topical
immunosuppressive
therapy and do not
improve to Grade 1
within the
retreatment period
OR requires
systemic treatment.
Discontinue
REGN2810.

Action/Supportive Care Guidelines
• Evaluation by an ophthalmologist is strongly recommended.
• Treat with topical steroids such as 1% prednisolone acetate suspension and
iridocyclitics.

• Evaluation by an ophthalmologist is strongly recommended.
• Treat with topical steroids such as 1% prednisolone acetate suspension and
iridocyclitics.

Symptoms

Differential
Diagnosis

a

Symptoms may
include (but are
not limited to):
• Blurred vision
• Diffuse
erythema and a
prominent
blush on the
sclerae
• Dryness of the
eyes
• Pain
• Photophobia

All attempts
should be made
to rule out other
causes such as
metastatic
disease,
infection, or
other ocular
disease (e.g.,
glaucoma or
cataracts).

• Treat with systemic corticosteroids such as prednisone at a dose of
1-2 mg/kg per day. When symptoms improve to ≤Grade 1, steroid taper
should be started and continued over no less than 4 weeks.
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Event(s)
Hepatic events
• Hepatitis
• Hepatitis,
Autoimmune

Grade 3–4

Nausea

R2810-ONC-1540 Amendment 5 Global

CTCAE
Management/
v4.03 Grade REGN2810 Dosing
Grade 1–2

≤Grade 1
Grade 2

Grade 3

Grade 4

J Immunother Cancer

Action/Supportive Care Guidelines

Symptoms

Differential
Diagnosis

a

• Monitor liver function tests more frequently until returned to baseline values. Symptoms may
include (but are
not limited to):
• Elevations in:
o AST >2.5 ×
ULN
o ALT >2.5 ×
ULN
o Total
bilirubin >1.5
× ULN
• Consider appropriate consultation and liver biopsy to establish etiology of
hepatic injury, if necessary.
• Fever
• Treat with high-dose IV glucocorticosteroids for 24–48 hours. When
• Malaise
symptoms improve to grade 1 or less, a steroid taper with dexamethasone
• Upper quadrant
4 mg every 4 hours or prednisone at 1–2 mg/kg should be started and
abdominal pain
continued over no less than 4 weeks.
• If serum transaminase levels do not decrease 48 hours after initiation of
systemic steroids, oral mycophenolate mofetil 500 mg every 12 hours may
be given. Infliximab is not recommended due to its potential for
hepatotoxicityb.
• Several courses of steroid tapering may be necessary as symptoms may
worsen when the steroid dose is decreased.
No change in dose
• Nausea should be treated aggressively, and consideration should be given in
Hold until ≤Grade 1.
subsequent cycles to the administration of prophylactic antiemetic therapy
Resume at same
according to standard institutional practice. Patients should be strongly
dose level. May
encouraged to maintain liberal oral fluid intake.
increase dosing
interval by 1 week if
it takes more than 4
weeks for toxicities
to resolve.
Hold until <Grade 2.
May increase dosing
interval by 1 week
for each occurrence.
Discontinue if
toxicities do not
resolve within
12 weeks.
Off protocol therapy
Withhold
REGN2810 if there
is a treatmentemergent concurrent
elevation of ALT
and bilirubin that
corresponds to an
upward shift of 2 or
more grades in both
parameters.
Withhold (and
consider
Discontinuation of)
REGN2810 when
AST or ALT
>5.0 times ULN
and/or total bilirubin
>3.0 times ULN.
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All attempts
should be made
to rule out other
causes such as
metastatic
disease,
progressive liver
disease, viral
hepatitis,
alternative drug
toxicity,
infectious causes
and/or myositis.
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Event(s)
Neutropenia
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing
≤Grade 1
Grade 2
Grade 3
Grade 4

J Immunother Cancer

No change in dose
No change in dose
No change in dose
See Table 3

Action/Supportive Care Guidelines

Symptoms

a

Differential
Diagnosis

For neutropenia, see general guidelines on hematologic toxicity in Table 3
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing

Pneumonitis events Grade 1
• Pneumonitis
• Interstitial lung
disease
• Acute interstitial
pneumonitis
Grade 2

Grade 3–4

J Immunother Cancer

Action/Supportive Care Guidelines

Consider hold of
• Radiologic findings should be followed on serial imaging studies at least
therapy. REGN2810
every 3 weeks.
may be continued
• Monitor for symptoms every 2–3 days.
with close
• Consider pulmonary consultation and/or bronchoscopy if clinically
monitoring.
indicated.
Hold REGN2810

Discontinue
REGN2810.

To rule out other causes such as infection:
• Consider pulmonary consultation with bronchoscopy and
biopsy/bronchoalveolar lavage (BAL).
• Consider pulmonary function tests.
• Follow radiologic findings on serial imaging studies every 1–3 days
If the patient is determined to have study drug associated pneumonitis:
• Monitor symptoms daily; consider hospitalization.
• Treat with systemic corticosteroids at a dose of 1–2 mg/kg/day prednisone or
equivalent. When symptoms improve to Grade 1 or less, steroid taper should
be started and continued over no less than 4 weeks.
• Treatment with REGN2810 may be resumed if the event improves to
≤ Grade 1 within 12 weeks and corticosteroids have been reduced to the
equivalent of methylprednisolone 10 mg by mouth daily or less. Repeat chest
imaging monthly as clinically indicated.
For Grade 2 pneumonitis that improves to ≤Grade 1 within 12 weeks, the
following rules should apply:
• First episode of pneumonitis: May increase dosing interval by one week in
subsequent cycles.
• Second episode of pneumonitis: Discontinue REGN2810 if upon rechallenge
the patient develops a second episode of ≥ Grade 2 pneumonitis.
• Consider pulmonary function tests with pulmonary consult.
• Bronchoscopy with biopsy and/or BAL is recommended.
• Treat with IV steroids (2–4 mg/kg per day prednisone or equivalent). When
symptoms improve to grade 1 or less, a high-dose oral steroid (1–2 mg/kg
prednisone once per day or 4 mg dexamethasone every 4 hours) taper should
be started and continued over no less than 4 weeks.
• Add prophylactic antibiotics for opportunistic infections.
• If IV steroids followed by high-dose oral steroids does not reduce initial
symptoms within 48–72 hours, treat with infliximab at 5 mg/kg once every
2 weeks. Discontinue infliximab upon symptom relief and initiate a
prolonged steroid taper over 45–60 days. If symptoms worsen during steroid
reduction, initiate a retapering of steroids starting at a higher dose of 80 or
100 mg followed by a more prolonged taper and administer infliximab.

Regeneron Pharmaceuticals, Inc.

Symptoms

Differential
Diagnosis

a

Symptoms may
include (but are
not limited to):
• Abnormal
breath sounds
• Chest pain
and/or
tightnessc
• Dyspneac
• Dry cough
• Fatigue
• Fever
• Hemoptysis

All attempts
should be made
to rule out other
causes such as
metastatic
disease, bacterial
or viral
infection.
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing

Renal events
• Nephritis
• Nephritis
autoimmune

Grade 1

• Renal failure

Grade 2

• Renal failure,
Acute

Grade 3-4

J Immunother Cancer

Consider
withholding
REGN2810 if event
does not improve
with symptomatic
treatment
Consider
withholding
REGN2810.

Discontinue
REGN2810.

Action/Supportive Care Guidelines
• Provide symptomatic treatment.
• Monitor creatinine weekly; when it returns to baseline, resume routine
creatinine monitoring per protocol.

• Systemic corticosteroids at a dose of 1–2 mg/kg/day of prednisone or
equivalent may be indicated. When symptoms improve to Grade 1 or less,
corticosteroid taper should be started and continued over at least 1 month.
• Consider prophylactic antibiotics for opportunistic infections.
• Consider renal biopsy.
• If elevations persist >7 days or worsen, treat as Grade 4.
• Renal consultation with consideration of ultrasound and/or biopsy as
appropriate.
• Monitor creatinine daily.
• Treat with systemic corticosteroids at a dose of 1–2 mg/kg prednisone or
equivalent once per day.
• When symptoms improve to grade 1 or less, steroid taper should be started
and continued over no less than 4 weeks.
• Discontinue REGN2810 if unable to reduce corticosteroid dose for irAEs to
≤10 mg.
• REGN2810 treatment may be restarted and the dose modified as specified in
the protocol.

Regeneron Pharmaceuticals, Inc.

Symptoms

a

Symptoms may
include (but not
limited to):
• Fatigue
• High blood
pressure
• Increased
serum
creatinine
• Swelling

Differential
Diagnosis
All attempts
should be made
to rule out other
causes such as
obstructive
uropathy,
progression of
disease, or injury
to other
chemotherapy
agents. A renal
consultation is
recommended.
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Event(s)
Skin events
• Dermatitis
exfoliative
• Erythema
multiforme
• Stevens-Johnson
syndrome
• Toxic epidermal
necrolysis
If considered to be
immune related,
≥ Grade 3 or result
in dose modification
or discontinuation:
• Pruritus
• Rash
• Rash generalized
• Rash maculopapular
• Vitiligo
Thrombocytopenia

J Immunother Cancer
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CTCAE
Management/
v4.03 Grade REGN2810 Dosing

Action/Supportive Care Guidelines

Grade 1–2

No change in dose

• Symptomatic treatment should be given such as topical glucocorticosteroids
(eg, betamethasone 0.1% cream or hydrocortisone 1%) or urea-containing
creams in combination with oral antipruritics (eg, diphenhydramine HCl or
hydroxyzine HCl).
• Treatment with oral steroids is at investigator discretion for Grade 2 events.

Grade 3

Hold REGN2810.

Grade 4

Permanently
discontinue
REGN2810.

• Consider dermatology consultation and biopsy for confirmation of diagnosis.
• Treatment with oral steroids is recommended, starting with 1 mg/kg
prednisone or equivalent once per day or dexamethasone 4 mg four times
orally daily. When symptoms improve to Grade 1 or less, steroid taper
should be started and continued over no less than 4 weeks.
• Dermatology consultation and consideration of biopsy and clinical
dermatology photograph.
• Initiate steroids at 1–2 mg/kg prednisones or equivalent. When symptoms
improve to grade 1 or less, steroid taper should be started and continued over
no less than 4 weeks.

≤ Grade 1
Grade 2
Grade 3
Grade 4

No change in dose
No change in dose
See Table 3
See Table 3

Regeneron Pharmaceuticals, Inc.

Symptoms

a

Differential
Diagnosis
All attempts
should be made
to rule out other
causes such as
metastatic
disease,
infection, or
allergic
dermatitis.
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Vomiting

Grade 3

Grade 4
a
b
c

R2810-ONC-1540 Amendment 5 Global

CTCAE
Management/
v4.03 Grade REGN2810 Dosing
≤ Grade 1
Grade 2

J Immunother Cancer

Action/Supportive Care Guidelines

Symptoms

Differential
Diagnosis

a

No change in dose
• Vomiting should be treated aggressively, and consideration should be given
Hold until ≤Grade 1.
in subsequent cycles to the administration of prophylactic antiemetic therapy
Resume at same
according to standard institutional practice. Patients should be strongly
dose level. May
encouraged to maintain liberal oral fluid intake.
increase dosing
interval by 1 week if
it takes more than
4 weeks for
toxicities to resolve.
Hold until <Grade 2.
May increase dosing
interval by 1 week
for each occurrence.
Discontinue if
toxicities do not
resolve within
12 weeks.
Off protocol therapy

The signs and symptoms may be associated with any of the diagnoses in the associated “Event(s)” column.
REMICADE (Infliximab) prescribing information
If symptoms indicate possible new or worsening cardiac abnormalities, additional testing and/or a cardiology consultation should be considered.
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GUIDELINES FOR BIOPSIES FOR LOCALLY
ADVANCED CSCC

This appendix provides timepoints and research procedures for biopsies in patients with locally
advanced CSCC. Because of the potential for sampling error with any single biopsy, two
separate sites (preferably on the same target lesion) should be biopsied for any biopsy
assessment. Regarding the required exploratory biopsies, if the investigator feels the biopsy
would create an unacceptable safety risk for the patient or cannot be performed without
interfering with the measurements of the target lesions, the biopsy requirement may be waived
for an individual patient after communication with the medical monitor.
Time points:
1. Baseline (required):
The study inclusion criteria require that the sponsor be provided with archived pathology
material that will be used for the purpose of confirmation of the diagnosis of CSCC by
central pathology review for all study patients. If the archived material is not sufficient for
confirmation of diagnosis of CSCC by central review, baseline “exploratory” biopsy material
(required for only Group 2 patients) may be used for central pathologic confirmation only if
it is determined that no other archived pathology material is available for confirmation of
diagnosis of CSCC by central pathology review. Remaining baseline tumor material can
only be used for exploratory assessments after central pathology confirmation of diagnosis of
CSCC has been established.
2. Baseline or at any scheduled response assessment (If needed to differentiate benign versus
malignant area of skin):
Areas of indeterminate-appearing tissue should be biopsied to distinguish malignant tissue
versus benign process (eg, scarring, fibrosis). In circumstances in which biopsies are planned,
it is preferred that these be performed on the day of a regularly-scheduled response
assessment.
3. On cycle 1 day 29 (±3 business days) for exploratory assessments, 2 biopsies (punch
biopsies, 3 to 5 mm each) should be obtained, preferably from the same externally visible
lesion from which the baseline biopsies were taken. Both samples will be provided to the
sponsor for exploratory assessments. The cycle 1 day 29 samples are not intended for local
pathology review.
4. At clinical complete response (required): Complete response status for externally visible
lesions requires biopsies of 2 sites on the same lesion which are histologically negative for
malignancy (see secondary objectives).
5. At progression (strongly encouraged): Two sites of externally visible progressing tumor
should be biopsied.
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Research procedures for ALL biopsies:
1. Where and How:
The technique and sites of biopsies will be selected by the investigator based on the sizes and
locations of lesions. Generally, biopsies will be 3 to 5 mm punches. Biopsies should not be
taken at the perimeter of a lesion because this could interfere with measurement of
bi-dimensional perpendicular diameters for response assessments. Whenever possible, biopsy
sites should be ≥5 mm from the edge of baseline lesional area.
2. How many:
For exploratory assessments: 2 biopsies of externally visible CSCC will be obtained at
baseline and again at cycle 1 day 29 (±3 business days). These required biopsies for Group 2
patients are called “Exploratory Biopsies” for the purposes of this study. Two biopsies at
time of progression should also be obtained. In the event that an investigator determines that
clinical circumstances interfere with the ability to obtain the recommended number of
minimal biopsies at baseline or cycle 1 day 29 (±3 business days), the monitor will be
contacted to discuss the number of biopsies that can be reasonably obtained and this will not
be deemed a protocol violation.
For indeterminate-appearing tissue: In addition to these biopsies for exploratory
assessments, biopsies should be taken at baseline and at any response assessment if there is
tissue that is indeterminate-appearing regarding presence of benign versus malignant tissue.
These optional biopsies are referred to as “Response biopsies” (eg, in response to a clinical
question), to distinguish from the required “Exploratory Biopsies” described above. When
the decision is made to perform a “Response biopsy” of a lesion (or an area of a lesion) to
clarify benign versus malignant status, 4 biopsies should be taken. This approach will
mitigate the possibility for sample error or misleading results with any 1 biopsy, because 2
sites in the “indeterminate appearing” tissue will be selected. At each of the selected sites, 2
biopsies should be performed that are approximately adjacent (1 for central review, 1 for
local pathology review). As such, 4 biopsies would be performed (2 sites, with paired
biopsies at each site: 1 for local pathology, and 1 for central = 4 total biopsies).
3. Annotation and Photography
The punch biopsies should be labeled (annotated) on the patient and photographed, such that
on review of the photograph the following information is clear for each biopsy site: the study
week and day of the biopsy (eg, Baseline, Cycle 1, Day 29, etc), the identifying number of
the biopsy (because at least 2 sites would be biopsied), and which samples are for central
review and which samples are for local review. The tumor will also be annotated with a skin
pen to indicate the tumor perimeter and delimiters of the longest bi-dimensional
perpendicular axes. All biopsies will be photographed and annotated, including the cycle 1
day 29 biopsies that are for exploratory assessments.
Annotated photographs must be uploaded into Canfield secure website (see Appendix 6).
4. Disposition of Samples
Biopsy samples required for exploratory assessments (baseline, cycle 1 day 29) will be
provided to the sponsor. It is also strongly encouraged that biopsy samples at time of
Regeneron Pharmaceuticals, Inc.
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progression be obtained for exploratory assessments, and these should also be provided to the
sponsor.
For each site that is biopsied to clarify indeterminate tissue, the entire block for one biopsy
sample (designated for central) must be submitted to the vendor as per the Central Laboratory
Manual. Because each biopsy site is sampled twice (closely adjacent samples) when there is
indeterminate-appearing tissue, the second sample may be used for local pathology review. If
only 1 adequate (eg, interpretable by pathologist) sample is obtained at a biopsy site, it will
be provided to the sponsor for central review to address the study objectives (Section 2).
5. Classification of Pathology Samples
For response assessments in which biopsies were performed, pathology results guide the
determination of the area of invasive CSCC versus benign tissue. Residual squamous
carcinoma in situ will not be deemed to be invasive cancer. A minute focus of residual CSCC
in an otherwise benign responding biopsy sample will not automatically supersede a
determination of partial response. However, the best response that can be recorded if the
pathology report demonstrates any residual CSCC is partial response (not complete
response).
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DIGITAL PHOTOGRAPHIC PROCEDURES

Image Capture
•

Close-up view with millimeter scale of the target area of the CSCC

•

Global view of the target CSCC area

Equipment
•

Camera: Canon SL1 with Ranging Lights

•

Lens: 60mm Canon Lens

•

Flash: Canfield TwinFlash RL

•

Millimeter scale attachment

•

Dedicated laptop with Canfield Capture Application (software includes capturing,
viewing and transferring images)

•

Canfield Tracing and Analysis application

•

Standardized background material

The supplied equipment is to be used exclusively for this study. No modification, adjustments, or
repairs of the camera equipment are to be undertaken without the expressed instruction of
Canfield Scientific, Inc.
Canfield will provide each study site with the necessary hardware as well as technical support as
needed. All supplied photographic equipment remains the property of the Sponsor.
Proper Patient Preparation and Positioning:
In these clinical photographs for the duration of the study, the only variable allowed to change is
the skin condition itself. Therefore, anything extraneous to the condition (furniture, etc.) is to be
eliminated from the photographic field, starting at the entry visit through the final visit. The
necessity of good end-of-study photographs should be stressed to patients to ensure their
cooperation. Lighting, framing, exposure, and reproduction ratios must be held constant. In the
end, the images should read like a time-lapse movie.
In the close up view, the area of interest is the individual target lesion itself. In the global view,
the area of interest includes the target lesion as well as relevant anatomical landmarks, e.g. side
of face, side of neck, upper torso, full view of shoulder, etc. Photographs should be taken with
the camera positioned at the same vertical height as the center of area of interest. Further, all
shots should be made with the axis of the camera lens perpendicular to the surface of area of
interest when possible. Glancing shots where the camera lens is not perpendicular to the patient’s
area of interest are to be avoided as these photographic angles may distort the image perspective
yielding inaccuracies when measurement of lesions is performed on photos by central review.
The supplied standardized background material is to be used. Do not use wrinkled or crimped
material.
The Canfield Capture software controls the setting of the camera specific to the protocol. The
lens is set for auto focusing. The close-up view is accomplished using the attached standardized
Regeneron Pharmaceuticals, Inc.
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mm scale. The global view is accomplished when the ranging lights converge on the target area.
Any doubt as to the correctness of the photographic technique should result in an immediate
re-shoot. At the baseline visit, a profile view (perpendicular to the skin’s plane) will also be
obtained of each lesion to capture any projection above the skin. For all lesions in which the
baseline profile view demonstrates significant projection above the skin, defined as ≥15mm, the
profile view will also be obtained at subsequent scheduled clinical assessments of response.
For each global view and each close up view, an unannotated photograph must be taken
followed by a manually annotated photograph.
For response assessments, Canfield imaging software should be used to assure that the
photograph is taken at the same position and angle as the Baseline photograph. The annotated
image from the prior visit should be referenced on the laptop screen prior to making annotations
on the new image.
Photographic Procedures:
1. Prior to capturing the patient images using the camera system, the photographer launches
the Canfield Scientific Canfield Capture Application by selecting the icon from the
desktop.
2. The photographer either creates a New Patient for an initial visit or, for a return subject,
highlights the appropriate existing Patient ID listed in the Canfield Capture database. The
visit name (as per study schedule) is selected by the photographer and the image date is
captured by the software.
3. With the patient’s target area positioned correctly in front of the camera system, the
Photographer adjusts the camera distance for accurate system focus. The first capture is a
Close-up view of patient’s target CSCC area(s) using the attached mm scale, consisting
of one individual CSCC lesion. The second capture is Global view of patient’s target
CSCC area(s), consisting of up to two individual CSCC lesions. For the global view the
camera is moved closer to or further away from the target until the two green ranging
lights converge to become one dot.
4. The Photographer captures the image and is then prompted to review image acceptability.
The Photographer either accepts the image and moves on to the next capture or does not
accept and recaptures the image.
5. After capturing the series of non-annotated lesion(s), the Investigator will annotate the
circumference and axes delimiters of lesion with supplied skin pen. If any biopsies are
taken at this visit (eg, baseline, cycle 1 day 29, at any regularly scheduled visit, or at
time of progression), each biopsy will also be annotated as per Appendix 5. The
annotated photo will include the largest area, including both palpable and visible
components of the lesion, as outlined by the investigator. Following the same
procedure as the non-annotated image capture the site will capture the series of annotated
lesion(s) images
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6. Following the session, the Photographer submits the images to Canfield. Upon exiting,
the software automatically reads, checksums, encrypts, packages, and duplicates the data
to submit to Canfield via internet or removable media submission.
a. Internet: A secure, validated, compliant web server set up at Canfield is used for
secure transfer of study images by study sites. Images are to be transferred the day
they are recorded. Only approved individuals by the Sponsor have access to
the website.
The application logs a record of this action to a local database and prompts the Photographer
when completed.
1. Upon completion of photography session, the Investigator will log in to the Canfield
tracing application may (optional) annotate the lesion and the software will provide
measurements (surface area, longest diameter, perpendicular diameter) of the lesion.
2. Trained Canfield staff review the data files for technical quality and acceptability and
communicate any comments to the site.
3. At the end of the study, a copy of site specific patient images will be provided to each
site. This is in addition to the Photography Result Reports available for printing from the
Clinical Services Website after each session. Remote access to all images by the Sponsor
is also provided.
Any questions or problems regarding the photographic portion of this study are to be forwarded
to the assigned Project Manager at Canfield Scientific.
Canfield Scientific, Inc.
253 Passaic Avenue
Fairfield, NJ 07004 United States
Toll-free telephone number: (800) 815-4375
Telephone number: (973) 276-0300
Facsimile number: (973) 276-0333
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EASTERN COOPERATIVE ONCOLOGY GROUP
PERFORMANCE STATUS

Grade

Description

0

Fully active; able to carry on all pre-disease performance without restriction.

1

Restricted in physically strenuous activity but ambulatory and able to carry out work of a
light or sedentary nature; eg, light house work, office work

2

Ambulatory and capable of all selfcare but unable to carry out any work activities; Up and
about more than 50% of waking hours

3

Capable of only limited selfcare; confined to bed or chair 50% or more of waking hours

4

Completed disabled. Cannot carry on any selfcare. Totally confined to bed or chair.

5

Dead

Source: Oken 1982
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FACTORS TO CONSIDER IN ASSESSING THE
RELATIONSHIP OF AES TO REGN2810 OR STUDY
CONDUCT.

Is there a reasonable possibility that the event may have been caused by the study drugs or
infusion procedure, study procedure, or concomitant treatment?
No:
•

due to external causes such as environmental factors or other treatment/s being
administered

•

due to the patient’s disease state or clinical condition

•

do not follow a reasonable temporal sequence following the time of administration of
the dose of REGN2810, study procedure, or combination treatment

•

do not reappear or worsen when dosing with REGN2810, study procedure, or
combination treatment is resumed

•

could not be explained by environmental factors or other treatment/s being
administered

•

could not be explained by the patient’s disease state or clinical condition

•

follow a reasonable temporal sequence following the time of administration of the
dose of REGN2810

•

resolve or improve after discontinuation of REGN2810, study procedure, or
combination treatment

•

reappear or worsen when dosing with REGN2810, study procedure, or combination
treatment is resumed

•

are known to be a response to REGN2810 or the infusion procedure, study procedure,
or combination treatment based upon pre-clinical data or prior clinical data

Yes:

NOTE: This list is not exhaustive.
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Signature of Sponsor’s Responsible Officers
(Medical/Study Director, Regulatory Representative, Clinical Study Team Lead, and
Biostatistician)
To the best of my knowledge, this protocol accurately describes the conduct of the study.
Study Title: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to
Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Protocol Number: R2810-ONC-1540
Protocol Version: R2810-ONC-1540 Amendment 5 Global

See appended electronic signature page
Sponsor’s Responsible Medical/Study Director:

See appended electronic signature page
Sponsor’s Responsible Regulatory Liaison:

See appended electronic signature page
Sponsor’s Responsible Clinical Study Team Lead:

See appended electronic signature page
Sponsor’s Responsible Biostatistician:
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CLINICAL STUDY PROTOCOL SYNOPSIS
Title

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to
Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell
Carcinoma (CSCC)

Site Locations

Up to 30 sites globally

Objectives

The primary objective of this study is to estimate the clinical benefit of REGN2810
monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell
carcinoma (CSCC) (Group 1) or with unresectable locally advanced CSCC
(Group 2), as measured by overall response rate (ORR), according to central review.
The secondary objectives of the study are:
•

To estimate ORR according to investigator review

•

To estimate the duration of response, progression-free survival (PFS), and
overall survival (OS) by central and investigator review

•

To estimate the complete response (CR) rate by central review

•

To assess the safety and tolerability of REGN2810

•

To assess the pharmacokinetics (PK) of REGN2810 (at select sites only)

•

To assess the immunogenicity of REGN2810

•

To assess the impact of REGN2810 on quality of life using EORTC
QLQ-C30.

Exploratory Objectives (Group 2 only)


To explore the pharmacodynamic effects of REGN2810 in tumor biopsies
obtained at baseline, during treatment, and at progression in CSCC patients
treated with REGN2810
o
o

o

o
o
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To estimate the complete response (CR) rate by central review



To assess the safety and tolerability of REGN2810



To assess the pharmacokinetics (PK) of REGN2810 (at select sites only)



To assess the immunogenicity of REGN2810



To assess the impact of REGN2810 on quality of life using European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-C30) (Appendix 1)

2.3.

J Immunother Cancer

Exploratory Objective (Group 2 only)

To explore the pharmacodynamic effects of REGN2810 in tumor biopsies obtained at baseline,
during treatment, and at progression in CSCC patients treated with REGN2810







.



3.

STUDY DESIGN

3.1.

Study Description and Duration

This is a phase 2, non-randomized, 2-group, multicenter pivotal trial evaluating the efficacy and
safety of REGN2810 in patients with advanced CSCC. After a screening period of up to 28 days,
patients will receive up to twelve 56-day (8-week) treatment cycles for a total of up to 96 weeks
of treatment. Each patient will receive 3 mg/kg REGN2810 IV on days 1, 15±3, 29±3, and
43±3 during each treatment cycle. Tumor assessments will be made at the end of each treatment
cycle. Extensive safety evaluations will occur on day 1 of each cycle; routine safety evaluations
will be conducted at each REGN2810 dosing visit.
A patient will receive treatment until the 96-week treatment period is complete, or until disease
progression, unacceptable toxicity, withdrawal of consent, or confirmed CR. Patients with
confirmed CR after a minimum of 48 weeks of treatment may elect to discontinue treatment and
continue with all relevant study assessments (eg, efficacy assessments). After completion of the
current study, patients may be eligible for enrollment into the companion protocol
(R2810-ONC-1425).
Regeneron Pharmaceuticals, Inc.
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The investigator and sponsor have the right to discontinue a patient from study treatment or
withdraw a patient from the study at any time.
Reasons for discontinuation of study treatment or withdrawal from the study may include, but
are not limited to:

4.3.2.



Patient withdrawal of consent at any time



Any medical condition that the investigator or sponsor determines may jeopardize the
patient’s safety if he or she continues in the study or continues treatment with study
drug



The investigator or sponsor determines it is in the best interest of the patient



Patient noncompliance (eg, not complying with protocol required visits, assessments,
and dosing instructions)



Pregnancy
Discontinuation of Study Treatment

A patient who permanently discontinues study treatment will be followed as detailed in
section 6.2.2.
4.3.3.

Withdrawal from Study Participation

During the treatment period and follow-up period, a patient who withdraws consent to continue
participation in the study will not be followed for any reason after consent has been withdrawn.
An excessive rate of withdrawals would render the study uninterpretable; therefore, unnecessary
withdrawal of patients should be avoided.

4.4.

Replacement of Patients

Patients prematurely discontinued from the study who had received at least 1 treatment with
REGN2810 will not be replaced.

5.

STUDY TREATMENTS

5.1.

Investigational Treatment

REGN2810 will be supplied as a liquid in sterile, single-use vials.
Instructions on dose preparation are provided in the pharmacy manual.
REGN2810 will be administered in an outpatient setting as a 30 minute IV infusion. Each
patient’s dose will depend on individual body weight. The dose of REGN2810 must be adjusted
each cycle for changes in body weight of ≥10%. Dose adjustments for changes in body weight of
<10% will be at the discretion of the investigator.
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5.6.

Treatment Logistics and Accountability

5.6.1.

Packaging, Labeling, and Storage

Open-label REGN2810 will be supplied as a liquid in sterile, single-use vials that will display the
product lot number on the label.
instructions will be provided in the pharmacy manual.

. Further storage

A pharmacist or other qualified individual will be identified at each site to prepare REGN2810
for administration.
Detailed preparation and administration
instructions will be provided to the sites in the pharmacy manual.
5.6.2.

Supply and Disposition of Treatments

Study drug will be shipped
to the investigator or designee at regular
intervals or as needed during the study. At specified time points during the study (eg, interim site
monitoring visits), at the site close-out visit, and following drug reconciliation and
documentation by the site monitor, all opened and unopened study drug will be
destroyed -or- returned to the sponsor or designee.
5.6.3.

Treatment Accountability

All drug accountability records must be kept current.
The investigator must be able to account for all opened and unopened study drug. These records
should contain the dates, quantity, and study medication dispensed to each patient, returned from
each patient (if applicable), and disposed of at the site or returned to the sponsor or designee.
All accountability records must be made available for inspection by the sponsor and regulatory
agency inspectors; photocopies must be provided to the sponsor at the conclusion of the study.
5.6.4.

Treatment Compliance

REGN2810 will be administered at the study site and recorded on the electronic case report form
(eCRF). All dosing records for each patient will be kept by the site. All drug compliance records
must be kept current and must be made available for inspection by the sponsor and regulatory
agency inspectors.

5.7.

Concomitant Medications and Procedures

5.7.1.

Concomitant Medications

Any treatment administered from the time of informed consent until 30 days after the last study
treatment will be considered concomitant treatment. This includes medications and other
therapies for which administration started before the study and will continue during the study, as
well as any therapies started in the 5 month follow-up period to treat a study-drug–related AE.
All concomitant treatments must be recorded in the study CRF with the generic name, dose, dose
unit, frequency, indication, and start/stop date, as appropriate.
Regeneron Pharmaceuticals, Inc.
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unrelated to the study medication or its administration, the medical monitor must be
consulted.


The clinical significance of an abnormal test value, within the context of the disease
under study, must be determined by the investigator.

Criteria for reporting laboratory values as an AE are provided in section 7.2.5.
6.3.4.

Pharmacokinetic and Antibody Procedures

6.3.4.1.

Drug Concentration Measurements and Samples

REGN2810 PK parameters will be determined by measuring REGN2810 concentrations in
serum samples using a validated assay at visits and time points indicated in Table 4 and Table 5,
and listed in Appendix 4. Actual time of each blood draw must be recorded. “Predose” is defined
as before the start of the first REGN2810 infusion. Predose samples may be collected ≤72 hours
prior to day 1 dosing. Subsequent PK sampling times will be based on the REGN2810 dosing
time that preceeds the PK sampling. Pre-infusion is defined as before the start of the REGN2810
infusion and “0 hour” is defined as immediately after the end of the REGN2810 infusion.
Any unused samples collected for drug concentration measurements may be used for exploratory
biomarker research or to investigate unexpected AEs.
6.3.4.2.

Anti-drug Antibody Measurements and Samples

Samples for ADA assessment will be collected prior to dosing at time points listed in Table 4
and Table 5.
Any unused samples collected for ADA assessment may be used for exploratory biomarker
research or to investigate unexpected AEs.
6.3.5.

Biomarker Measurements and Samples

Speculated pharmacodynamic,
biomarkers related to REGN2810
treatment exposure, clinical activity, or underlying disease will be investigated in tumor biopsy
tissue collected at baseline, after treatment with REGN2810, and at progression, if available.

. Biomarker results will be reported separately from the clinical study report.
6.3.5.1.

Tumor Biomarker Procedures

For patients with locally advanced CSCC (Group 2), tumor biopsies will be collected per the
timepoints and methodology in Appendix 6.
Expression levels (mRNA and/or protein) of PD-L1, GITR, and LAG-3, as well as the number
and distribution of TILs (defined by lineage markers CD4, CD8, CD25, FoxP3) will be assessed
in tumor biopsy samples. Additional biomarkers may be measured tissue permitting.
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Tumor tissue, as well as RNA and DNA isolated from tumor tissue, will be used to assess
changes in potential pharmacodynamic biomarkers induced by REGN2810 treatment from
baseline.
Main exploratory potential biomarkers of interest include, but are not limited to:


Tumor RNA expression



Number and distribution of TILs (CD8+ T cells, CD4+ T cells, T regulatory cells, and
tissue permitting, other subtypes such as B cells, myeloid-derived cells, NK cells, etc.)



Expression levels (mRNA and/or protein) of PD-L1, GITR, and LAG-3, and possibly
other check-point modulators



Mutations in known oncogenes and potential tumor neoantigens



Tumor mutation burden

Additional biomarkers may be measured (for example, exome sequencing, single cell RNA
analysis, microsatellite instability, T cell clonality) tissue permitting.

6.3.5.2.

Genomics Sub-Study – Optional

Patients who agree to participate in the genomics sub-study will be required to sign a separate
genomics sub-study ICF before collection of the samples. Blood for genomic DNA extraction
should be collected on day 1/baseline (predose), but may be collected at any study visit. Patients
are not required to participate in the genomics sub-study in order to enroll in the primary study.
DNA samples for the genomics sub-study will be double-coded as defined by the ICH guideline
E15. Sub-study samples may be stored for up to 15 years after the final date of the clinical study
report and may be used for research purposes. The purpose of the genomic analyses is to identify
genomic associations with clinical or biomarker response to target modulation, disease prognosis
and progression, or other clinical outcome measures.
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8.

STUDY VARIABLES

8.1.

Demographic and Baseline Characteristics

Baseline characteristics will include standard demography (eg, age, race, weight, height), disease
characteristics including medical history, and medication history for each patient.

8.2.

Primary and Secondary Variables

8.2.1.

Primary Efficacy Outcome Measure

The primary efficacy endpoint for this study is overall response rate (ORR) during the
12 treatment cycles. Overall response rate will be assessed separately for patients with metastatic
CSCC or unresectable locally advanced CSCC:


For patients in Group 1, RECIST version 1.1 will be used to determine ORR
(Eisenhauer 2009) (Appendix 2).



For patients in Group 2, composite response criteria will be used to determine ORR
(Appendix 3). In patients achieving a CR, tumor biopsies will be used in the final
determination of complete versus PR.

Patients who are deemed not evaluable (NE) by RECIST version 1.1 (Group 1; Appendix 2) or
inevaluable by the composite response criteria (Group 2; Appendix 3) will be considered as not
reaching PR/CR for ORR.
8.2.2.

Secondary Outcome Measures

The secondary efficacy outcome measures are:


Duration of response



Duration of disease control



PFS



OS



CR rate



Change in scores of patient-reported outcomes on EORTC QLQ-C30 (Appendix 1)



AEs



REGN2810 concentrations in serum (Appendix 4; at select sites)



Anti-REGN2810 antibodies

8.2.3.

Exploratory Outcome Measures

The following exploratory analyses are planned:
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8.3.

Pharmacokinetic Variables

Serum concentration of REGN2810 will be assessed at multiple time points throughout the study
treatment and follow-up periods, and the PK will be analyzed.
Pharmacokinetic variables may include, but are not limited to, the following:


AUCall – area under the curve (AUC) computed from time zero to the time of the last
concentration



AUCall/Dose – AUCall-to-dose ratio



CL – clearance



Ceoi – concentration at end-of-infusion



Ceoi /Dose – Ceoi-to-dose ratio



Clast – last positive (quantifiable) concentration



Ctrough – pre-infusion concentration



tlast – time of the last positive (quantifiable) concentration



teoi – time of end-of-infusion



Vss – volume of distribution at steady state



Vz – volume of distribution of the terminal phase

8.4.

Anti-drug Antibody Variables

Regeneron plans to evaluate the impact of the immunogenicity of REGN2810.
Anti-drug antibody variables include status (positive or negative) and titer as follows:


Total number of patients whose ADA response is negative



Total number of patients whose ADA response is positivity at any time



Pre-existing immunoreactivity – defined either as a positive ADA assay response at
baseline with all post-treatment ADA results negative, or a positive assay response at
baseline with all post-treatment ADA assay responses less than 4-fold over baseline
titer levels.
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Integrated Analysis of a Phase 2 Study of Cemiplimab in
Advanced Cutaneous Squamous Cell Carcinoma:
Extended Follow-up of Outcome and Quality of Life
Analysis
[[Please note, where text is underlined, an animation will be timed with the recording
to highlight those data]]
Slide 1

My name is Professor Danny Rischin, MD, from the Department of Medical
Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. On behalf of my
coauthors, this video abstract will provide an overview of our manuscript titled
‘Integrated Analysis of a Phase 2 Study of Cemiplimab in Advanced Cutaneous
Squamous Cell Carcinoma: Extended Follow-up and Quality of Life Analysis’.
Cemiplimab is a high affinity and highly potent human IgG4 monoclonal antibody that
binds to the PD-1 receptor. We have previously reported primary data from Groups 1
to 3 of the open-label, international Phase 2 study of patients with advanced CSCC,
and the methods for this study have previously been presented. Here, we present up
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to 3-year follow-up from the largest and most mature prospective dataset for this
disease.

Slide 2

This table provides baseline characteristics of the 193 patients included in the study.
Most patients were male, with a median age of 72 years. Most patients had a
primary cancer site of head and neck. The median duration of exposure was 51.1
weeks, and the median number of doses was 18.
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Slide 3
-

As you will see in this table, the objective response rate for all three groups
combined was 46.1% per independent central review, with a 95% confidence interval
of 38.9 to 53.4%. Looking at the data by individual groups, the objective response
rate was 50.8% for Group 1, 44.9% for Group 2, and 42.9% for Group 3. Additionally,
median duration of response has not been reached. Median duration of follow-up
was 15.7 months among all patients.
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Slide 4

One of the key takeaways from this graph is that cemiplimab had deepening
responses over time, evidenced by increasing CR rates compared to primary
analyses. Complete responses for Group 1 increased from 6.8% in the primary
analysis to 16.9% in the first follow-up analysis and to 20.3% at this subsequent
follow-up analysis. For Group 2, there were no complete responses at the interim
analysis, but the complete response rate was 12.8% at the primary analysis and is
unchanged at this follow-up analysis. For Group 3, the complete response rate
increased from 5.4% at the primary analysis to 16.1% at this follow-up analysis.
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Slide 5

Another key takeaway from this study is that cemiplimab demonstrates impressive
duration of response. Looking at the Kaplan–Meier curve estimating ongoing
response over time, among patients who experienced objective responses, 91% of
these responses had observed durations of 6 months or greater. The Kaplan–Meier
estimated percent of responses ongoing at 12 months is 87.8% and at 24 months is
69.4%.
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Slide 6

In addition to duration of response, as you can see in this graph, the median
progression-free survival is 18.4 months. The Kaplan–Meier estimated progressionfree probability at 24 months was 44.2%.
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Slide 7

These data show that overall survival was impressive with cemiplimab. Median
overall survival has not been reached for the total patient population. The Kaplan–
Meier estimated probability of overall survival at 24 months was 73.3%.
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Slide 8

In addition to robust clinical activity, treatment with cemiplimab was associated with
improvement in global health status/quality of life as measured by the EORTC QLQC30 instrument. Here, we show the least squares mean change from baseline
scores in the global health status/quality of life and pain scales over time. As can be
seen from this figure, improvements in both scales were observed from cycle 2, with
statistically and clinically meaningful improvement from baseline in pain observed as
early as cycle 3 and sustained over the course of treatment to cycle 12. Significant
improvement in global health status/quality of life was observed during initial cycles
and reached the clinically meaningful threshold of 10 points or more by cycle 12.
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Slide 9

This figure shows the proportion of patients with a clinically meaningful improvement
or deterioration (10 point or greater change) or maintenance (absence of a 10 point
or greater change) in global health status/quality of life, functioning and symptoms
scales at cycle 6 and cycle 12. By cycle 6, most of these patients had experienced
clinically meaningful improvements or maintenance in global health status/quality of
life, functioning, and symptoms. Overall, 91% of patients experienced clinically
meaningful improvement or stability in global health status/quality of life scores at
cycle 12, and most patients experienced sustained improvement or maintenance of
their functioning and symptoms by cycle 12.
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Slide 10

In total, 99.5% of patients experienced at least one treatment-emergent adverse
event, TEAE, of any grade regardless of attribution. TEAEs of any grade led to
discontinuation in 9.8% of patients, and Grade ≥3 TEAEs led to discontinuation in
7.3% of patients. The most common TEAEs of any grade were fatigue, diarrhea, and
nausea. In total, 48.7% of patients experienced at least one Grade ≥3 TEAE
regardless of attribution. In addition, 29.5% patients experienced at least one
sponsor-identified immune-related adverse event (irAE) of any grade, and 9.3%
patients experienced at least one Grade ≥3 irAE. No new TEAEs resulting in death
were reported for any group in this longer-term follow up, compared with previous
reports.
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Slide 11

In summary, this analysis confirms the substantial clinical activity of cemiplimab,
including new findings of improved complete response rates over time compared to
primary analyses, and impressive and increasing duration of response in patients
with advanced CSCC. In addition, treatment with cemiplimab resulted in a clinically
meaningful reduction in pain as early as cycle 2, maintained to cycle 12. Further,
clinical response to cemiplimab was associated with reduction in pain. The majority
of patients experienced clinically meaningful improvements or maintenance in global
health status/health-related quality of life, functional scales and symptoms. In
addition, no new safety signals were observed compared with the previous analysis.
These results provide further support for cemiplimab as an agent with favorable data
to support its use for the treatment of advanced CSCC.
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Dr Pedro Romero
Editor-in-chief, Journal for ImmunoTherapy of Cancer
Dear Dr Romero,
On behalf of my co-authors, we would like to thank you, the editors, and reviewers for the
evaluation of our manuscript (jitc-2021-002757). Please find below our responses (in blue text)
to the peer review comments.
Please note, based on previous discussions with the Journal for ImmunoTherapy of Cancer
editorial office, we also submit a graphical abstract and script for a video abstract alongside the
revised manuscript.
We hope that the changes we have made make the manuscript suitable for publication in the
Journal for ImmunoTherapy of Cancer.
We look forward to hearing back from you soon.
Best regards,
Prof Danny Rischin
Department of Medical Oncology
Peter MacCallum Cancer Centre
Melbourne
Australia
Tel: 011 (03) 9656 1804
E-mail: Danny.Rischin@petermac.org
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Response to Reviewers’ comments
Reviewer: 1
Major:
1. Novelty of this study is limited. Although QoL info was provided, no substantial update info
on survival is gained with a one-year longer follow-up time, e.g., median DOR, median OS has
not been reached.
 Response: We thank the reviewer from this comment. As the reviewer notes, the most
important new information in this report is the QoL data. Cemiplimab provided
meaningful improvement/stability in global health status/quality of life and maintained
a low symptom burden, including a durable reduction in pain. Additionally, the longer
follow-up provides clinically meaningful efficacy data, particularly as regards emerging
durability of ongoing responses in a patient population that faced a very grim prognosis
prior to the availability of immune checkpoint blockade.

2. QoL was measured in different time intervals (groups 1/2 at 8 weeks, group 3 at 9 weeks), is
there any statistical effort trying to address this issue? Also should mention some details of the
mixed effects model, e.g., if intercept and slope are both allowed to be random, etc. What
software was adopted for the statistical analysis, SAS, R, etc.?
 Response:
o In response to the first part of this comment, no statistical methods were used
to address the issue regarding the different time intervals. However, we were
transparent in the reporting of our results by showing both cycles and equivalent
months (per figure 3) as well as indicating the different cycle lengths in the
footnotes. We have added further clarification in the Figure 3 footnote. Despite
the difference in cycle duration, no differences were observed between Groups
1+2 and Group 3 when analysed as individual cohorts. Therefore, these data
have been combined collectively and reported per cycle.
o For the second part, the mixed models repeated measures models (MMRMs)
used an AR(1) covariance structure. Covariates controlled in the model included
dose group and baseline pain score. The study visit was considered as a random
effect. The analysis was conducted using SAS version 9.4. We have now inserted
these details in the Methods section on p. 10.
3. The definition of “responder” on Page 10 is confusing. Readers may misinterpret the
“responders” as the more generally defined as patients who achieved PR/CR radiologically.
 Response: Since the important point here is the criterion used for a clinically
meaningful change (and not the definition of “responder”), the responder language has
now been removed and replaced with a sentence reading, “Using this criterion, the
number of patients experiencing a clinically meaningful change in symptom score was
evaluated at cycle 6 and cycle 12”
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Minor:
1. The abstract is confusing. Please provide 95% CI for CR rates. “Estimated proportion of
patients with ongoing response at 12 months was 87.8%”, taking into account that the “median
time to CR was 11.2 months”, does this mean within 0.2 months there are around 12% pts
progressed? Please specify what the index date of the “12 months” statement is, the initiation
of cemiplimab or the date that the patient reached the first objective response.
 Response:
o In the tumor response table (Table 2), in the interest of readability, we have
provided the 95% CI for the combined CR rate, because doing so for the
individual Group may provide no meaningful interpretation as the numbers are
small.
o The statement about estimated proportion of patients with ongoing response
includes those with PRs or CRs. As the prior sentence is on CR, we think the
reviewer may have misunderstood this statement. As such, we have added
“Among patients with PRs or CRs”, to clarify the statement *Please see next
bullet].
o The index date is the time of first objective response. The new statement now
reads: “Among patients with partial response or CR, the estimated proportion of
patients with ongoing response at 12 months from the first objective response
was 87.8%...”
2. Please use the same unit across the manuscript, e.g., the time measurement be unified into
months or weeks, or cycles, etc.
 Response: Please see our response to Major comment #2
3. Background: please check the statement that “CSCC is the second most common cancer in
the US”, do the authors mean “the second most common skin cancer”?
 Response: CSCC is the second most common cancer, as well as the second most
common skin cancer. To address the reviewer comment, we have replaced “most
common cancer” with “most common skin cancer”.
4. What is “rwlc” short for?
 Response: In the US, the generic name designated by the FDA uses this suffix
(“cemiplimab-rwlc”), so when we are referring to the FDA approval, we use the term
“cemiplimab-rwlc”.
5. Please provide rationale/reference of using 105 days as the threshold of durable DCR.
 Response: As stated in Table 2 footnote, the use of at least 105 days to measure
durable DCR was to account for scheduling windows in the protocol. Given the
aggressive nature of advanced CSCC and the low efficacy of conventional chemotherapy,
a disease control for 105 days or longer is evidence that treatment may have altered the
natural history of disease (Coewy 2019).
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Reviewer: 2
In detail:
If the authors wish to make a deal out of the comparison of their study to others in the
discussion, they need to provide better context by indicating the length of follow up for each
study and providing response data at equivalent follow up times since one of the central ideas
expressed in this current work is that responses in SCCa may occur quite slowly over time.
 Response: We thank the reviewer for this comment. We specified in the paragraph the
differences between the studies, particularly the duration of follow-up. However, to
avoid misinterpretation that the paragraph is presenting a head-to-head comparison,
we have revised the text.
Given the longer follow up, I saw that the authors stated that no new toxicities emerged that
had not previously been seen, but did they mean types of toxicities or cases of toxicities?
 Response: The intended meaning is that there were no new types of toxicities and no
change in frequencies of known toxicities. To clarify, we have updated the statement to
“There were no new safety signals or types of toxicities compared to previous analyses”.
In the discussion, what does the following statement mean: “Furthermore, DOR and OS are
longer than what has been previously described with other agents.”
 Response: The cited source analyzes clinical response for the common therapies used
to treat patients with mCSCC or laCSCC prior to the approval of cemiplimab. We have
clarified the statement so that it is not misinterpreted as if we were comparing
cemiplimab with another immunotherapy here.
At the end of the discussion, how can the following statement make sense: “….impressive and
increasing DOR in patients…” since the DOR doesn’t change, the follow up to detect it changes;
it should just state that the DOR is impressive.
 Response: The duration of response has increased over time (i.e., response is ongoing),
as indicated by the Kaplan–Meier 12-month and 24-month estimates of DOR in Table 2.
The sentence has been changed to reflect this.
The authors have the third from last line in the discussion flipped; it should read “Further,
clinical response to cemiplimab was associated with reduction in pain.”
 Response: The sentence at the end of Discussion has been changed as suggested.
The data on achieving a CR belongs in the results section, not the discussion.
 Response: The paragraph on CR rate has been moved to the Results section.
Please decide on cemiplimab versus cemiplimab rwlc, and explain the latter if it is preferred
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Response: In the US, the generic name designated by the FDA uses this suffix
(“cemiplimab-rwlc”), so when we are referring to the FDA approval, we use the term
“cemiplimab-rwlc”.

In the introduction please add how much more follow up is provided
 Response: The last paragraph in the introduction now indicates how much follow-up is
provided in this manuscript.
Simply point out that in the results section where it is stated that “By cycle 6, among all
patients reporting clinically meaningful change….” by definition there are likely benefiting
patients since they had made it past 6 cycles
 We have added language indicating that a substantial fraction of patients benefitted
from the treatment.

Associate editor:
Please address all of the specific concerns and stipulations of the two reviewers, and ensure
that the value added of the work is emphasized above and beyond previous reports.
Response: We have now provided responses to the reviewer comments, made changes to the
manuscript as appropriate, and emphasized the added value of the present work vs prior
reports.
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Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma:
extended follow-up of outcomes and quality of life analysis
Objective: To provide pooled longer-term data from three groups of a phase 2 study of cemiplimab 3 mg/kg intravenously (IV) every 2 weeks (Q2W) or 350 mg
IV every 3 weeks (Q3W) in patients with locally advanced (la) or metastatic (m) cutaneous squamous cell carcinoma (CSCC), and to determine duration of
response (DOR) and impact on quality of life (QoL).

3 mg/kg Q2W IV
for up to 96 weeks
(Group 1; Group 2)

per independent central review

n=78

Cemiplimab

20
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16.1
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12.8 12.8
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Group 1 (mCSCC)
3 mg/kg Q2W

mCSCC

Group 2 (laCSCC)†
3 mg/kg Q2W

Group 3 (mCSCC)
350 mg Q3W

†

At the time of the Group 1 primary analysis, a pre-specified Group 2 interim analysis was performed. Among the 23 laCSCC patients included in this
pre-specified interim analysis, there were no complete responses.

n=56
Clinicaltrials.gov: NCT02760498

Median DOR not reached; estimated percentage of
patients who remained in response at 12 months
was 87.8%

87.8%

Number of patients at risk
Group 1 (n=59)
Group 2 (n=78)
Group 3 (n=56)
Total (N=193)

Group 1 (mCSCC) 3 mg/kg Q2W (n=59)
Group 2 (laCSCC) 3 mg/kg Q2W (n=78)
Group 3 (mCSCC) 350 mg Q3W (n=56)
Total (N=193)
0

2

4

6

8

10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
Month

30
35
24
89

30
33
24
87

29
32
24
85

28
30
23
81

23
27
21
71

23
25
21
69

23
22
20
65

23
21
19
63

23
17
17
57

20 18 16 16 16 10 9
14 10 8 6 6 5 4
11 5 0 0 0 0 0
45 33 24 22 22 15 13

6
0
0
6

2
0
0
2

0
0
0
0

0
0
0
0

0
0
0
0

Change from baseline in Global Health Status/
health-related QoL (GHS/HRQoL) and pain scores
0

25
*p<0.0001
20

Cycle
Approximate months
n (GHS/HRQoL)
n (pain)

–5

–8.0*
–9.7*
–11.5*

15

–10.7*
–12.1*
–13.4*

12.8*
11.8* 11.1*
–13.8*

–10

9.4*
–15

10
–13.6*
5

7.8*

8.6*

3
6
122
125

4
8
104
105

7.0*

6.5

5
10
104
105

6
12
101
101

4.7
0
Baseline 2
0
4
150
136
152
137

8.2* –16.3* 8.6*

–14.3*
–20

–18.2*

–25
7
14
84
84

8
16
73
73

9
18
65
65

10
20
59
59

11
22
52
52

Improvement

0

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Least squares mean (standard
error) change from baseline
in pain scores

350 mg Q3W IV
for up to 54 weeks
(Group 3)

Primary
n=12
20.3
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16.9

25

Least squares mean (standard
error) change from baseline
in GHS/QoL scores

n=59

Median duration of follow-up: 15.7 months

Complete response rates per independent central review

laCSCC
Complete response rates (%)

mCSCC

46.1%

Kaplan–Meier curves for DOR per independent central review
Probability of no
progression or death

Objective response rate

Improvement

Cemiplimab
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24
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Summary: In patients with advanced CSCC, cemiplimab 3 mg/kg Q2W or 350 mg IV Q3W was associated with sustained substantial clinical activity,
including improved complete response rates over time, durable pain control, and QoL improvement.
Authors: Danny Rischin*, Nikhil I. Khushalani, Chrysalyne D. Schmults, Alexander Guminski, Anne Lynn S. Chang, Karl D Lewis, Annette. M. Lim, Leonel Hernandez-Aya, Brett G. M. Hughes,
Dirk Schadendorf, Axel Hauschild, Alesha A. Thai, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Siyu Li, Zhen Chen, Emmanuel Okoye, ChiEh-I Chen, Vera Mastey, Medha Sasane,
Israel Lowy, Matthew G. Fury, Michael R. Migden. *Correspondence: Danny.Rischin@petermac.org

Rischin D, et al. J Immunother Cancer 2021; 9:e002757. doi: 10.1136/jitc-2021-002757

